Content

About this Report

Exemplary Governance

Message from the Chairman Green Operation Patient-Centric Caring for Employees Health Equity and Sustainable Advancement Future Built on Integrity Innovation and R&D People-oriented Approach Welfare Sharing

About InnoCare

Corporate Governance 22 Climate Change 36 Innovative R&D 60 Compliant Employment 96 Industry Cooperation 122

Risk Control 26 Environmental Management 46 Quality Assurance 73 Talent Development 99 Inclusive Healthcare 126

ESG Management

Business Ethics 32 Resource Conservation 48 High-Quality Service 87 Employee Care 103 Social Responsibility 128

Pollution Prevention and Control 52 Responsible Procurement 91 Safety and Health 108

Appendix

Green Office 56

ESG Key Performance Table 132

HKEX Codes 143

Guidelines for the Shanghai Stock

Exchange 148

Feedback 149InnoCare 2025 ESG Report About this report

About this Report

Introduction to the Report Sources of Information

This 2025 Environmental Social and Governance Report (ESG Report) is issued by InnoCare Pharma Limited The information and data cited in this Report are derived from the Company's official documents statistical reports

(hereinafter referred to as “InnoCare” “the Group” or “the Company”). It aims to present the strategies manage- and financial reports and have been collated summarised and reviewed by relevant departments. Unless otherwise

ment approach and practices of InnoCare and its major subsidiaries included in the annual report in relation to specified all monetary amounts in this Report are presented in Renminbi (RMB).environmental social and governance matters.Reporting Principles

Reporting Scope

Materiality principle: This Report follows the principles and requirements of the Environmental Social and Govern-

The information and data disclosed in this Report cover InnoCare and its major subsidiaries included in the scope ance Reporting Code issued by SEHK while also aligning with the capital market’s focus on the Company’s sustainable

of the annual report. Unless otherwise stated the Reporting Period covers from January 1 2025 to December 31 development. Through various forms of communication and engagement with stakeholders the Company conducts

2025 (hereinafter referred to as the “Reporting Period” “this year” or “in 2025”). benchmarking analysis against industry peers to identify and prioritize material issues relevant to its operations.

These issues have been reviewed and endorsed by the Board of Directors and senior management. For further details

List of Names and Abbreviations of Subsidiaries Contained in This Report please refer to the “Material Issue Identification” section.Quantitative principle: This Report regularly collects and aggregates quantitative key disclosure indicators including

Main subsidiaries Abbreviation in the report all environmental categories and certain social categories specified in the ESG Reporting Code. These indicators are

systematically collected throughout the year and are ultimately consolidated for public disclosure in this Report.Beijing InnoCare Pharma Tech Co. Ltd. Beijing InnoCare For ESG quantitative data please refer to the relevant chapters of this Report.Balance principle: This Report aims to objectively and fairly present the Company’s efforts in various ESG aspects

Beijing Tiancheng Pharma Tech Co. Ltd. Beijing Tiancheng including environment employee product responsibility and community. Both positive and negative indicators

are disclosed to reflect objective facts.Nanjing Tianyin Jian Hua Pharma Tech Co. Ltd. Nanjing Tianyin Innocare Consistency principle: This Report maintains consistency in disclosure scope compared to previous sustainability

reports with uniform disclosure and statistical methods applied throughout. The meanings of the ESG key quanti-

Guangzhou InnoCare Pharma Tech Co. Ltd. Guangzhou InnoCare tative performance indicators disclosed are explained including calculation bases and assumptions. Consistency

in indicators across different Reporting Periods is maintained as much as possible to ensure comparability.Shanghai Tianjin Pharma Tech Co. Ltd. Shanghai Tianjin Approval and Accessibility

This Report was approved by the Board of Directors on March 25 2026. It is available in Simplified Chinese Tradi-tional Chinese and English and can be viewed and downloaded from the Company’s official website （https://Basis of Preparation www.innocarepharma.com/en） the SEHK website （www.hkexnews.hk） and the Shanghai Stock Exchange

website（http://english.sse.com.cn/）.This Report has been compiled in strict accordance with Appendix C2 Environmental Social and Governance

Reporting Code under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited Disclaimer

(hereinafter referred to as the “SEHK”) with reference to the relevant recommendations set out in the Guidelines

No. 14 of Shanghai Stock Exchange for Self-regulation of Listed Companies - Sustainability Report (Trial). In addition The Board of Directors and management undertake that this Report contains no false records misleading statements

this Report has been prepared with reference to the GRI Sustainability Reporting Standards (GRI Standards) and or material omissions and bear responsibility for the truthfulness accuracy and completeness of its contents. Some

responds to the disclosure requirements related to the United Nations Sustainable Development Goals (UNSDGs) content in this Report may contain forward-looking statements which are subject to uncertainties and risks that

the Sustainability Accounting Standards Board (SASB) the ten principles of the United Nations Global Compact may lead to significant differences between actual results and expectations. The Company does not undertake any

(UNGC) and the IFRS Sustainability Disclosure Standard No. 2 Climate-related Disclosures obligation to update forward-looking statements contained in this Report.

4 5Message from the Chairman

InnoCare 2025 ESG Report

Message from the Chairman

Pioneering a New Era Moving Forward Together Toward the Future 2025 marks the tenth anniversary of the estab-

lishment of InnoCare and is a pivotal year as we accelerate into the “InnoCare 2.0” stage of rapid development. The

Company achieved profitability for the first time secured market approval for two innovative new drugs sustained

the commercial expansion of its core products accelerated its global footprint and achieved breakthroughs across

its R&D pipeline. This demonstrates our robust capability to translate cutting-edge science into sustainable long-term

value creation. In parallel with this rapid progress we have deeply integrated the ESG concept into our corporate

development strategy. With innovation as our sail we navigate the deep sea of scientific exploration enabling more

breakthrough therapies to journey from the laboratory to the clinic; with quality as our bedrock we forge the founda-

tion of trust through unwavering rigor safeguarding the commitment entrusted with every life; with sustainability

as our current we infuse the concept of sustainable development into our DNA imparting enduring vitality to our

operations; and with responsibility as our anchor we deeply root the enterprise in the fabric of society demonstrating

our value through the practice of inclusive benefit.Riding the Wave of Sustainability to continuously building an integrated biopharmaceuti- and strictest requirements are maintained at every Through efforts in medical insurance inclusion

Navigate Our Future cal platform spanning discovery clinical development stage. We continuously enhance our internal control patient assistance programs innovative payment

and commercialization.. We consistently increase R&D processes strengthen risk management welcome models and public health education we strive to

Green forms the very foundation of InnoCare's investment focus on cutting-edge technologies with rigorous internal and external audits and maintain lower treatment barriers improve drug accessibility.development. The Company actively responds to the annual R&D investment reaching RMB 951.6 million. efficient pharmacovigilance and emergency response In 2025 orelabrutinib received approval for a 1L CLL/

national "dual carbon" strategy deeply embedding the In 2025 we achieved significant progress across our mechanisms to ensure every product is safe effective SLL indication and was successfully included in China's

principles of green and low-carbon development into pipeline and executed two landmark business devel- and reliable. This reflects our unwavering commitment National Reimbursement Drug List (NRDL) ensure

every facet of corporate governance and operations. opment transactions. These strategic deals materi- to quality. We believe that quality excellence stems more patients benefit from scientific advancement.By systematically establishing a robust climate ally enhanced the global competitiveness and value from a culture of total employee participation. Through InnoCare is committed to working with all sectors of

governance framework we proactively identify and realization potential of our clinical-stage assets. systematic quality training and culture-building initi- society to write a collective story of safeguarding lives

manage environmental risks and opportunities setting Furthermore with the launch of tafasitamab and zurle- atives the Company instills a deep sense of quality and promoting health for all.and striving to surpass scientific energy conservation trectinib (ICP-723) we have successfully evolved from awareness in every employee. Simultaneously we

and emission reduction targets. In resource a single-product company to a multi-product enter- conduct marketing and services with a strong sense

Future Outlook

utilization and pollution prevention we promote prise covering diverse therapeutic areas. We recognize of responsibility maintaining open communication Looking forward we will continue to adhere to the

green production and a circular economy optimizing that innovation is rooted in our talent. The Company channels with our customers to ensure patients’ voices original intention of "science drives innovation for

processes reducing consumption and committing has assembled a high-caliber international R&D team are heard and their needs are met. InnoCare will with the benefit of patients" and seize opportunities in the

to building an eco-friendly enterprise. From clean

production in our facilities to energy saving practices of over 500 professionals. Through a comprehen-

consistent rigor earn and uphold the trust placed in us. process of change. We look forward to illuminating

- sive incentive and intellectual property protection Responsibility as Our Anchor Building a more new coordinates on the global pharmaceutical in our offices we work to translate green principles research and development star map through contin-

into action by all employees. In 2025 through a system we foster an innovative culture and safeguard Shared Harbor of Health uous innovation at the source; We are committed

series of technological upgrades and management our achievements. InnoCare remains unwavering in As a socially responsible biopharmaceutical to becoming the most solid reliance for doctors and

optimizations we enhanced resource efficiency and its commitment to exploring new frontiers in human

health through sustained pioneering innovation. CompanyInnoCare consistently integrates patient

patients worldwide with world-class quality and relia-

reduced our environmental footprint. InnoCare will well-being and social value into its DNA. The ble services; We promise to maintain our reverence for

continue to honor its green commitments pursuing Quality as Our Haven Safeguarding the Company firmly believes that the true value of life environmental responsibility and social responsi-

harmonious coexistence with nature and safeguarding Vessel of Patient Life innovation achievements is ultimately reflected in the bility while pursuing commercial success. InnoCare is

a green beautiful and blissful home for all. respect for and improvement of life. To that end we willing to work hand in hand with all parties to jointly

Innovation as Our Sail Charting a New Quality is the lifeline of InnoCare and the cornerstone actively foster industry collaboration and knowledge sail towards a more magnificent future.Course for Global Healthcare of our commitment to placing “patients’ lives above sharing present research findings on leading global all else.” The Company has established a comprehen- academic platforms and partner with stakeholders

Innovation is the engine and core value of InnoCare. sive quality management system that spans the entire across sectors to conquer healthcare challenges.The Company is committed to providing break- drug lifecycle—from R&D and production to post-mar- We are dedicated to advancing inclusive healthcare. Jisong Cui

through treatment options for patients worldwide and ket monitoring—ensuring the highest standards

Chairman and Chief Executive Officer

6 7InnoCare 2025 ESG Report About InnoCare

About InnoCare Key Performance

Exemplary Governance Sustainable Advancement

Company Overview

Received the highest information disclo-

InnoCare is a leading fully integrated commercial-stage biopharmaceutical high-tech enterprise committed to devel- 43% 57%

oping and providing cutting-edge innovative therapies for patients with cancer and autoimmune diseases worldwide. sure rating of Class A from the Shanghai of directors are independent

Under the leadership of top industry experts and a seasoned management team the Group has built an integrated of directors are femaledirectors Stock Exchange

platform spanning drug discovery clinical development manufacturing and commercialization with proprietary

capabilities across the entire value chain. With operations in Beijing Nanjing Shanghai Guangzhou Hong Kong Conducted 26 specialised compliance training sessions on 0 litigation cases or administrative

and the United States the Company has established a growing global presence and is continuously advancing the penalties involving unfair competition

development and accessibility of its innovative therapies worldwide. business ethics covering 2173 person-times corruption bribery or money laundering

Leveraging the management team’s global vision and strong local execution the Group has built a balanced and occurred

highly competitive pipeline covering haematologic malignancies a range of autoimmune diseases and solid

tumours. The Company has successfully commercialized three products in China including its core products

orelabrutinib tafasitamab and zurletrectinib continuously consolidating its leading franchise in haematologic Green Operation Future Built on Integrity

malignancies actively expanding into autoimmune disease treatment and proactively advancing its solid tumor

pipeline. Through continuous exploration of novel targets development of breakthrough therapies and sustained 100% 100% 0

investment in innovative medicines the Company is committed to becoming a biopharmaceutical leader in develop- incidents of penalties due to excessive

ing and delivering innovative therapies for patients worldwide and contributing to the improvement of public health. compliance rate for waste gas compliance rate for waste

and wastewater discharge disposal pollutant discharge or other violations

Mission Vision and Values Energy use intensity in 2025 Greenhouse gas emissions Industrial wastewater discharge inten-

To leverage cutting-edge science technology and driving decreased by 57.71% intensity in 2025 decreased by sity in 2025 decreased by 61.31%

force to offer new drugs for patients and improve public compared with 2023 60.75% compared with 2023 compared with 2023

health

Patient-Centric Innovation and R&D

Mission

A total of

accounting for 42.26% of whom more than 52% hold

532 R&D personnels of total employees master’s or doctoral degrees

Vision

Values Filed 41 patent applications in multiple countries and regions and obtained 43 patent grants

0 group adverse reaction incidents caused by drug defects and 100%

0 product recall incidents caused by quality issues customer complaint resolution rateDedicated&Responsible Persistent

To become a Biopharmaceutical leader & PerseverantCreative&Innovative

that develops and delivers innovative Collaborative&Team-oriented Pursuit

therapies for patients worldwide of Excellence Orelabrutinib tafasitamab and zurletrectinib (ICP-723) are in the commercialization stage with multiple other

innovative drugs advancing through clinical phases.

8 9InnoCare 2025 ESG Report About InnoCare

Caring for Employees People-oriented Approach Awards and Honours in 2025Launched the upgraded “InnoCare Nomination Award for the 4th Beijing Municipal People's 2025 Beijing Top 100 Private Enterprises in Science and 52% 0 cases of violations Government Quality Management Award Technology Innovationinvolving child labor or BoLe” employee referral programme

of employees are female Grant organization/institution: Grant organization/institution:

forced labor with referred hires accounting for Beijing Municipal People's Government Beijing Federation of Industry and Commerce

61% of new recruits

Top 100 Beijing High-end Precision and Advanced Beijing March 8th Red Flag Collective

16% Employee training Enterprises (2025)up from the investment amounted Conducted 1 employee Grant organization/institution: Grant organization/institution:

previous year to RMB 867300 satisfaction survey Beijing Enterprise Federation Beijing Federation of Trade Unions

with employee 0 with cumulative safe working Beijing Pilot Enterprise for the Integration of Advanced Top 100 Chinese Pharmaceutical Innovation Enterprises satisfaction reaching hours reaching Manufacturing and Modern Service Industries (Leading Type) (2025)

72.7 work-related injuries 5109000 Grant organization/institution: Grant organization/institution:% during the year Beijing Municipal Development and Reform Commission E-Pharm Executive

Top 50 Independent Innovation Enterprises in the Best Companies to Work for in Asia

Conducted with a total of Conducted Pharmaceutical Industry

19 2457 person- 13 Grant organization/institution: Grant organization/institution: safety training emergency drills ACFIC Medical and Pharmaceutical Chamber of Commerce HR Asia

programmes times participating

Excellent Practices of the Board of Directors of Listed Best Practices for Board Offices of Listed Companies in 2025

Companies 2025

with 202 person- 100% pass rate in 0 employees suspected of Grant organization/institution: Grant organization/institution:

times participating employee health exami- occupational diseases or with China Association of Listed Companies China Association of Listed Companies

nations occupational diseases

Top 100 Most Innovative Listed Healthcare Companies (2025) 2025 Cailian Press Zhiyuan Award "ESG Pioneer

Enterprise"

Cumulative protection with employee insur- Successfully passed the renewal Grant organization/institution: Grant organization/institution:

investment reached RMB ance coverage at audit for ISO 45001 Arterial Network Cailian Press

500000 100% certification

“Sunshine” Annual Award for Excellent Newly Approved “New Quality Productive Forces” Industrial Practice

Innovative Pharmaceutical Product Demonstration Case

Grant organization/institution: Grant organization/institution:

21st Century New Health Research Institute Global Times

Health Equity and Welfare Sharing

2025 Forbes China Top 100 Outstanding Business Women Outstanding Achievement Award of Traditional Chinese Medicine

Public welfare investment amounted to

236700 Development AssociationRMB Grant organization/institution: Grant organization/institution:

Forbes Traditional Chinese Medicine Development Association

10 11ESG Management

InnoCare 2025 ESG Report

ESG Management ESG Governance Structure and Responsibilities

InnoCare continues to deepen ESG management fully integrating the concept of sustainable development into

the Company's daily operations and long-term strategy continuously improving the ESG governance structure and *?Identify evaluate and monitor the ESG risks of the Group

operating mechanisms and ensuring the effective implementation of ESG management strategies. At the same time Board of Directors *?Ensure that appropriate and effective ESG risk management and internal control systems are in

we focus on safeguarding the legitimate rights and interests of all stakeholders strengthening communication with place

stakeholders and ensuring the creation of lasting value for all stakeholders in the pursuit of sustainable development. *?Formulate the Group's ESG development strategies ensuring alignment with the overall business

direction

ESG Governance Structure *?Review ESG issues reported by the ESG Working Group including the annual ESG report and other

key developments

To continuously strengthen the level of ESG management InnoCare has referred to regulatory requirements and

industry standards and based on its own development reality constructed an ESG management structure that is

led by the Board of Directors coordinated and promoted by the ESG Working Group and implemented by various

functional departments with clear responsibilities implemented at each level.*?Report regularly to the Board of Directors on ESG policies progress and emerging issues

Board of Directors ESG Working Group *?Oversee and coordinate ESG matters of the Group

*?Assist the board in assessing ESG risks

*?Develop ESG management strategy and medium to long-term management work plan

ESG Working Group *?Coordinate various functional departments for the efficient execution of ESG initiatives

*?Regularly communicate ESG matters with investors

Public Relations Legal Pharmacovigilance Administration

Human Resources R&D Investor Relations IT Functional

Departments

*?Integrate ESG principles into daily business operations

Purchasing EHS Finance Production Quality *?Implement the ESG plan and directives set by the Board and the ESG Working Group

*?Collect organize and report ESG related data and updates

ESG Governance Structure

Special training on "ESG and Sustainable Development"

In 2025 InnoCare systematically optimized various systems and processes of corporate governance based

on the concept of sustainable development further improving its long-term governance mechanism by

clear responsibilities and standardized operations. To enhance the awareness and practical ability of the

governance team in addressing sustainable development issues the Company actively organizes directors

and senior management personnel to participate in the “ESG and Sustainable Development” special train-

ing hosted by the Beijing Listed Companies Association continuously strengthening strategic leadership

and performance capabilities.

12 13ESG Management

InnoCare 2025 ESG Report

Material Issues Identification Double Materiality Matrix

In order to continuously strengthen the effective integration of sustainable development strategy and corporate

governance and actively respond to the widespread concerns and expectations of various stakeholders regarding Developing a The financial materiality assessment results were integrated with the impact materiality assessment

Double Materiality

the Company’s long-term value InnoCare strictly complies with the provisions on double materiality in the Guide- results to derive the materiality scores of the issues which were then prioritized to form the double Matrix

lines No. 14 of Shanghai Stock Exchange for Self-regulation of Listed Companies — Sustainability Report (Trial) and *? materiality issues matrix.the Guidelines for Self-Regulation of Listed Companies No. 4 – Preparation of Sustainability Reports. The Company Reviewing the

has systematically carried out and continuously deepened the identification assessment and dynamic optimiza- Double Materiality The double materiality issues matrix was submitted to the Board of Directors for approval resulting

tion of its double materiality issues thereby further enhancing the scientific and forward-looking nature of its ESG Matrix in the finalized double materiality issues matrix for 2025.management.The Group conducted a comprehensive assessment of the impact materiality and financial materiality of ESG issues

based on industry characteristics and business realities. In the impact materiality assessment the Group identified 24

key issues based on regulatory orientation and industry trends and clarified the prioritization through stakeholder

*?Employee health and *?Compliance and risk *?Employees’ rights and benefits

research. Simultaneously by interviewing the main responsible departments of ESG matters analyzing historical safety management *?R&D and innovation

data financial performance and future financial planning the Group determined the financial materiality of each *?Employee training *?Biodiversity *?Intellectual property protection

issue. Based on the above materiality InnoCare developed a double materiality matrix for 2025 providing a clear and development *?Diversity equity and *?Drug accessibility

basis for improving the ESG information disclosure system reasonably allocating short medium and long-term *?Emissions manage- inclusion *?Communication with Stakeholders

resources and formulating subsequent ESG management plans. ment *?Sustainable supply

*?Product quality and chain management

Double Materiality Issue Identification Process safety *?Environmental

*?Resource and energy management

management *?Corporate governance

*?Business ethics and *?Addressing Climate

Double Materiality Issues anti-corruption Change

Identifying

Impact *?Impact materiality assessment methodology: Based on regulatory requirements industry trends

Materiality peer benchmarking and capital market attention the Group established quantitative assessment standards covering the scale scope irremediability and likelihood of the impacts. *?R&D ethics

Issues

*?Stakeholder engagement: By distributing stakeholder survey questionnaires on ESG materiality *?Responsible marketing

issues understand the importance judgments of key stakeholders on environmental social and *?Customer service assurance

corporate governance (ESG) issues determine the weights of stakeholders and identify the actual *?Social welfare

impacts of different issues on various stakeholder groups.*?Information security and privacy protection

*?Threshold setting and prioritization: Reasonable materiality thresholds were set to prioritize issues

forming the final impact materiality assessment results for each ESG topic. *?Industrial cooperation and development

Identifying

Financial *?Financial materiality assessment methodology: The Group reviewed financial materiality assess-

Materiality ment requirements from regulators and major ESG ratingagencies identifying risks and opportuni-

Issues ties affecting business operations financial position operating results and cash flow. The significant

financial implications were evaluated clarifying financial risks and opportunities for each issue and Important Very Important

identifying a list of key issues with financially material impacts.*?Financial indicator correlation: Financial indicators linked to identified risks and opportunities Financial materiality

were analyzed. Based on input from financial management the financial materiality of each issue

was comprehensively assessed. Environmental issues Social issues Governance issues

*?Financial materiality Threshold Setting: Using both qualitative and quantitative analysis the Group

categorized financial impacts into levels and set corresponding thresholds. InnoCare's Double Materiality Matrix for 2025

*?Integration of inputs and conclusion formulation: Communicate with the main responsible depart-

ments highly related to ESG issues investigate past historical data financial impact and future

financial planning and organize the financial materiality assessment results of each ESG issue.*?

1415

Impact materiality

Important Very ImportantESG Management

InnoCare 2025 ESG Report

Communication with Stakeholders

Stakeholders Issues of Concern Communication Mechanisms

InnoCare has always attached great importance to interactive communication with stakeholders and is committed to

establishing a comprehensive and multi-level two-way communication mechanism timely identifying and respond-

ing to issues of concern to all parties effectively conveying the Company's strategy and ESG practice achievements *?Regular employee meetings

and continuously improving the brand value and transparency of the enterprise. In 2025 the Group systematically *?Employee representative conference*?Employees’ rights and benefits

promoted stakeholder communication actively listened to feedback and improved related work through various *?Rationalization suggestions column*?Employee health and safety

forms such as organizing shareholder meetings employee representative meetings and participating in industry *?Communication activities such as train-*?Diversity equity and inclusion

forums. Employees

ing and lectures

*?Employee training and develop- *?Employee care activities

ment

InnoCare 2025 Communication with Stakeholders *?Employee complaints and feedback

*?Employee satisfaction surveys

Stakeholders Issues of Concern Communication Mechanisms

*?Business ethics and anti-corrup- *?Supplier access review

*?Corporate governance tion *?Supplier evaluations and surveys

*?Compliance and risk management *?Regular Board meetings Suppliers

*?Sustainable supply chain manage- *?Supplier communication and on-site visits

ment

Management *?Business ethics and anti-corrup- *?Supplier training

tion

*?Shareholders’ meeting

*?Industrial cooperation and devel- *?Industry conference exchange and discus-

*?Regular reports and Company announce- Public Welfare Organiza- opment sion

*?Corporate governance ments tions/Non-Governmental

*?Compliance and risk management *?Investor conferences medical summits Organizations

Shareholders and In- *?Business ethics and anti-corrup- etc

vestors tion *?“Entering Listed Companies” events

*?SSE e-interaction *?Media communication

*?Hotline and email for investor inquiries *?Volunteer public welfare activities

Community Represent- *?Social welfare *?Patient Care Activities

atives *?Corporate culture communication

*?Compliance and Risk Management *?Government meetings

*?Business ethics and anti corrup- *?Project cooperation-

tion *?Fulfillment of all statutory and regulatory

Government and Regula- *?Emissions management obligations

tory Agencies *?Resource and energy management *?Periodic submission of operational reports in accordance with regulations

*?Environmental management *?Monitoring by government staff

*?Customer complaints and feedback

*?Product quality and safety *?Customer communication email and

dedicated hotline

*?Responsible marketing

Consumers *?Product service and quality assurance*?Customer service assurance

*?Communication instructions for informa-

tion security and privacy protection

16 17ESG Management

InnoCare 2025 ESG Report

Multi-party Collaboration for Building a Pharmaceutical Innovation Ecosystem Cultural Cohesion and Value Communication on the 10th AnniversaryOn August 17 2025 the 2025 International Conference on Biopharmaceutical Innovation themed “A In August 2025 InnoCare launched its corporate song Promise to Life expressing the Company’s missionDecade of Excellence: Shaping the Future with Intelligence” was successfully held. The conference brought vision and values through art. The song conveys InnoCare’s dedication to exploring the light of life its

together top global scientists and industry leaders establishing a multi-stakeholder exchange platform commitment to innovation and its aspirations for a promising future. Concurrently we released 10thinvolving government academicians physicians investors media and other parties (“government-aca- Anniversary: Employee Stories which chronicles from the staff’s perspective The Company’s decade-longdemia-industry-research-medicine” collaboration) providing crucial support for the development of the journey of innovation—from a founding team to a workforce of over a thousand from the laboratory to

pharmaceutical innovation ecosystem. production lines and from pioneering science to benefiting patients. This publication reflects the Compa-

InnoCare has consistently advanced in sync with the industry. Focusing closely on four key drivers—policy ny’s long-term commitment to driving sustainable development with a people-centered approach.support capital empowerment talent development and industrial transformation—the Company has

achieved a series of significant accomplishments contributing to China’s emergence as a strategic hub

for global biopharmaceutical innovation. In the coming decade the Company will continue to center its

efforts on three core strategic objectives: innovation commercialization and internationalization thereby

supporting the high-quality development of China’s biopharmaceutical industry and benefiting patients

worldwide.Lyrics and Score of Promise to Life

2025 International Conference on Biopharmaceutical Innovation

181901

Exemplary Governance

Sustainable Advancement

SDGs Addressed in this Chapter

InnoCare places a premium on exemplary corporate governance continuously refining

its governance framework and decision-making processes. We have established a

comprehensive end-to-end risk management and control system and strictly adhere to

the highest standards of business ethics and conduct thereby supporting the Group's

long-term and sustainable development.InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Corporate Governance Composition of the Board of Directors

InnoCare is committed to building a scientific standardized efficient and transparent corporate governance system The independence and diversity of the Board of Directors are core to ensuring InnoCare's sustainable development.continuously optimizing the corporate governance structure continuously improving the diversified composition of As of the end of the Reporting Period the Board of Directors had a total of 7 directors including 3 independent

the board of directors and effectively protecting the legitimate rights and interests of investors through improving directors and 4 female directors. The proportion of independent directors was about 43% and the proportion of

investor communication mechanisms and strengthening information disclosure providing solid governance female directors was 57%.guarantees for the sustainable and high-quality development of the enterprise. The Group adheres to stringent standards in upholding director independence explicitly requiring independent

Corporate Governance Structure directors to maintain an impartial position and provide objective advice in the execution of their oversight duties.In the process of selecting independent directors the Group focuses on reviewing the independence of candidates'

InnoCare has formulated its Articles of Association in accordance with laws and regulations such as the Company identities and relationships and requires them to sign relevant independence documents to ensure the effective

Law of the People’s Republic of China the Securities Law of the People’s Republic of China the Code of Corporate performance of independent directors from a procedural perspective effectively improve the supervisory efficiency

Governance for Listed Companies and the Hong Kong Companies Ordinance combined with actual circumstances and decision-making quality of the Board of Directors and enhance the fairness and transparency of corporate

to ensure scientific and high-quality governance. In addition in 2025 based on the latest regulatory requirements governance.the Group revised 9 systems including the Management Measures for A-share Fundraising and the External Guarantee In the nomination and appointment of Board members the Group comprehensively considers a multidimensional

Management System and formulated the Management System for Director and Senior Management Resignation range of factors including candidates' professional experience expertise knowledge structure gender and age

and the Investor Relations Management System to continuously improve the Company’s governance system and distribution cultural and educational background ethnicity and length of service thereby systematically advancing

enhance the level of corporate governance. Board diversity. The members of the Board of Directors of InnoCare have a profound industry accumulation and

InnoCare has established a three-level governance structure with the Shareholders’ General Meeting Board of Direc- a complex professional background covering fields such as business operation management biopharmaceutical

tors and Senior Management as the core. Through clear division of responsibilities and authorization arrangements technology clinical research and development cutting-edge life sciences and financial investment management

it ensures that all governance layers operate efficiently and collaboratively on the basis of legal compliance effectively providing cross disciplinary and high-level professional support and forward-looking guidance for the Company's

safeguarding the common interests of all shareholders and assisting the long-term development of the Company. strategic formulation and major decisions.Corporate Governance Structure

Shareholders’

*?Convened in accordance with the Articles of Association.General Meeting

*?Responsible for key decisions such as approving overall business and investment plans electing

or replacing directors and reviewing annual reports and major financial matters.*?One shareholders' general meetings were convened in 2025.*?As the executive body for resolutions of the General Meeting of Shareholders and the decision-

making body for the Company's operations and management it is responsible for convening the

General Meeting of Shareholders and reporting on its work; formulating operational management

Board of strategies and supervising their implementation by senior management; and monitoring the

Directors Group's operational and financial performance.*?Oversees three specialized committees: the Audit Committee Remuneration Committee and

Nomination Committee each responsible for specific areas of governance and oversight to

ensure the fairness and independence of corporate governance decisions.*?In 2025 the Group held a total of 10 Board meetings. The Board Audit Committee convened

5 times the Board Nomination Committee convened 3 times and the Board Remuneration

Committee convened 4 times.Senior

Management *?As the executive level of the board of directors' decision-making based on professional functions

responsible for supervising the daily operations and management of the Group and regularly

reporting operational and financial performance to the board of directors.

22 23InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Diversity of the Board of Directors' Composition Protection of Investors' Rights and Interests

In order to effectively protect the core rights and interests of shareholders such as the right to know participation

Commission Appointment 1

Industry/Professional and decision-making the Group has formulated and continuously improved the Investor Relations Management

Title Name Gender Age

Audit Remuneration Nomination Background System systematically constructed a standardized and normalized investor communication mechanism continu-

Committee Committee Committee ously improved information disclosure mechanism strengthened the trust relationship and connection between

investors and the Company and jointly built a long-term and stable value cooperation ecosystem.Pharmaceutical Information Disclosure

R&D microbiology

bioscience with

Chairman The Group strictly adheres to the relevant laws regulations and regulatory provisions of the listing location adheres

Jisong Cui Female 62 M C more than 25 years of

and CEO experience in R&D and to the principles of openness fairness and transparency in disclosure continues to strengthen information disclosure

Company management that has a significant impact on investors' value judgments and decisions and gradually expands the breadth and

in the pharmaceutical

industry. depth of voluntary disclosure content to help investors comprehensively and accurately understand the Company's

strategic direction operating results and development prospects. During the Reporting Period the Group published

Biological sciences and a total of 126 A-share announcements and documents as well as 67 H-share announcements through the official

Executive

Renbin Zhao Female 57 biotechnology bio- websites of the Shanghai Stock Exchange the Stock Exchange of Hong Kong Limited and the Company. During

Director chemistry and molecu-

lar biology. the Reporting Period the Group was awarded the highest level of information disclosure on the Shanghai Stock

Exchange - A level - for its outstanding performance in the authenticity accuracy completeness and timeliness of

Biological sciences and

biotechnology bio- information disclosure.Shi Yigong Male 58 physics and biophysical

Non Exec- chemistry; Academician In parallel in response to the distinctive characteristics of the biopharmaceutical industry and key investor concerns

utive Di- of the Chinese Academy the Group proactively and voluntarily discloses timely updates on the clinical trial progress and pivotal R&D develop-of Sciences.rector ments of its major pipeline assets such as orelabrutinib ICP-332 ICP-488 and zurletrectinib (ICP-723). This ongoing

Biomedicine with ap- practice enhances R&D transparency and assists investors in accurately assessing the development trajectory and

Xie Ronggang Male 40 M proximately 10 years of long-term value of the Group’s innovation pipeline.investment experience.Investor Communication

Accounting and busi-

ness administration The Group continues to improve its diversified communication system for investors optimize online and offline Hu Lan Female 54 C C with over 20 years of ac- communication channels and formulate the Shareholder Communication Policy and the Investor Relations

counting experience.Management System as institutionalized guarantees. The Group strengthens two-way interaction with shareholders

through timely issuance of shareholder meeting notices active response to shareholder inquiries and effective

Inde- Life sciences infectious

Dong Dandan Female 42 M M M diseases molecular mi- protection of shareholder voting rights ensuring efficient and smooth communication and continuously improving

pendent crobiology. corporate governance transparency and shareholder participation.Non-exec-

utive Di- Biochemistry and cell "Shareholders Come" - Investors Visit InnoCare Activity

rector biology expert Chair Profes-

Kunliang sor and PhD Supervi-

Male 62 M sor at the School of Life

Guan Sciences Westlake Uni- On June 17 2025 the Group successfully held the themed open day event "Shareholders Come –

versity with 30 years of Investors Visit InnoCare" which attracted nearly 70 attendees including institutional investors analysts

research experience in

biology. and representatives of major financial media. During the

event visitors toured the Company's exhibition hall and R&D

laboratories on-site gaining in-depth insight into the Company's

strategy and R&D progress through face-to-face discussions.This activity significantly enhanced the interactivity and

—

transparency of shareholder communication further solidifying

the foundation for investor rights protection.

1?"C" represents the Chairman of the Committee of the Board. "M" represents a member of the relevant board committees.

Investors Step into InnoCare event site

24 25InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Risk Control Responses to Major Risks in 2025

InnoCare has established and continuously optimized a risk assessment mechanism and compliance management

system dynamically identifying evaluating and responding to various internal and external risks laying a solid Main Risks Management Practices

foundation for the long-term sustainable development of the business.*?Regularly conduct monthly comprehensive operational analysis assess potential opera-

Risk Management tional risks and deploy corresponding response strategies.*?Establish a monthly cross departmental marketing meeting mechanism collaborate to

InnoCare has established a risk management organizational structure consisting of the Board of Directors the Audit develop marketing and production plans clarify sales forecasts orders production and

Committee and the Internal Control Department. This forms a clear top-down three-tiered governance and control procurement arrangements.Business Risk

structure providing robust assurance for the Company’s overall risk management. *?Promote standardized contract templates and strengthen the approval management of

contract signing and business expenses.Risk Management Structure and Responsibilities *?Designate the Compliance and Internal Control Department as the main responsible depart-

ment for risk management responsible for reviewing and supervising key projects and

activities.Board of *?Serves as the key decision-making body for internal risk management and control.Oversees the planning implementation and ongoing monitoring of the Company's

Directors risk management strategy. *?The R&D project is initiated by the medical department based on sufficient argumentation

identifying potential risks and submitting them to the monthly management meeting for

risk assessment and decision approval identifying and controlling risks from the source.R&D Risk

*?After the project is approved the project management team strictly implements stand-

*?Supervises and reviews the effectiveness of the Company's internal control and risk ardized processes clarifies risk registration monitoring nodes and division of responsi-Audit

management systems. Provides independent assessments and recommendations bilities ensuring that the project approval process is traceable and risks can be controlled.Committee to ensure proper oversight.*?Establish a comprehensive system for monitoring and reporting adverse drug reactions both

Internal Control

*?Responsible for implementing risk management strategies at the management level; internally and externally. Through unified training public opinion monitoring and process

Department &

*?Regularly assessing the internal control system and measures; Risk of Adverse Drug standardization we ensure that internal personnel and third-party suppliers can effectively

Compliance and identify and report in a timely manner.*?Identifying assessing and addressing major risks. Reactions

Internal Audit Department *?Regularly integrate and analyze all reported information and develop and promote the

implementation of corresponding risk control and quality improvement measures based

on the analysis conclusions forming a management loop.The Group continues to promote a systematic risk management process regularly conducting comprehensive risk

identification analysis and evaluation in key areas such as R&D clinical operations procurement management

supply chain management product supply quality management commercial operations financial management *?By implementing the annual budget management system optimizing internal resource

and human resources. Based on the evaluation results and business reality the Group has identified risk control allocation and actively exploring diversified financing channels the Company's financial

risk resistance and response ability can be systematically enhanced.objectives in various fields continuously developed and optimized targeted risk control measures and implemented Financial Risk

*?Establish a standardized financial report preparation and review mechanism clearly define

responsible persons to ensure accountability. The progress and effectiveness of the Group's related work are regularly the process specifications and review responsibilities for monthly quarterly and annual

reported to the audit committee forming a closed-loop management mechanism from identification response to financial reports and ensure timely and accurate financial information.supervision and reporting.*?Establish strict distributor screening standards standardize credit risk assessment and

dynamically adjust distributor credit ratings every six months.Credit Risk

*?Establish a systematic accounts receivable management mechanism to ensure timely

updates of credit information and achieve effective control of credit risks.

26 27InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Main Risks Management Practices

Theme training on Steady Progress Integrity as Our Compass

*?Establish a sound EHS responsibility system for all employees. On June 30 2025 the Group continued to strengthen the risk and compliance awareness of all employees

*?Establish a comprehensive EHS management system systematically identify EHS risks and and established a normalized publicity and education mechanism based on the exchange platform ofcarry out hierarchical control of risks. Steady Progress Integrity as Our Compass. The platform has set up a column titled “Management Talks*?Regularly conduct internal audits external evaluations and employee feedback continu- on Compliance” to promote the top-down dissemination of compliance concepts. The Group focuses on

ously optimize the EHS management system based on the results of EHS risk monitoring

EHS Risk key risk areas enhances the risk identification and prevention capabilities of all employees enhances the

and evaluation and ensure effective control of EHS risks. overall compliance culture atmosphere and risk resistance ability of the Company.*?Regularly conduct EHS training to enhance employees' safety awareness.*?Develop comprehensive emergency plans for safety production accidents and sudden

environmental events regularly organize emergency drills and enhance the ability to

respond to emergencies.*?Establish a sound compliance management system standardize employee agreement

signing and supplier behavior management and dynamically follow up on domestic and

Partner foreign compliance regulatory requirements updates.Compliance Risk *?Clarify the standards and materials for partner qualification review and have the procure-

ment department independently complete the admission qualification review. New admit-

ted partners are required to provide due diligence reports in accordance with regulations.Internal Training Communication Materials

*?Establish and continuously improve the information security management system regularly

update the management system strictly regulate visitor information management and

external document circulation.*?Implement full link data security management covering the complete data lifecycle from

Information information systems to personal terminals.Security Risk *?Continuously strengthen information security protection capabilities including build-

ing disaster recovery infrastructure strengthening data backup and encryption measures

upgrading the protection level of cloud data centers and regularly organizing vulnerabil-

ity scanning penetration testing and information security training for all staff to build a

comprehensive security defense line.The Group has established a normalized risk awareness cultivation mechanism and through regular organization of

risk themed training and policy promotion we ensure that the Company’s risk governance concept is effectively trans-

mitted to all employees continuously improving the organization’s risk identification and prevention capabilities.

28 29InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Internal Control Management The Group regularly organizes specialized internal control training to ensure that employees at all levels timely

grasp the requirements of internal control standards. The training covers key job groups such as new employees

InnoCare attaches great importance to internal control management constructs a system including the Company commercial teams and clinical operation teams comprehensively enhancing the ability to build an internal control

System Document Management Regulations and the Internal Audit Management System and continuously updates risk culture and deepening the internal control management thinking of all employees. In 2025 the Group conducted

it based on changes in internal and external risks promoting the continuous improvement of the internal control specialized internal control training for all employees. This program included training on contract approval seal

system. The Group has achieved comprehensive coverage of core business processes such as fund management usage and archiving process training compliance practice training tailored to different functional teams and special-

procurement and payment asset management and production inventory by promoting institutional standardiza- ized training on commercial contract documentation standards. These initiatives effectively enhanced employees'

tion optimizing control matrices conducting internal control evaluations and conducting internal control testing. competency in compliant operations at their respective positions and ensured adherence to internal controls.In addition the Company reports on the progress of internal control to the Board’s Audit Committee of the Board of

Directors on a quarterly basis listens to opinions and follows up on implementation. The Internal Control Depart-

ment also provides risk management and control consulting providing suggestions on reducing business risks and Specialized Internal Control Training - Contract Approval - Seal Usage - Archiving Process and

improving operations to achieve safe and efficient operations. Operational Requirements

Internal Control Management System The Group has conducted specialized internal control training for all employees focusing on the end-to-end

operational standards for the “Contract Approval Seal Usage and Archiving” process. The training system

Internal Control Standardization explains the key control points compliance requirements and system operations of contract initiation

*?Standardize and update policy document templates unify their structure and clarify their content. review signing and archiving aiming to strengthen employees' understanding and execution of the

*?Determine the responsibilities of the responsible department including cross departmental responsibility negotiation contract lifecycle management system and prevent legal and operational risks from the business source.answering questions summarizing and conveying common problems.*?Establish a regular review mechanism and event driven responsive revision and abolition process.*?Clarify the filling requirements and upload standards for the “Policy/System Application Form” in the OA system.*?By regular follow-up timely communication archive management and permission control ensure that the system is trace-

able and executable and form a management loop.Internal Control Matrix

*?Establish and continuously improve internal control activities around key links such as fixed assets EHS pharmacovigilance

sales receipts and procurement payments. Through regular evaluation and dynamic adjustment mechanisms effectively

identify and respond to various operational risks.*?By constructing a full process control process covering R&D and clinical projects systematically sorting out seal management

mechanisms and improving standardized procedures for procurement receipt and payment we continuously improve

the compliance and execution efficiency of business processes. Specialized Internal Control Training

Internal Control Assessment Mechanism

*?The Internal Audit Department conducts special audits to check the design soundness and execution compliance of the

internal control system. The Internal Control Department regularly conducts internal control evaluations to evaluate the

effectiveness of control measures and jointly constructs an evaluation system covering the three dimensions of design

execution and effectiveness comprehensively identifying potential management deficiencies.*?In response to the discovered problems the Internal Audit Department and the Internal Control Department promptly report

and communicate with the Management and relevant business departments collaborate to develop corrective measures

clarify the responsible units and completion deadlines and track and verify the progress of the rectification promote effec-

tive problem-solving and achieve a management loop from problem identification to rectification implementation.Internal Control Testing

*?Conduct internal control testing around key business processes promptly identify control weaknesses in operation imple-

ment targeted improvement measures and ensure the achievement and effective implementation of risk control objectives.*?According to the degree of impact internal control defects are classified into major significant and general levels. As of the

end of the Reporting Period no significant or significant internal control defects were found within the Group and all identi-

fied general defects have been rectified achieving a 100% closed-loop rectification.

30 31InnoCare 2025 ESG Report Exemplary Governance Sustainable Advancement

Business Ethics and anti-corruption clauses into contracts jointly building an integrity value chain.InnoCare always adheres to integrity and compliance and continuously promotes the construction and improve- Business Ethics Training

ment of the business ethics governance system with this as the core. By continuously strengthening the promotion

To ensure that compliance awareness is embedded and effective constraints are established the Group has

of integrity culture and improving effective complaint reporting mechanisms we actively create a clean transparent

established a systematic compliance promotion mechanism covering training auditing and supervision.and honest working atmosphere.As of the end of the Reporting Period the Group conducted a total of 26 specialized compliance training sessions

Business Ethics Governance targeting key positions and business processes. The training content comprehensively covered anti-corruption

The Board of Directors of InnoCare is fully responsible for the supervision and review of business ethics related policy interpretation commercial bribery risk prevention updates on the latest regulations and practical guidance

matters. The Audit Committee and Compliance Committee provide specific guidance and supervision to the Internal on internal systems with a cumulative total of 2173 participant attendances effectively improving the compliance

Control Department and the Legal Compliance Internal Control and Audit Department in implementing business awareness and practical ability of all staff and building a solid personnel foundation for corporate compliance

ethics related work thereby systematically regulating the business behavior of the entire Group and ensuring that governance.ethical standards are integrated into daily operations and management practices. Reporting Management

The Group strictly adheres to laws and regulations such as the Anti-Money Laundering Law of the People's Republic

of China the Pharmaceutical Industry Compliance Management Practices Interim Provisions on Banning InnoCare attaches great importance to the construction of a business ethics supervision and reporting mechanism. and the

Commercial Bribery Employee Handbook In strict accordance with relevant national laws and regulations it has formulated and continuously improved inter- and continues to improve internal governance systems such as the the

Anti-Corruption and Anti-Bribery Policy the Anti-Fraud and Reporting Management System and the Guidelines nal regulations such as the Anti-Fraud and Reporting Management System systematically standardized reporting

for Interaction and Exchange with External Stakeholders channels and handling procedures to ensured that all complaints and reports are addressed promptly and effectively. Clearly define the standards and control mechanisms

for business ethical behavior and always adhere to the principle of zero-tolerance for any behavior that violates The Group has established multiple accessible channels for reporting and complaints encouraging all stakeholders

business ethics. including employees and partners to report actual or suspected misconduct via dedicated hotlines email letters

The Group strictly adheres to the Anti-Unfair Competition Law of the People's Republic of China and other means. After receiving the report the Group will strictly follow the established investigation process to and resolutely

carry out verification work. For cases that have been verified to be true especially those involving litigation risks the

resists any act of obtaining trading opportunities through unfair means. The Group has a dedicated compliance and

Group will resolutely promote rectification and handle them seriously in accordance with the law and regulations

audit department responsible for supervising and reviewing business activities and establishing smooth reporting

effectively maintaining the integrity of the enterprise's business environment and compliance culture.channels to ensure the effective operation of internal supervision mechanisms. The Company has established a

comprehensive contract approval system process and related system with the legal department reviewing the Compliance and Internal Audit Reporters decide whether The authorized Audit Committee to submit

commercial terms antitrust and unfair competition clauses in the contract to ensure compliance with relevant Department/Audit Committee personnel carry out provides feedback on the case to relevant

laws and regulations. authorize responsible personnel internal the investigation public or regulatory

(suitable personnel team

In addition the Group always adheres to the principle of fairness and reasonableness in entering into contract investigations results authorities/external or department within the Group) auditors

terms and clarifying the rights and obligations of all parties in cooperation with distributors and suppliers. In 2025

the Group and its employees did not have any lawsuits or administrative penalties related to unfair competition. Reporting Handling Process

The Group conducts special business ethics audits based on operational needs develops detailed plans for high-risk To effectively protect the legitimate rights and interests of whistleblowers the Group has established and strictly

business areas proactively identifies potential risks and promotes high-quality implementation of anti-corruption implemented the Whistleblower Protection System and the Reporting Confidentiality System. These policies explicitly

and integrity management through investigation and improvement. The Internal Audit Department conducts audit prohibit the disclosure of a whistleblower's identity or the specifics of a report without their consent. At the same

work with a risk-oriented approach while the compliance department conducts annual systematic risk assessments time to ensure that whistleblowers are fully protected during the investigation process the Group firmly prohibits

identifies potential corruption and bribery risk points through data analysis and cost sampling evaluates the effec- all discriminatory and retaliatory actions against whistleblowers and through system design and process control

tiveness of control mechanisms and reports the evaluation results and improvement suggestions to the Company's comprehensively guarantees the personal dignity and occupational safety of whistleblowers creating a safe and

Top Management. The Company regularly reports on the implementation of anti-corruption policies at management trustworthy internal supervision environment.meetings and reviews major compliance issues. Reporting hotline: (010) 66609747

The Group has established clear codes of conduct prevention mechanisms and disciplinary standards based on its

internal system. All employees are required to understand and sign the Anti-Commercial Bribery Agreement to ensure Reporting Email:legal_compliance@innocarepharma.com

that they are aware of and comply with relevant laws and regulations. At the same time the Company extends the Channels Mailing Address: Legal and Compliance Department InnoCare Pharma Building 8

integrity system and business ethics practice requirements to suppliers distributors and other partners through the

Guidelines for Interaction and Exchange with External Stakeholders and by incorporating anti-commercial bribery Peking University Medical Industrial Park Changping District Beijing 102206

In 2025 the Group did not encounter any lawsuits or major administrative penalties related to unfair competition

corruption bribery or money laundering.

323302

Green Operation治 理卓越

Future Built on I行nt稳eg致rity远.SDGs Addressed in this Chapter

InnoCare has always adhered to the concept of sustainable development and has

thoroughly implemented China's "dual carbon" goals. The Group actively responds

t诺o诚 th健e 华ch以al企le业ng卓e 越of治 c理lim为a核te心 ch a持n续ge健 b全y 治co理nt架in构uo与u决sly策 s机tre制ng t建he立n覆in盖g e全n链vi条ro的nm风e险nt管al

g控o体ve系rna n并ce严 c格ap遵ab循il最itie高s 標an準d 的re商so业ur道ce德 ef行fic为ie準nc则y. It 助is 力co本m集m团itte长d期 to稳 a健dv发an展ci。ng green andlow-carbon operations striving to build a resource-efficient and environmentally friendly

benchmark enterprise and contributing to a sustainable ecological future.InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Climate Change InnoCare Climate Scenario Selection

Based on the disclosure framework advocated by the International Sustainability Standards Board (ISSB) 2 the

Group systematically carries out climate-related management from four dimensions - governance strategy risk Scenario Scenario Scenario Characteristics Temperature Rise

management and metrics and targets. The Group proactively identifies and analyses climate-related risks and type Selected

opportunities and deeply embeds climate response measures into its overall development vision with the aim of

comprehensively enhancing its resilience to climate challenges. In this context the global community is working to-

gether to promote strong climate policies and the

Governance energy system is rapidly transitioning towards re-

newable energy resulting in a significant reduction

The Group is committed to building and continuously optimising a multi-level climate governance architecture. SSP1-2.6 Below 2 ° C

in dependence on fossil fuels. Greenhouse gas emis-

As the highest decision-making body for climate management the Board of Directors assumes overall leadership

sions have been rapidly controlled with the poten-

and oversight responsibilities for related matters. Functional departments across the Group integrate climate risk

tial to control global temperature rise within 2 ° C and

management into their daily operations ensuring the substantive implementation of climate strategies and carbon

reduction tasks through normalised execution and implementation mechanisms. Physical sce-

strive to achieve the goal of 1.5 ° C.nario 3

Strategy

This scenario represents a development path that

The Group has conducted in-depth identification and assessment of the potential impacts of climate change is highly dependent on fossil fuels and has weak cli-

comprehensively analysing its multidimensional effects on business operations. The Group dynamically adjusts its mate policies. Global fossil energy consumption con-SSP5-8.5 Above 4 ° C

management strategies and response mechanisms and continuously enhances its environmental adaptability and tinues to grow and greenhouse gas emissions remain

climate resilience through the scientific optimisation of resource allocation. high which may lead to a global temperature rise of

Scenario Selection and Time Horizons over 4 ° C by the end of this century.The Group is committed to adopting scientific and systematic approaches to identify and assess the impacts

of climate-related risks and opportunities on the Company. During the Reporting Period in accordance with This scenario sets a strict goal for the global energy

International Financial Reporting Standard S2 - Climate-related Disclosures and Consultation Conclusions on system to achieve net zero carbon dioxide emissions

Proposals to Enhance Climate-related Disclosures under the Environmental Social and Governance Framework Net Zero Emis- by around 2050. Its core path includes the absolute

and taking into account the characteristics of the industry and the Group's actual operations the Company selected sions Scenario dominance of renewable energy comprehensive 1.5°C

climate scenarios developed by mainstream international institutions and conducted scenario analysis with reference (NZE) electrification of terminal energy use and wide-

to the industry in which it operates. spread application of breakthrough technologies

such as carbon capture and hydrogen energy.Transforma-

tion

scenario 4 This scenario is only based on the climate and energy

policies currently issued and implemented by various

countries reflecting the possible future under the ex-

Stated Poli-

isting policy framework. Under this path the deploy-

cies Scenario Above 2.0 ° C

ment of clean energy is accelerating but the global

(STEPS)

emission reduction is slow making it impossible to

achieve the temperature control goals of the Paris

Agreement.——

2?The International Sustainability Standards Board (ISSB): An independent international standard-setting organization established by the

International Financial Reporting Standards (IFRS) Foundation. It was officially launched on November 3 2021 at the 26th United Nations Climate 3?The Shared Socioeconomic Pathways (SSPs) scenarios published by the Intergovernmental Panel on Climate Change (IPCC).Change Conference aiming to develop sustainability reporting standards that are aligned with the International Financial Reporting Standards (IFRS). 4?The Transition Scenario published by the International Energy Agency (IEA).

36 37InnoCare 2025 ESG Report Green Operation Future Built on Integrity

At the same time taking into account InnoCare’s long-term development strategy as well as industry trends and

the macro environment the Group clearly defined short-term medium-term and long-term time horizons and

conducted climate risk and opportunity assessments across different time horizons.Short-term Medium-term Long-term

1-3 years 3-10 years More than 10 years

Risk and Opportunity Assessment

The Group classifies climate change management subjects into risks and opportunities with risks further divided

into physical risks and transition risks. During the Reporting Period we updated the inventory of climate-related

risks and opportunities to ensure its comprehensiveness and timeliness. The current inventory covers 2 physical

risks 3 transition risks and 6 opportunities. The Company assessed the identified risks and opportunities under

different scenarios and across different time horizons and formulated targeted response measures accordingly.The

Company aligns with the low-carbon transition trend and is committed to driving sustainable high-quality growth

in the course of green transformation.Climate Change Identification and Response

Degree of Impact

Time Potential Financial

Risk Type Climate-related Risks Potential Impact Response Measures

Horizon Impact

SSP1-2.6 SSP5-8.5

Short-term Low Low

*?It is expected that the frequency and destructive power of extreme weather *?Establish a real-time meteorological warning system

Typhoon disasters such as typhoons and floods will increase in the future which may Medium-term Low Low to ensure timely acquisition and release of extreme

cause damage to production facilities threat to employee health and inter- weather information in daily operations;

ruption of business continuity leading to an increase in operating costs and a Long-term Low Low *?Rising operating costs *?Improve the emergency management system and

Acute risk decline in operating revenue. *?Decline in operating response process develop feasible emergency plans

*?If the Group lacks an efficient emergency response mechanism in the event of Short-term Low Low income and ensure that the Group can quickly carry out

extreme weather events it is difficult to ensure the stability of business opera- disposal and recovery work after sudden disasters

Flood tions which will have a negative impact on the Company's business performance Medium-term Low Low fully ensuring the smooth operation of research and

and brand image leading to a loss of operating revenue. development and production.Long-term Low Low

Physical risk

Low Low

Short-term

Low Low *?Continuously invest special funds to enhance the *?Asset value decrease resilience and ability of existing equipment and facil-

Global Warm- *?The long-term climate risks caused by global warming such as sustained sea ities to withstand long-term climate disasters;

ing / Average level rise extreme high temperatures and droughts will threaten the normal Low Low

*?Increase in equip-

Chronic risk operation of business. Our operating points located in coastal areas may face Medium-term ment maintenance *?Flexibly adjust the operation time according to

temperature challenges such as asset value damage relocation pressure and personnel costsLow Low specific weather conditions and develop a special

rise health and safety. *?Decline in operating high-temperature emergency rescue plan to compre-

income hensively ensure the life safety and physical and Low Low mental health of Company employees.Long-term

Low Low

38 39InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Climate Change Transition Risk Identification and Response

Degree of Impact

Climate-related Potential Financial

Risk Type Potential Impact Time Horizon Response Measures

Risk Impact

IEA NZE 2050 IEA STEPS

*?The ESG working group dynamically tracks the

*?The increasingly strict regulatory trend of global and

Short term Low Low evolution of laws and regulations develops work domestic climate policies and laws and regulations has - plans and regularly submits special reports to the

raised higher standards for enterprises' environmental board of directors;

governance capabilities which not only limits business

activities that generate high carbon footprints but also *?Optimize the energy consumption structure and

correspondingly increases the compliance costs of enter- emission management strategy of our group Policy and regula- prises; Medium-term Low Low *?Rising operating costs improve energy efficiency through the imple-

tory risk mentation of energy-saving technology renova-*?The regulatory authorities and capital markets in each tion projects and ensure compliance with various

operating location continue to improve their regulatory environmental protection requirements;

requirements for environmental information disclosure. If

the Group fails to strictly fulfill its disclosure obligations in *?Strengthen the disclosure quality of climate-re-

accordance with the standards it will face potential compli- Long-term Low Low lated information and scientifically set the

ance risks. Company's energy-saving and carbon reduction

phased goals.Short-term Low Low

*?Establish and improve a regular communication

mechanism with various stakeholders accurately

*?Given the increasing attention of various stakeholders to identify and respond to the expectations and

the climate performance of enterprises if the Group fails to *?Rising financing costs demands of all parties;

Transition Risk Reputation risk take substantive response actions or lacks transparency and timeliness in climate-related information disclosure it may Medium-term Low Low *?Decline in operating

*?Disclosure of the Group's strategic planning and

income practical progress in climate governance through trigger social questioning and damage brand reputation the annual ESG reporting system showcasing

thereby shaking the foundation of long-term development. the long-term investment in low-carbon trans-

formation to the public and maintaining a good

corporate image.Long-term Low Low

Short-term Low Low

*?Continuously deepen refined energy manage-

ment prioritize the selection of low energy

*?Our group needs to upgrade low-carbon technology and consumption and high efficiency equipment

iterate processes for various equipment in the production during the procurement phase and reduce

process. By phasing out high energy consuming facilities technology selection risks from the source;Technical risk and introducing energy-saving processes this will increase Medium-term Low Low *?Rising operating costs *?Actively layout clean energy applications

capital and daily maintenance costs in the short term increase financial support for process optimi-

leading to an increase in operating costs. zation reserve project budgets and minimize

the impact of technological transformation on

Company operations.Long-term Low Low

40 41InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Climate Change Opportunities

Degree of Impact

Opportunity Climate-related Potential Financial

Potential Impact Time Horizon Response Measures

Type Opportunities Impact

IEA NZE 2050 IEA STEPS

Short-term Low Low

Strategically expanding the application scope and procure- *?Promote energy-saving projects and technolog-

Requirements for ment proportion of renewable energy reducing dependence ical development

Energy source the use of renewable on traditional fossil fuels and laying a solid foundation for re- Medium-term Low Low *?Decline in operat-ing costs *?Reduce the use of non renewable resources and

energy sponding to energy market fluctuations and ensuring busi- energy in the design and manufacturing process

ness continuity. and implement recycling and reuse projects.Long-term Low Low

Short-term Low Low

Opportunities for re- *?Implement process optimization equipment

Resource effi- Reduce operating costs by improving the efficiency of energy *?Decline in energy upgrade facility renovation and technologyducing energy con- Medium-term Low Low

ciency water materials and other resources. costs *?Innovation and other measures to improve

sumption energy efficiency

Long-term Low Low

Short-term Low Low

Global market de-

Continuously insight into market trends proactively capture

mand for low-car-

low-carbon health trends rely on deep scientific research ac-

bon *?Rising R&D costs *?Implement and expand the proportion of product

Market cumulation to develop pharmaceutical products that meet Medium-term Low Low

Green products and *?Increase in operat-

green certification and energy-saving technology

green and sustainable standards and actively explore emerg- ing income application.services

ing green market space while meeting patient needs.Growth in demand

Long-term Low Low

Short-term Low Low

*?By reducing unnecessary physical testing paths

Products and Digital R&D oppor- Accelerate innovative drug screening and clinical trial man-

Medium term Low Low *?Reduced R&D costs and resource consumption while reducing -

Services tunities agement using AI and digital tools. research and development carbon emissions

intensity the product launch cycle is shortened.Long-term Low Low

42 43InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Risk Management Metrics and Targets

InnoCare is fully aware of the substantive challenges climate change poses to business continuity and has formally To deepen its long-term climate governance and ensure the effective implementation of its emission reduction

integrated climate risk management into the Group’s existing operational risk management system. Supported commitments InnoCare has established total energy consumption and greenhouse gas emissions as core perfor-

by the coordinated governance structure formed by the Board of Directors the Audit Committee and the Internal mance dimensions for measuring the effectiveness of climate governance and has scientifically set corresponding

Control Department the Group has established a top-down climate risk transmission mechanism to ensure clear energy-saving and carbon-reduction targets. The Group conducts regular monitoring and annual reviews of key

responsibilities and efficient operation. In 2025 the Group further clarified its climate risk management procedures indicators enabling precise evaluation of progress in climate action and target achievement.At present the company

including risk identification assessment and prioritisation response monitoring and reporting. mainly reduces carbon emissions through active emission reduction measures and has not yet adopted internal

carbon pricing for management purposes.Regularly identify changes in climate-related risks and their potential impact

Risk Identification on the Company through data monitoring business process evaluation and InnoCare Energy-saving and Emission-reduction Targets

external agency consultation.Target Indicator Target Progress

In order to further clarify the priority of climate change response measures Using 2023 as the base year reduce energy Energy use intensity in 2025 decreased

Risk Assessment and Priori- we evaluate the degree of impact of various risks and opportunities form a Energy Saving use intensity (MWh/RMB 10000) by 10% by by 57.71% compared with 2023 exceed-

tisation risk and opportunity impact ranking and screen out key climate-related risks 2028 ing the target

and opportunities.Using 2023 as the base year reduce green- Greenhouse gas emissions intensity in

Greenhouse Gas

We develop targeted response plans based on the severity of possible impacts house gas emissions intensity (tonnes CO2e/ 2025 decreased by 60.75% compared Emissions

Risk Response for different climate scenarios. RMB 10000) by 10% by 2028 with 2023 exceeding the target

Risk Monitoring Regularly monitor and report on the progress of climate risk management and

daily risk management work. Greenhouse Gas Emission Data of InnoCareand Reporting

Indicator Unit 2023 2024 2025

Total greenhouse gas emissions

tCO e 8752.97 9417.28 11048.97

(Scope 1+Scope 2) 2

Scope 1 Greenhouse gas emis-

tCO2e 20.01 22.75 769.73sions

Scope 2 Greenhouse gas emis-

tCO2e 8732.97 9394.52 10279.24sions

Greenhouse gas emission inten-

tCO e/RMB 10000 0.12 0.09 0.047

sity (Scope 1+Scope 2) 2

44 45InnoCare 2025 ESG Report Green Operation Future Built on Integrity

To ensure the highest level of compliance for construction projects the Company conducts rigorous environmental

Indicator Unit 2023 2024 2025 impact assessments for all new and expansion projects in accordance with the law and actively implements the

requirements set out in the Opinions on Strengthening the Environmental Impact Assessment of Construction

Total greenhouse gas emissions Projects Involving New Pollutants in Key Industries. In 2025 all projects put into operation by the Beijing Campus

tCO2e / / 49589.36(Scope 1+Scope 2+Scope 3) completed the environmental protection acceptance process upon completion and no environmental protection

violations occurred in its construction projects nationwide.Scope 3 Total greenhouse gas The Group has established a regular supervision mechanism and regularly organises internal EHS self-inspections

tCO2e / / 38540.39emissions and external environmental audits. During the Reporting Period Guangzhou InnoCare a subsidiary of the Group

successfully passed the third-party renewal audit for ISO 14001 Environmental Management System certification

and continues to hold this international certification. During the Reporting Period the Group was not subject to

Scope 3 Greenhouse Gas Emis- any material environmental administrative penalties and did not experience any environmental pollution accident.sions - Purchased Goods and Ser- tCO2e / / 2163.73

vices

Scope 3 Greenhouse Gas Emis-

sions - Upstream Transport and tCO2e / / 2.32

Distribution

Scope 3 Greenhouse Gas Emis-

sions - Downstream Transport tCO2e / / 36374.34

and Distribution

Environmental Management

InnoCare regards environmental friendliness as a fundamental principle of corporate development and fully

implements the concept of sustainable development. The Group strictly complies with environmental protection

laws and regulations and has established a systematic environmental management system to ensure ecological

protection and resource conservation across all operational links. By promoting green modes of operation the

Company fulfils its corporate responsibility for environmental protection.Environmental Management System

To ensure the standardisation and normalisation of environmental management InnoCare has established a

comprehensive EHS management system and built an environmental management structure. The Environment

Occupational Health and Safety Department serves as the core organisation and coordination unit for the Group’s

environmental management work guiding functional departments in implementing environmental protection

measures and monitoring and recording environmental performance in day-to-day operations.The Group strictly complies with laws and regulations such as the Environmental Protection Law of the People’s

Republic of China and steadily advances the development of its environmental management system. Through

continuous optimisation of the management system and in light of the actual operating conditions of each site the

Group has formulated and implemented 64 internal rules and procedures covering key control areas such as waste

gas wastewater noise and solid waste achieving full-process coverage of environmental management.

46 47InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Environmental Emergency Management The Group continues to advance the energy intensity target set in 2023 and dynamically optimises its energy-saving

and emission-reduction plans in light of its 2025 operating performance. The Company has strengthened energy

InnoCare attaches great importance to source prevention and control of environmental risks and is committed to conservation supervision across all business links to ensure that every carbon reduction measure translates into

building an environmental management mechanism that combines routine management with emergency response. substantive energy-saving results.The Group strictly follows regulatory requirements such as the Measures for the Administration of Emergency

Response Plans for Environmental Emergencies and the Administrative Measures for the Filing of Emergency

Response Plans for Environmental Emergencies of Enterprises and Public Institutions (Trial) and has systematically Energy intensity target:

prepared and filed documents including the Emergency Response Plan for Environmental Emergencies the On-site Using 2023 as the base year reduce energy use intensity (MWh/RMB 10000) by 10% by 2028

Disposal Plan for Environmental Emergencies and the Emergency Response Card for Environmental Emergencies.To further enhance environmental risk awareness and practical emergency response capabilities among all employ-

ees the Group carried out environmental emergency drills on multiple occasions during the Reporting Period effec-

Energy-saving and Emission-reduction Plans by Operational Stage

tively improving employees’ ability to handle sudden environmental incidents and strengthening the Company’s

environmental risk prevention and control capabilities.Purchase

Environmental Emergency Drill at InnoCare

*?When purchasing similar products prioritize equipment with lower energy consumption;

*?In 2025 the electrical equipment purchased for the Guangzhou InnoCare new project has reached the second level energy

efficiency standard with some equipment such as air compressors and refrigerators meeting the first level energy efficiency

On November 7 2025 Guangzhou InnoCare organised its annual environmental emergency drill to enhance standard.the Company’s emergency response and handling capabilities for sudden environmental incidents. The drill

simulated a fire in a centrifuge in Workshop F resulting in a large volume of accident wastewater entering

the rainwater drainage network. The emergency response team reacted promptly by closing the rainwater Research and development

gate valve to intercept the wastewater and divert it into the accident water tank after which the wastewater

*?Require employees to promptly adjust high energy consuming equipment such as laboratory fume hoods to the lowest gear

was transferred to the sewage treatment system for proper treatment to ensure compliant final discharge. after completing research and development experiments to reduce energy consumption.Resource Conservation

InnoCare firmly implements the development path of green conservation and takes multiple measures to optimize Production

the management mode of energy and resources. While reducing process waste it steadily promotes the achieve-

ment of various energy-saving and emission reduction goals and accelerates the construction of a green circular *?Optimize the production process route of orelabrutinib raw material reduce the cost of raw material materials reduce 2

and sustainable growth model through positive practical measures. production process steps and reduce equipment usage. It is expected to reduce the production of approximately 600 tons

of chemical waste annually;

InnoCare firmly follows the development path of green conservation and has adopted multiple measures to *?In the production process adjust the temperature and humidity control requirements of the pharmaceutical cold chain

optimise the management of energy and resources. While reducing process waste the Group steadily advances the warehouse reasonably based on the material properties reduce unnecessary steam humidification time and thus reduce

achievement of its energy-saving and emission-reduction targets accelerating the formation of a green circular energy use; By optimizing the spray drying process in the formulation production workshop the blank spray time was reduced from 9 hours to 1 hour saving 11760 kilowatt hours of electricity and reducing carbon emissions by 11.55 tons.and sustainable growth model through practical actions. *?Guangzhou InnoCare has added a duty mode in the air conditioning system of the factory area and the new project adopts

a local reactive power compensation scheme for power supply. Solar water heaters have also been constructed for the

Energy Management production of shower hot water heating; During the Reporting Period a total of approximately 610000kWh of chilled water

and electricity energy was saved and approximately 881 tons of industrial steam were saved.The Board of Directors of InnoCare is the highest governing body for sustainability matters and is responsible for

reviewing and approving the Group’s ESG goals and strategies including those related to energy management.The Group has established dedicated departments responsible for energy management led by the Engineering

Department to implement energy management plans and optimise energy-use efficiency. Through diversified online and offline communication and awareness-raising activities the Group has embedded

the concepts of energy conservation and carbon reduction into its corporate culture and promoted their implemen-

The Group strictly complies with legal requirements such as the Energy Conservation Law of the People’s Republic of tation through institutionalised and regular management measures. Through regular 5S inspections covering all

China and has formulated and implemented a series of internal control systems including the Energy Management departments the Company clarifies requirements on workplace cleanliness and electricity conservation continu-

Procedures. Clear standardised requirements have been established in areas such as energy metering and monitoring ously strengthening employees’ awareness of energy saving in their daily work and fostering broad participation.statistical analysis consumption quota management and energy-saving technical transformation laying a solid

institutional foundation for refined and digitalised energy governance.

48 49InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Water Resource Management Material Management

InnoCare is fully aware of the importance of water resource protection and is committed to improving the efficiency InnoCare has deeply integrated green environmental protection quality enhancement and efficiency improvement

of water recycling and reuse. The Group strictly implements laws and regulations such as the Water Law of the into its materials management system systematically advancing full life-cycle management of raw and auxiliary

People’s Republic of China and carries out refined water-saving plans across the entire process of water abstraction materials as well as packaging materials. By optimising production processes and deepening packaging reduction

and use. Through water-saving and consumption-reduction upgrades to equipment and facilities the Company and recycling the Group has significantly improved resource efficiency while strictly controlling quality and safety

continuously increases the reuse rate of reclaimed water and eliminates resource waste at the source. At present continuously reducing its environmental footprint and providing key support for sustainable manufacturing and a

none of the Group’s business locations is located in an area with water stress. green supply chain.Packaging Material Management

We continue to promote the scientific management and efficiency optimisation of packaging materials. Through

Water Conservation Measures iterative improvements to packaging material application schemes in production the Group fully implements the

principles of “lightweighting reduction and recyclability” in packaging management. While ensuring product safety

and quality the Company reduces material redundancy through process improvement and standardised manage-

ment and is committed to building a green packaging system across the full life cycle.Key initiatives for reducing packaging materials at Guangzhou InnoCare:

*?Adopting water-saving devices such as induction faucets and variable frequency water pumps to reduce water resource

waste caused by dripping and leakage; For commercial solid dosage products standardised cartons are fully adopted as outer

Promoting packaging packaging boxes together with standardised right-angle anti-counterfeiting sealing labels

standardisation effectively reducing the variety of packaging materials lowering inventory backlog and

freeing up warehouse space;

Optimising supplier Suppliers are continuously urged to improve carton production processes so as to reduce

processes the loss of packaging materials during production and transportation;

*?Configure a municipal reclaimed water recovery system and a water storage tank to recycle reclaimed water for toilet Improving production The embossing method for carton batch number steel stamps has been optimised reducing

flushing park road cleaning and green irrigation improving the level of water resource recycling; marking methods packaging material loss caused during the labelling process.Raw and Auxiliary Materials Management

We uphold the concept of green production and continue to promote refined management and efficiency

improvement in the use of raw and auxiliary materials. By optimising production processes and improving material

utilisation efficiency the Group seeks to achieve both resource conservation and environmental protection while

ensuring product quality and safety.*?Recycle clean air conditioning condensate and collect it into the reservoir; Recycling rainwater for green irrigation; During Guangzhou InnoCare has carried out key initiatives focused on saving raw and auxiliary materials and improving

the Reporting Period approximately 2000 tons of water resources were recycled and reused;

production efficiency. While continuously ensuring drug production quality the Company has achieved significant

results through process and technology improvements:

Based on a change assessment reducing the methanol blank-spraying time for orelabrutinib

solid dispersion from nine hours to one hour process validation has been completed and

Optimisation of the the change has been filed with the drug regulator. After adjustment each batch saves 200

spray-drying process kg of methanol with annual cumulative savings of 8400 kg of methanol 11760 kWh of

electricity and approximately 11550 kg of carbon emissions;

After assessing the change from three consecutive batches to six consecutive batches for

*?Recycling the concentrated water generated by the purified water system for cooling tower make-up water; During the orelabrutinib solid dispersion production and completing corresponding cleaning valida-

Reporting Period approximately 30000 tons of water resources were recycled and utilized. Extension of the tion the production process was further optimised. While ensuring cleaning quality met

continuous production standards each cleaning cycle saves 3520 kg of methanol with annual cumulative sav-

cycle ings of 56320 kg of methanol and approximately 77440 kg of carbon emission reductions

demonstrating the Company’s continued progress in process technology.

50 51InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Pollution Prevention and Control Wastewater Management

InnoCare firmly follows the path of green and sustainable development and regards pollution prevention and control InnoCare strictly complies with the Water Pollution Prevention and Control Law of the People’s Republic of China

as a core element of environmental management. The Group deeply integrates the concept of pollution reduction into and has internally implemented the Water Pollution Control Management Procedures to establish standardised

the entire production and operation process continuously strengthens the standardised and systematic manage- wastewater treatment processes. In 2025 the Group continued to implement the Operating Procedures for Waste-

ment of waste and emissions and rigorously implements source control and process supervision. The Company water Treatment Systems Operating Procedures for Wastewater Treatment Systems in the API Pilot Workshop and

is committed to building a pollution prevention and control system that covers the full value chain and reducing Management Procedures for Monitoring of Rainwater Discharge Outlets further consolidating the standardised

environmental impact through concrete action. management foundation for wastewater control.InnoCare has established a stringent emission control system to manage all types of waste throughout their full life

cycle - from generation and collection to final disposal - so as to minimise the negative environmental impacts of *?Classify and collect wastewater generated during production and operation according to the princi-production and operations. The Group has formulated systematic waste reduction plans and continuously strength- Treatment ples of “rainwater and sewage separation clean and sewage separation and differentiated treat-ens its environmental governance foundation through routine waste classification and resource recovery practices. Methodment”.*?After pre-treatment the raw material wastewater is collected together with other wastewater

through the sewage pipe network and sent to the self-built sewage treatment system. Chemical

precipitation biodegradation and other processes are used to treat and meet the standards before

Target Indicator Target Progress being discharged into the municipal pipeline network. Accident emergency pools emergency

gate valves and other facilities are set up according to regulations to ensure that the wastewater is

discharged in accordance with the standards;

*?According to the requirements of environmental impact assessment and pollution discharge permit

install online monitoring facilities for wastewater operate and maintain online monitoring equip-

Industrial wastewater discharge inten-

Using 2023 as the base year reduce indus- ment for wastewater discharge outlets grasp discharge data in real time and achieve centralized

Wastewater 3 sity in 2025 decreased by 61.31% monitoring and management of wastewater discharge.trial wastewater discharge intensity (m /

compared with 2023 exceeding the

RMB 10000) by 10% by 2028

target

Reduction *?Optimize the production cleaning process and reduce the amount of wastewater generated from

Measures the source;

*?Classify and collect clean water for greening and cooling tower replenishment.Waste Gas Waste gas treatment compliance rate Waste gas treatment compliance rate

remains at 100% remained at 100% in 2025

Waste Waste disposal compliance rate remains at Waste disposal compliance rate

100% remained at 100% in 2025

The Group strictly follows national and local emission standards and regularly monitors all categories of pollutant

discharge indicators to ensure that all waste is discharged in compliance after effective treatment. Based on actual

operational conditions the Company scientifically plans pollutant reduction pathways actively promotes process

iteration and upstream optimisation and strives to reduce pollutant generation at source. During the Reporting

Period all solid waste generated by the Group was properly handled in compliance with regulations and all pollutant

discharges met applicable standards.

52 53InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Waste Gas Management

Hazardous Waste

InnoCare strictly complies with laws and regulations such as the Air Pollution Prevention and Control Law of the

People’s Republic of China and the Emission Standard of Air Pollutants for Pharmaceutical Industry. Based on internal

systems including the Air Pollution Control Management Procedures and the Operating Procedures for Waste Gas Treatment *?Hazardous waste shall be disposed of in compliance by qualified processing units.Treatment Systems in the API Pilot Workshop the Group has established a systematic waste gas management system. Method

Advanced treatment facilities and monitoring arrangements have been deployed at all key waste gas emission points

to ensure compliant treatment and discharge.*?Waste organic solvents with recycling value shall be handed over to hazardous waste treatment

Reduction units with recycling qualifications for recycling.*?For the waste gas generated in the preparation workshop processes such as condensation recov- Measures *?Regularly conduct audits and inspections of the laboratory to ensure that chemical manage-

Treatment ery water spraying and activated carbon adsorption are adopted for treatment. After treatment it ment and hazardous waste disposal comply with institutional requirements.Method is discharged at high altitude while strengthening the control of unorganized waste gas emissions

to reduce the impact on the environment;

*?For the waste gas of raw materials methods such as alkali spraying water spraying and activated

carbon adsorption are adopted for treatment and the activated carbon is regularly replaced to Guangzhou InnoCare continues to upgrade pollutant treatment technologies and has carried out a number of

improve the efficiency of waste gas removal; notable practices in the refined management and source reduction of hazardous waste through the introduction

*?For laboratory waste gas it is first collected through facilities such as fume hoods and universal of digital and intelligent management tools. The Group is committed to continuously improving the sophistication

covers and then treated using alkali spraying and activated carbon adsorption processes; of waste management through technological upgrades and laying a solid foundation for cleaner production and

*?In response to the odor from the sewage station while ensuring that each sewage tank is covered green operations.and sealed centralized collection is carried out through pipelines water spraying and UV photol-

ysis are used for treatment and UV lamps are regularly replaced to ensure the treatment effect.Hazardous Waste Management and Reduction Measures at Guangzhou InnoCare

Reduction *?In terms of waste gas reduction the Company strengthens source control and behavioral norms in

Measures laboratory management and reduces waste gas generation by reducing open operations promot- Intelligent systeming closed operation facilities and centralized collection and treatment.*?Build an intelligent management system for hazardous waste to achieve refined and traceable management of the entire

lifecycle of hazardous waste.Solid Waste Management

InnoCare always strictly follows the Law of the People's Republic of China on the Prevention and Control of

Environmental Pollution by Solid Waste the Regulations on the Administration of Medical Waste and relevant Recycling and utilization of waste methanol

industry technical specifications for waste disposal. The Group has formulated and implemented the Solid Waste

Management Procedures adheres to the core principles of "reduction resource recovery and harmless treatment"

and continuously advances standardised solid waste management and recycling to ensure compliant disposal of *?By optimizing the cleaning process to reduce the moisture content of waste methanol and developing hazardous waste treatment suppliers with recycling qualifications the disposal method of waste methanol will be changed from incineration

all types of solid waste. to recycling further exploring its reuse value;

*?In 2025 the comprehensive utilization of waste methanol reached 196.92 tons resulting in a total reduction of 266.37 tons

Solid Waste Treatment Methods and Reduction Measures in carbon emissions.Non-hazardous Waste

Replacing renewable carbon

Treatment *?General industrial solid waste is uniformly cleared and transported by the municipal sanitation

department and is recycled and reused according to the actual situation or collected and

Method processed by the municipal sanitation department. *?Replace the activated carbon adsorption device in the waste gas treatment facility with high-quality renewable carbon and

commission qualified third parties to regenerate the regularly replaced activated carbon to restore the pore structure and

adsorption performance of the activated carbon;

*?In 2025 a total of 12770 kilograms of waste activated carbon will be reduced and the terminal disposal of hazardous waste

Reduction *?Promote paperless office practices set up waste paper recycling points and sorting bins and will be reduced to avoid the risk of secondary pollution resulting in a total reduction of 36.16 tons of carbon emissions.Measures implement classified recycling and sound treatment of related waste.

54 55InnoCare 2025 ESG Report Green Operation Future Built on Integrity

Green Office Green Office and Energy-saving Management Measures

InnoCare has consistently followed the path of low-carbon and environmentally friendly development and actively

explored best practices in green office operations. By comprehensively promoting water conservation electricity Application of energy-saving equipment

conservation and paperless working across office spaces the Group taps into the potential for emission reduction in

administrative operations effectively reduces resource consumption intensity steadily advances green operations

and helps build an environmentally friendly workplace. *?Promote the use of high-efficiency LED environmentally friendly lighting systems throughout the office area

We regard green office as an important practice for sustainable development and integrate energy conservation

emission reduction and environmental concepts into daily operations through systematic measures. The Company

not only promotes high-efficiency energy-saving equipment and intelligent management models across office areas

but also focuses on cultivating employees’ awareness of resource conservation forming a working mechanism that Intelligent control mode

combines institutionalised management with behavioural guidance. At the same time the Group actively promotes

facility optimisation and improvements to the working environment for example by installing noise reduction

devices for equipment thereby continuously enhancing the overall effectiveness and management standards of *?Set the red line for air conditioning temperature control (no less than 26 ° C in summer and no more than 20 ° C in winter) and regulate electricity consumption behavior

green office practices. *?Based on spatial functional differences multiple intelligent control modes such as time control sound and light sensing

ultrasonic and infrared sensing and single room multi switch control are scientifically configured to achieve refined

energy-saving

Green Recycling of IT Assets and Carbon Reduction

In 2025 InnoCare standardised the recycling and treatment of 174 kg of retired IT equipment achieving

a recycling and reuse rate of 99.71%. This directly reduced net carbon emissions by 50.74 kg of CO2e. By Green office promotion

avoiding high-energy and high-emission processes such as raw material extraction manufacturing and

waste landfilling the initiative achieved a total carbon reduction of 3050 kg of CO2e. This practice combined

asset disposal with environmental protection reducing the carbon footprint of office operations through

*?Post water-saving signs in public areas to guide employees to save water

practical resource circulation actions while supporting sustainable development goals such as responsible

*?Fully implement paperless office through the comprehensive deployment of security information systems

consumption and production and climate action thereby demonstrating the Company’s environmental

*?At the end of this report period we reduced the use of 4361 sheets of paper effectively reducing the comprehensive

responsibility. environmental costs of printing transportation and related waste disposal

Management and supervision mechanism

*?Regular joint supervision and inspection are carried out by the EHS department and the administrative department to

ensure the effective implementation of various green office measures through regular inspections

Equipment and environment optimization

*?Continuously promote facility improvement to optimize the working environment. In 2025 a noise reduction soundproof

box will be installed for the ultrasonic cleaning machine reducing its operating noise from 103dB (A) to 77dB (A) meeting

Certificate of Greenhouse Gas Footprint and Environmental Benefits for Technology Equipment and surpassing the control requirements of 85dB (A).

565703

Patient-Centric

Innovation and R&D

SDGs Addressed in this Chapter

InnoCare adheres to a "putting patients' lives above all else" principle and

regards safe and effective drugs as the fundamental guarantee for the sustainable

development of the enterprise. The Company strengthens research and

development management continuously improves innovation capabilities and

strictly controls quality throughout the entire product lifecycle continuously

optimizes customer ser vice experience while adhering to Responsible

Procurement steadily promoting product and service quality to a higher level.InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Innovative R&D focusing on multiple promising novel targets and therapeutic areas. We are developing a diverse range of innovative

therapeutic modalities—including small molecules monoclonal antibodies bispecific antibodies and antibody-

InnoCare focuses on providing innovative treatment plans with clinical value for patients with malignant tumors drug conjugates—targeting hematologic malignancies solid tumors and autoimmune diseases.and autoimmune diseases worldwide implementing the research and development concept of "science drives

innovation for the benefit of patients" and has built a fully integrated platform spanning drug discovery clinical

development manufacturing and commercialization. At the same time the Group attaches great importance to InnoCare' s Core R&D Technology Platform

intellectual property protection continuously improves relevant systems and processes systematically manages and

maintains innovative achievements and ensures that scientific research investment can be effectively transformed

into competitive advantages and sustained innovation momentum.Governance Technology Name Description / Technological Advancement

InnoCare has established a well-defined and comprehensive ESG governance structure. The Board of Directors is

clearly responsible for R&D innovation and intellectual property protection ensuring efficient allocation of R&D *?Used for structure–activity relationship (SAR) studies the platform

resources and controllable management of R&D risks. enables the design of new compounds based on the 3D crystal structure

Compound optimization plat- of protein–drug molecules. Through structural alert filtering physico-

Strategy form chemical property prediction and in silico ADME evaluations it guides

the next round of compound synthesis thereby accelerating the discov-

InnoCare regards innovative research and development as a strategic priority for the Company and continues to ery of highly druggable candidates.increase investment in research and development. In order to maintain long-term innovation vitality the Group

coordinates and promotes research and development layout from multiple dimensions such as platform facilities *?Systematic screening of crystal forms and salt forms using XRPD DSC

and talent constructs a comprehensive research and development system that balances research and development Drug crystallization TGA DVS and other techniques to identify the optimal API polymorph

and establish patent protection strategies for crystal forms. The platform

quality and efficiency advances its pipeline of product candidates with clinical and market potential and strives research platform also supports crystal form characterization of APIs and formulations to

to benefit patients worldwide.In 2025 the Company’s R&D investment amounted to RMB 951.6 million accounting facilitate stability studies.for 40.07% of its operating revenue.*?Leveraging the Company’s robust preclinical and clinical R&D capabilities

the platform utilizes biomarkers as indicators and integrates cross-func-

Production Translational medicine tional expertise across biology pharmacology/clinical pharmacology In-house R&D Clinical development Commercialization pharmacokinetics toxicology and clinical development. This interdis-

research platform ciplinary approach enables effective evaluation of clinical trial data and

*?Building a diversified *?Establishing clinical devel- *?Beijing and Guang- *?Setting up a profes- enhances the efficiency of drug development.and advanced R&D opment and registration zhou are two major sional commerciali-

platform teams centered in China innovative drug zation team to cover

*?With first-class R&D and the United States bases creating a hundreds of hospi- R&D and industrialization *?The platform improves drug dissolution through solid dispersion technol-

centers in Beijing *?Building a rich product comprehensive tals across the country

Nanjing and Guang- pipeline and exploring platform for new and comprehen-

platform for solubilizing prepa- ogies such as spray drying and hot-melt extrusion thereby address-

ing formulation bottlenecks commonly found in innovative drugs and

zhou we are able the potential of combin- drug creation sively promoting the ration technology of insoluble

to carry out R&D ing products under devel- market education of the

enhancing their druggability.drugs

independently opment with standard or product for the benefit

other therapies of more patients *?The platform adopts a proprietary linker–payload (LP) technology aimed

at delivering potent and highly targeted therapies for cancer treatment.It enables the development of highly differentiated ADC products that

Integrated Biomedical Platform improve efficacy while optimizing safety. Key features of the platform

R&D Platform Development include:ADC platform *?1. Irreversible bioconjugation technology. It ensures stable conjugation

The Group adheres to a strategy centered on independent innovation. By gaining deep insights into patients' unmet between antibody and linker to enhance ADC stability.medical needs and closely integrating cutting-edge science with clinical translation we have progressively estab- *?2. Hydrophilic linker. It improves ADC stability with a drug-to-antibody

lished a portfolio of internationally leading technology platforms. These include Molecular Glues Antibody-Drug ratio (DAR) of 8.Conjugates (ADCs) Bispecific and Multispecific Antibodies AI-enabled Molecular Design in vivo pharmacology *?3. Innovative payload. It incorporates highly cytotoxic payloads with

strong bystander killing effects.molecular dynamics simulation and bioinformatics analysis which together provide a systematic technological

foundation for novel drug discovery and optimization. The Group continues to drive progress in early-stage discovery

60 61InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Guangzhou InnoCare the subsidiary of the Group is dedicated to establishing internationally advanced manufactur- R&D Team Development

ing capabilities. This includes building production lines that utilize spray drying and hot-melt extrusion technologies We recognize that our people are the foundation of sustained innovation. We actively recruit and develop top-tier

for the manufacture of solid dispersions and solid dosage forms. The site is also equipped with three core formulation scientific and clinical talent globally forming specialized R&D and clinical development teams. This continuous

technology platforms focused on: (1) solubilization of poorly soluble drugs (2) development of modified-release oral investment in talent strengthens our in-house capabilities and provides a robust foundation for long-term innovation.solid dosage forms and (3) targeted drug delivery systems. These integrated capabilities are designed to address

the critical industry challenge of poor drug solubility and bioavailability thereby continuously strengthening our We have built a diverse highly educated and multidisciplinary R&D team with a presence in key regions including

innovation and product development foundation. China and the United States. Leveraging deep industry expertise and a keen ability to identify product differentiation

and clinical trial opportunities this team is adept at unlocking the therapeutic potential of our pipeline assets across

R&D Center Construction a wide range of indications.The Group focuses on enhancing the overall capabilities of its R&D centers. It is equipped with advanced scientific To foster a culture of innovation and exploration we have implemented incentive programs that reward core team

research facilities including various laboratories standard animal housing diagnostics and biology platforms members for outstanding contributions to key R&D projects and innovative achievements. As of the end of the

in its Beijing Nanjing and Guangzhou R&D centers. This provides robust support for independent research and Reporting Period our R&D team comprised 532 members representing 42.26% of our total workforce with over

development activities in chemistry biology pharmacology pharmacokinetics toxicology drug polymorphism 52% holding master's or doctoral degrees.studies and CMC. At the same time we maintain close collaboration with leading clinical CRO companies in the

industry to advance clinical development globally. Through scientific and rational registration and submission As of the end of the Reporting Period

strategies we enhance the approval efficiency of our products accelerating the delivery of innovative results to

benefit patients.R&D team comprised the proportion of R&D the proportion of master's and

InnoCare and Tsinghua University Co-establish a Beijing Key Laboratory 532 personnel reached doctoral degree holders exceededmembers 42.26% 52%

During the Reporting Period the "Beijing Key Laboratory of Intelligent Design and Delivery of Oral Drugs"

jointly applied for by Tsinghua University as the host institution and InnoCare as a co-construction unit was Beyond strengthening our internal capabilities we emphasize collaborative innovation with external partners to

successfully approved. The laboratory focuses on AI-driven design and delivery technologies for oral drugs. build long-term mutually beneficial relationships. Strategic partnerships in clinical development enhance our R&D

By integrating the scientific research capabilities of both parties it aims to accelerate original innovation and efficiency and translational success. We actively engage with the global scientific community by presenting our latest

achievement transformation. This milestone marks the formal entry of their industry-university-research advancements in hematologic malignancies solid tumors and autoimmune diseases at leading academic confer-

collaborative innovation into a new stage of systematization and platformization. ences. Through these exchanges and international collaborations we continuously integrate advanced knowledge

and practices thereby enhancing our overall R&D prowess and contributing to the broader innovation ecosystem

with the ultimate goal of delivering new therapies to patients faster.Risk Management

Intellectual Property Protection

The Group incorporates intellectual property (IP) protection as a core component of its ESG governance. It strictly

complies with relevant laws and regulations including the Patent Law and the Trademark Law of the People's

InnoCare and Tsinghua University Co-establishing the Beijing Key Laboratory

Republic of China. A series of internal policies have been established supported by a three-tier governance struc-

ture (Decision-Making – Execution – Business). Under this framework the Chief Technology Officer (CTO) provides

InnoCare and Westlake University Reach Strategic and Scientific Research Cooperation overarching leadership while the dedicated Intellectual Property Department is responsible for the comprehensive

portfolio management of patents trademarks and trade secrets. Close collaboration with R&D departments ensures

the operation of a robust IP protection and management system.In May 2025 InnoCare signed a Strategic Cooperation Framework Agreement and a Scientific Research In 2025 we refined the InnoCare Intellectual Property and Trade Secret Protection Policy and established the InnoCare

Cooperation Agreement with Westlake University. Leveraging their respective advantages the two parties will Patent Maintenance Procedures. These documents further clarify responsibilities define scopes and streamline IP

establish cooperation in areas such as innovative drug R&D platform co-construction talent cultivation and management processes. A patent classification system was implemented categorizing patents into core strategic

achievement transformation. This partnership aims to jointly advance the in-depth application of innovative and contingent portfolios for tiered management thereby enhancing the systematic approach and operational

technologies in new drug R&D and accelerate the discovery and development process of innovative drugs. efficiency of our patent activities.

62 63InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

IP Protection Measures Intellectual Property Training and Exchange Activities

The Group strengthens full-cycle IP management through simultaneous efforts in internal governance and external The Group is committed to cultivating employees' awareness of protecting intellectual property. It has invited external

partnership management. This dual approach mitigates IP-related risks and safeguards the effective development patent attorneys and trademark attorneys on multiple occasions to assist in improving internal intellectual property

and compliant utilization of innovation outputs. During the Reporting Period the Company was not involved in any management standards and to keep abreast of industry trends and the latest patent layout strategies. During the

material litigation concerning intellectual property rights. Reporting Period the Group newly acquired a commercial patent database and organized specialized training for

R&D personnel on its usage further improving their capabilities in obtaining patent information.Measures and Actions for IP Protection

Furthermore the Group actively participates in various intellectual property protection conferences organized by the

government and social organizations exchanging the latest developments in intellectual property protection with

*?We regularly assess both internal and external IP management risks. In collaboration with R&D teams peers and jointly promoting the sharing of concepts and deepening of practices in intellectual property protection

Internal we conduct global patent landscape and freedom-to-operate (FTO) analyses prior to project initia-

tion. We also provide ongoing patent strategy support and surveillance throughout a drug's lifecycle within the pharmaceutical industry.Management from development to market launch and conduct tailored patent analyses (e.g. on patentability and

competitive intelligence) for R&D projects. For core technologies we implement a comprehensive IP-Related Conferences and Awards

protection strategy that combines trade secrets and patents throughout the entire R&D and commer-cialization process. “Overseas Patent Strategy Layout and Planning*?The Group and its employees sign the Agreement on Confidentiality Proprietary Information and Intel- “ organized by the Capital Intellectual Property Services Associationlectual Property Protection and the Non-competition Agreement to clarify the rights and obligations

of both parties in relation to the protection of intellectual property rights. "Overseas Patent Strategy Layout and Planning

" organized by the Capital Intellectual Property Services Association

*?In external activities such as technology licensing and collaborative R&D a stringent partner qualifi- 2025 Work Training Conference for Beijing Intellectual Property Pilot and Advanta-

cation and legal capability review mechanism is established. Agreements clearly define terms regard- geous Units hosted by the Beijing Intellectual Property Office

ing patent ownership maintenance responsibilities benefit distribution and liability for infringement.External *?When external cooperation projects involve confidential information the Group signs contracts with the Successfully passed the re-evaluation for Beijing Intellectual Property Advantageous

Cooperation relevant parties including confidentiality agreements to ensure that the contracts provide adequate Units retaining the qualification as a Beijing Intellectual Property Advantageous Unit.protection of the intellectual property rights of both parties.*?Collaborating with external specialized law firms to establish cross-border intellectual property rights

protection channels safeguarding the Company's intellectual property interests in partnerships and Research and Development Ethics

ensuring the compliant transformation and value enhancement of innovation achievements.*?The Group Cooperates with external trademark attorneys to jointly monitor potentially similar trade- InnoCare fully considers ethical principles and social value when conducting R&D activities such as clinical research

marks and promptly takes countermeasures to mitigate associated risks. and animal experiments. Focusing on protecting the rights and interests of participants and ensuring animal welfare

*?The Group invites renowned external patent attorneys from time to time to engage in exchanges with the Company has established and improved an R&D ethics management system continuously enhancing the

the Group's IP leaders to improve internal IP management practices. management level of R&D ethics work.Participants rights

To standardize the protection of participants' rights and interests InnoCare has established an ethics committee

to conduct independent ethical reviews of all aspects of drug clinical trials. Through internal systems such as the

The Group has formulated and implemented the "InnoCare Intellectual Property Reward Guidelines" providing Ethics Committee Framework and SOP the responsibilities and workflow of each department are clearly defined

annual awards to employees who have made outstanding contributions to the Company's related invention patent and ethical risks are systematically identified and managed. At the same time the Group has established a dedicated

work thereby stimulating innovation vitality across the entire organization. During the Reporting Period the Group department independent of the business department to review and supervise the ethical compliance of the clinical

filed 41 patent applications and obtained 43 patent grants in multiple countries and regions continuously strength- research process further strengthening the compliance management of the entire clinical trial process.ening intellectual property protection throughout all stages from R&D to commercialization of its products. The Group adheres to the highest ethical and scientific standards in research and development ethics strictly follow-

ing the Drug Administration Law of the People's Republic of China the Drug Registration Management Measures

(2020 Edition) the Good Clinical Practice for Drug Trials (2020 Edition) the Helsinki Declaration the Guidelines for the

As of the end of the Reporting Period Construction of Ethical Review Committees for Clinical Research Involving People and the Good Clinical Practice for

Drug Trials (GCP). And a series of internal systems and procedures have been established including the third version

total number of patent applications number of patent authori- of the technical guidance principles and industry standards to clarify the regulations for the entire clinical research

submitted reached zations reached process and the requirements for participating clinical research employees ensuring that participants participate

41 43 in the trial under compliant and safe conditions and fully safeguarding their legitimate rights and interests such as the right to know voluntary participation and privacy. In 2025 the Group did not engage in any improper or

non-compliant behavior related to the welfare of experimental participants.

64 65InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

In 2025 The Group is committed to minimizing the use of experimental animals and implementing the 3R principle

(Replacement Reduction and Refinement) in animal experiments. By optimizing the feeding environment dietary

the Group did not engage in any improper or non-compliant behavior related conditions and experimental plan design we aim to minimize the number of animals used alleviate animal pain

to the welfare of experimental participants. and improve their welfare status Strive to reduce the burden on experimental animals while meeting scientific

research needs. In 2025 the Group did not engage in any inappropriate or non-compliant behavior related to

The Group formulates a rigorous clinical trial plan and ensures that trial participants sign the Clinical Trial Agreement animal welfare.and Informed Consent Form informing them of potential risks potential adverse events changes to the clinical study

plan safety information and other detailed information ensuring that participants understand the nature risks

benefits and their own rights of the study. This process is continuously supervised by an independent ethics review In 2025

committee. During the implementation of clinical trials the Company takes the safety and rights of the participants

as the premise as well as the authenticity and reliability of the data. The project operations are strictly carried out

in accordance with the trial plan and the trial data and records are checked to ensure that the trial process is stand- the Group did not engage in any inappropriate or non-compliant behavior

ardized the data and results are scientific authentic and reliable. related to animal welfare.On this basis the Company continues to carry out employee compliance training iteratively optimize standard

operating procedures and ensure compliance throughout the entire process strictly follow the annual audit plan

to carry out comprehensive audits of clinical trial projects cooperative suppliers and quality systems in order to

strengthen the authenticity and reliability of clinical data and ensure the legitimate rights and safety of trial partic-

ipants. In response to audit findings conduct in-depth root cause analysis implement targeted corrective and Minimize the use of U s e a l t e r n a t i v e

preventive measures continuously reduce risks in drug clinical trials through process optimization and capability laboratory animals by

avoiding unnecessary methods—such as

enhancement strictly adhere to the ethical bottom line of pharmaceutical research and development and effectively Reduction Replacementexperiments. When molecular and cell

fulfill the Company's social responsibility and ethical commitments in the field of medical and health. During the animal testing is essen- biology techniques—

Reporting Period no serious clinical trial quality or ethical disputes were found. tial reduce the number where possible to reduce reliance on

To enhance the ethical awareness and compliance level of employees in clinical research the Group regularly of animals involved to the minimum required. animal experiments.provides internal and external training for clinical research related personnel covering laws and regulations internal

systems and operational processes related to clinical trial and research ethics. It helps employees to timely grasp the

latest requirements and consciously follow them in actual work. At the same time employees can promptly report

any improper or irregular behavior that violates GCP or harms the rights and interests of the participants through

the Company's reporting channels.Refinement

Animal Welfare

InnoCare has established an Institutional Animal Care and Use Committee (IACUC) composed of internal and

external experts dedicated to supervising the protection and use of animal welfare in the Group. We promise to Develop humane and scientifically sound procedures improve experimental techniques and optimize

use experimental animals with a responsible attitude adhere to the highest ethical and scientific standards in protocols to minimize discomfort and distress for

animal welfare and fully guarantee animal welfare. animals during studies.The Group strictly complies with the Guidelines for Ethical Review of Experimental Animal Welfare of the People's

Republic of China (GB/T 35892-2018) and the Guidelines for the Management and Use of Experimental Animals of

the United States of America and other laws and regulations. We have developed management systems such as

the Ethics Committee Management Procedure for Experimental Animal Welfare and the Care and Behavior Plan Principle for the Protection of Laboratory Animals

for Experimental Animals to carry out ethical review and process supervision of animal welfare. In 2025 the Group

successfully completed its internal animal welfare review and passed external supervision and inspection organized

by government departments obtaining a newly issued animal use permit. There were no animal welfare or ethical

disputes throughout the year and animal facility management is at an international leading level. In addition we

also require our Company's relevant suppliers to comply with international animal welfare standards and ensure

humane and cautious treatment of experimental animals.

66 67InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Laboratory Animal Care Measures Indicators and Objectives

Progress of Pipeline under Research

Feeding

*?Providing sterilized feed that will keep the animals healthy and clean and sterile drinking water. Leveraging our efficient R&D platform and strategiccollaboration we have built a robust and diversified product

*?Checking daily and changing and adding drinking water promptly. pipeline and are systematically advancing our R&D portfolio. Guided by a management team with extensive experi-

ence across R&D manufacturing and commercialization we have established an integrated biopharma platform that

excels in both the quality and pace of innovation. Our resulting pipeline achieves an optimal balance of innovation

and risk targeting multiple high-potential cutting-edge therapeutic areas. We are on a clear trajectory to become a

leading global biopharmaceutical Company dedicated to developing and delivering innovative therapies for patients

Living Environment *?Using cages that meet the requirements of the national standard and are clean sterile and

with cancer and autoimmune diseases worldwide.well ventilated.*?Replacing the cage box at the specified time and frequency.Physical and Men-

tal Needs *?Meeting the physiological needs of animals such as defecation urination maintenance of

constant body temperature normal activity and provision of nesting materials.*?Providing snacks and toys on a regular basis to ensure mental health of the animals.Social Need

*?Ensuring mice live in colonies.*?Ensuring that mouse cages that need to be placed separately are not placed on the outermost

side of the cage as much as possible.*?Trying to avoid operations that cause discomfort to the animals. If operations that cause pain

Daily Operation and discomfort to the animals are needed anesthetics should be used and the anesthesia

process should be monitored to avoid overdose of anesthesia leading to death of the animals. InnoCare's Pipeline of Drug Candidates

*?The animal should be properly cared for after anesthesia such as insulation measures.Phase-out Disposal

*?Euthanasia of culled laboratory animals or animals in obvious discomfort is carried out in a

timely manner to minimize animal suffering.*?The presence of other animals is avoided during the operation.In order to enhance employees’ knowledge of animal ethics and enhance their awareness of animal welfare protection

and care the Group regularly conducts animal ethics training for new employees responsible for animal experiments

and animal center management personnel including relevant regulatory knowledge and experimental techniques.The Group also encourages employees to actively report misconduct or violations related to animal welfare.

68 69InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

clinical development for multiple other indications including a Phase II/III study for Vitiligo a global Phase

II study for Prurigo Nodularis a Phase II/III study for Chronic Spontaneous Urticaria and a Phase II study

In the field of hematological malignancies for moderate-to-severe Plaque Psoriasis among others. With the continued progress of these studies

the Company made significant progress in 2025 advancing commercial execution late-stage clinical clinical data from multiple indications are expected to be obtained sequentially in 2026 providing impor-

development and global program expansion around three core therapies—orelabrutinib (a BTK inhib- tant support for subsequent registrational development. Another TYK2 allosteric inhibitor ICP-488 is also

itor) tafasitamab (an anti-CD19 monoclonal antibody) and Mesutoclax (ICP-248 a BCL-2 inhibitor)—to actively advancing in clinical development. Currently the Phase III clinical trial of ICP-488 for the Psoriasis

build a leading product portfolio. Orelabrutinib continued to expand its indication coverage while making indication completed patient enrollment in February 2026 and the analysis of the primary efficacy endpoint

steady progress in global registration strategy: it was approved in Singapore for r/r MZL and the New Drug is expected to be completed in 2026. Concurrently the Company is promoting its clinical development in

Application (NDA) for r/r MCL was successfully submitted in Australia. These achievements further validate new autoimmune disease indications such as Cutaneous Lupus Erythematosus (CLE) for which a Phase II

orelabrutinib's differentiated competitive advantages and solidify its position as a globally leading BTK clinical trial has been approved and patient enrollment is planned to commence. Additionally the Investi-

inhibitor.Tafasitamab achieved an important commercialization milestone with regulatory approval in gational New Drug (IND) application for a Phase II clinical trial in Sj?gren’s Syndrome has been submitted.May 2025 and first prescriptions issued in September 2025 establishing a solid foundation for full-year Meanwhile the Company continues to advance next-generation innovative immunomodulatory mechanism

commercial contribution from 2026 onwards. Meanwhile our next-generation BCL-2 inhibitor mesutoclax projects into the clinical stage. This includes the VAV1 molecular glue project ICP-538 which received IND

further strengthened the long-term depth of the franchise with five ongoing clinical studies including three approval in February 2026 and initiated subject enrollment in March and the oral IL-17 small molecule

registrational trials addressing key areas of unmet medical needs. These include a Phase III fixed-duration project ICP-054 for which global partnerships and clinical development in China are being pursued with

combination regimen with orelabrutinib for 1L CLL/SLL a registrational study in BTK inhibitor treated MCL its IND application submitted in February 2026. The Company has formed an R&D landscape in autoimmune

and a Phase III registrational trial in r/r MCL. In parallel global clinical development of mesutoclax in acute diseases anchored by late-stage registration programs and bolstered by a continuous influx of innovative

myeloid leukemia (“AML”) and myelodysplastic syndromes (“MDS”) is progressing in China US and other mechanisms. This strategy is focused on building a differentiated autoimmune portfolio aimed at developing

regions underscoring the program’s global potential.Together these three therapies form the core of our first-in-class and best-in-class oral therapies with the potential to deliver meaningful clinical benefits and

hemato-oncology strategy combining near-term commercial growth with a robust pipeline of differenti- address key limitations of existing treatments thereby translating scientific innovation into sustainable

ated late-stage assets. The following sections provide a detailed overview of the regulatory clinical and long-term growth.commercial progress of each product within our hemato-oncology portfolio.In the field of autoimmune diseases In the field of solid tumors

leveraging its strength in oral small-molecule drug discovery the Company has built a differentiated and the Company continues to advance innovative drug development through technology platforms such as

comprehensive portfolio targeting both B-cell and T-cell-mediated disease pathways to address major targeted small-molecule drugs and Antibody-Drug Conjugates (ADCs). Zurletrectinib (ICP-723) has been

autoimmune diseases. The clinical development of orelabrutinib in autoimmune diseases continues to approved in China for the treatment of NTRK fusion-positive solid tumors marking the Company's first

progress. Among them the Phase III pivotal clinical trial for Immune Thrombocytopenia (ITP) has completed approved solid tumor therapy. The NDA for its pediatric solid tumors is also expected to be submitted in

patient enrollment and a New Drug Application (NDA) is expected to be submitted in the second quarter of 2026. In terms of innovative technology platforms the Company has established a proprietary Antibody-

2026. Positive Phase IIb data for Systemic Lupus Erythematosus (SLE) were disclosed in late 2025. Phase III Drug Conjugate (ADC) platform and developed an in-house intellectual property system for linker-payload

clinical development was initiated in the first quarter of 2026 with patient enrollment already underway.. technology. Our proprietary platform which integrates a proprietary antibody conjugation hydrophilic

Furthermore to accelerate the global development of orelabrutinib in Multiple Sclerosis (MS) and maximize linkers and highly potent cytotoxic payloads is designed to enhance the stability anti-tumor activity and

its international clinical and commercial potential the Company entered into an exclusive license agreement therapeutic index of our ADC candidates.. ICP-B794 (a B7-H3-targeted ADC) is undergoing dose escalation

with Zenas BioPharma Inc. in October 2025 to advance global Phase III studies for Primary Progressive MS and early clinical data have shown promising efficacy and safety. Building on the ADC platform the Company

(PPMS) and Secondary Progressive MS (SPMS). The Company has built a strong TYK2 franchise comprising will continue to introduce multiple differentiated innovative drug candidates further enriching its solid

two differentiated oral molecules targeting T-cell-mediated inflammation.. Soficitinib (ICP-332) a novel TYK2 tumor product pipeline. The IND application for ICP-B208 (a CDH17-targeted ADC) was submitted in March

inhibitor is being evaluated across five autoimmune indications with multiple data readouts expected. For 2026. Upon approval it will rapidly advance to the clinical stage. Several other ADC projects are also under

moderate-to-severe atopic dermatitis (AD) the Phase III registrational trial completed patient enrollment in development.late 2025 with primary efficacy analysis expected in mid-2026.t. Simultaneously the Company is advancing

70 71InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

External Authorization and Cooperation Quality Assurance

In January 2025 the Company entered into an exclusive license agreement with Prolium Bioscience Inc. (hereinafter InnoCare implements quality management across the entire product lifecycle. We have established a comprehensive

referred to as “Prolium”) for the development and commercialization of ICP-B02. According to this agreement Prolium Quality Management System (QMS) that spans R&D production testing and post-market activities. This system

has obtained exclusive rights to ICP-B02 for the exclusive global rights to ICP-B02 in non-oncology indications and enables systematic control over all critical stages to ensure end-to-end product quality.in oncology indications outside of Asia.In October 2025 InnoCare and Zenas BioPharma (hereinafter referred to as “Zenas”) reached a significant licensing Quality Management System

agreement granting Zenas exclusive rights to develop manufacture and commercialize orelabrutinib for multiple InnoCare has established a top-down quality management organizational structure with clearly defined responsibili-

sclerosis globally and for non-oncology indications outside Greater China and Southeast Asia as well as related rights ties at each level. The Group President as the ultimate responsible officer for product and service quality holds final

to two preclinical molecules (a new oral IL-17 AA/AF inhibitor and a CNS-penetrant oral TYK2 inhibitor). This partner- decision-making authority on major quality issues and exercises overall oversight. Senior management including

ship enables the program to leverage a dedicated international development platform while allowing InnoCare to Vice Presidents overseeing various functions comprises the leadership team responsible for planning and direct-

focus on its broader portfolio. These transactions validate the global competitiveness of our innovation engine and ing all quality management activities. They ensure that the Quality Management Department Pharmacovigilance

accelerate the internationalization path for the assets. Department Production Management Department and other operational units efficiently execute their respective

quality mandates. This collaborative framework drives the effective and consistent operation of our QMS.R&D Awards

During the Reporting Period the innovation performance of the Group received widespread attention and was President of the Group

awarded multiple research and development awards by industry and professional institutions fully reflecting the

Company's strength and influence in innovation and research and development.Chief VP of VP of Quality VP of Clinical Chief Technology Regulatory Development and Commercial Chief Operating VP of Human

Officer (CTO) Affairs Management Officer(COO)Medical Research Officer Resources

Production Formulation Regulatory Quality Analytical Phormocovigilance Commercial and Management Affairs Management Diversified Supply Chain Procurement IT HR Department Department Department Department

InnoCare's R&D-Related Awards in 2025 Department Department Department Department Department Department Business Department

Process EHS

Chemistry

Department Department

Top 50 Independent Innovation Enter- Top 100 Chinese Pharmaceutical ProjectMonogement

prises in the Pharmaceutical Industry Innovation Enterprises (2025) Department

Top 100 Most Innovative Listed Health- Ranked among the Top 500 Private InnoCare Quality Management Organizational Structure

care Companies (2025) Enterprises in R&D Investment (2025)Top 100 Beijing “Specialized Refined Top 100 Beijing High-end Precisionand New”Enterprises (2025) and Advanced Enterprises (2025)

Orelabrutinib (novel BTK inhibitor) was Tafasitamab (Monuoki CD19 mAb)

recognized as a “New Quality Produc- won the “Sunshine” Annual Award fortive Forces” Industrial Practice Demon- Excellent Newly Approved Innovative

stration Case Pharmaceutical Product

ICP-248 (Mesutoclax) a novel BCL-2 inhibitor was listed in the “100 New Technologies and Products List” at

the 2025 Zhongguancun Forum

72 73InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

To continuously ensure the quality safety and compliant operation of drugs throughout their entire lifecycle

InnoCare systematically monitors developments in domestic and international drug regulations and technical Quality

standards and timely identifies and responds to the updates of relevant laws regulations and technical specifica- management

tions. In 2025 the primary laws regulations and standards that the Group follows and has integrated into its QMS in the

include but are not limited to: product R&D

Drug Administration Law of the People's Republic of China

Measures for the Supervision and Administration of Drug Production Post-market Entire process Quality

Measures for the Administration of Drug Registration product quality management in management

Good Manufacturing Practice for Drugs (Revised in 2010) (GMP) management the production

system process

China Good Clinical Practice for Drug Trials (GCP)

Good Laboratory Practice (GLP)

Good Pharmacovigilance Practice (GVP)

Good Supply Practice (GSP)

Pharmacopoeia of the People’s Republic of China (2025 edition) Product verification

management

21 CFR Part 210

U.S.A

21 CFR Part 211

InnoCare's Entire Process Quality Management System

European union European Union EudraLex - Volume 4 The Group has established a quality audit mechanism regularly organizes product quality self inspection and

formulates the "Corrective and Preventive Measures Management Regulations" and "Deviation Management

Regulations" to track rectify and verify discovered problems continuously improving the quality management

level. During the Reporting Period the Group and its subsidiaries completed their annual self inspection work in

Other markets PIC/S GMP and corresponding market regulations accordance with the self inspection plan and formed a self inspection report. In 2025 each subsidiary of the Group

completed quality audits in accordance with the audit plan conducted impact assessments and root cause analysis

of identified issues formulated and implemented corrective and preventive measures and improvement action

At the same time the Group has developed the Quality Manual and thousands of standard operating process plans continuously followed up on the implementation of rectification and promoted the continuous improvement

documents internally including the Corrective and Preventive Measures Management Regulations and the Quality of the quality management system.Risk Management Regulations to systematically drive the execution of all quality management activities. Among

them Guangzhou InnoCare has developed approximately 4700 quality system documents including standard

operating procedures quality standards analysis methods process procedures production inspection records

and other documents and records.In 2025 in order to further improve the quality management system and ensure its compliance and efficient operation

Guangzhou InnoCare conducted a systematic review and dynamic update of quality management related system

documents. This revision comprehensively considers the conclusions of internal quality system review business

process optimization needs and the latest changes in external regulations and standards including the new regula-

tory requirements of the Chinese Pharmacopoeia (2025 version) and the application and compliance requirements

for PIC/S GMP in international markets such as the Australian TGA. The focus is on revising the Quality Manual the

External Document Management Regulations the Quality Risk Management Regulations and the Management

Procedure for the Qualified Person to ensure that all quality activities are more standardized and controllable and

to promote the continuous improvement and enhancement of the quality management system.

74 75InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Guangzhou InnoCare Undergoes Registration Verification and GMP Compliance Inspection of

Guangzhou InnoCare Accepts Group Headquarters Audit Zanubrutinib Tablets

In June 2025 Guangzhou InnoCare underwent a five-day audit of the Group headquarters which covered In July 2025 Guangzhou InnoCare underwent a combined NDA review and GMP inspection (a “four-in-one”

the entire quality system including the production testing and warehousing of active pharmaceutical inspection in China) conducted by the Food and Drug Audit and Inspection Center (CFDI) of the National

ingredients (APIs) and finished drug products and conducted a comprehensive and in-depth review of the Medical Products Administration on the raw materials and formulations of Zanubrutinib. During the five

quality management system. day inspection process a comprehensive in-depth and systematic review was conducted around the

research and development production and quality control system of the variety.During the audit process the audit team objectively evaluated the compliance effectiveness and contin-

uous improvement of the quality management system through various methods such as on-site obser- With a solid foundation in daily quality management and efficient cross departmental collaboration the

vation personnel interviews record sampling and system tracking. In response to the identified areas Company successfully completed and passed this audit laying a solid compliance foundation for the

for improvement during the audit the Guangzhou Company quickly organized relevant departments to marketing approval of Zanubrutinib tablets and promoting the continuous improvement and enhancement

conduct a root cause analysis and developed detailed corrective and preventive measures. All rectifications of the Company's quality system.were completed as planned.The Group always regards external supervision as a crucial means to strengthen its compliance foundation and

identify opportunities for enhancement. It regularly accepts external regulatory agencies' supervision and inspection

of the Group's quality management system to ensure that the Group's quality management meets the requirements

of relevant international regulations and industry norms and on this basis strengthens internal management and

improves product quality. During the Reporting Period each company of the Group underwent a total of 7 GMP related

compliance inspections by the Chinese drug regulatory department 1 registration verification of Zanubrutinib tablets

1 Australian TGA audit and 1 GSP related compliance inspection by the Chinese drug regulatory department all of

which passed the inspections smoothly.During the Reporting Period each company of the Group underwent a total of

GMP related compliance inspections by the registration verification of Zanubrutinib

Chinese drug regulatory department tablets

71

Australian TGA audit GSP related compliance inspection by the

1 Chinese drug regulatory department1

76 77InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Quality and Safety Management Quality Risk Management

InnoCare always prioritizes product quality and safety implements systematic risk management for key nodes that

may affect product quality and formulates quality control systems and operating procedures throughout the entire

product production lifecycle standardizes pharmacovigilance and product recall work and effectively maintains

patient medication safety. Prior to clinical trials we conduct a thorough analysis of non-clinical safety data the safety

Quality Risk Management Drug R&D profiles of similar drugs and the drug's mechanism of action. This helps identify potential

InnoCare actively builds a quality risk management system that covers drug research and development production safety risks early on allowing us to develop targeted risk control strategies.and other links formulates the Quality Risk Management Regulations identifies evaluates controls and continuously

monitors potential quality risks in each link ensuring the effective implementation of quality management work

in each stage and comprehensively reducing the possibility of quality accidents. The Group has also developed

SOP-0000073 Emergency Plan for Drug Safety Issues and regularly conducts safety emergency drills to strengthen

A comprehensive quality control and risk management system is applied across the entire

the quality risk emergency response and disposal capabilities of relevant employees.product lifecycle. This includes testing of raw and auxiliary materials in-process checks final

product testing and stability assessments.In accordance with the Introduction of the Guidelines for Quality Risk Management of Differ-

Drug Manufacturing ent Medicinal Products in Shared Facilities we take steps to minimize risks related to co-pro-

duction.We use structured tools such as Failure Mode and Effects Analysis (FMEA) Hazard Analysis

and Critical Control Points (HACCP) along with statistical methods to evaluate and manage

quality risks.We collect and monitor safety data through pharmacovigilance activities performing signal

Pharmacovigilance detection risk identification and assessment. Based on the findings we implement appro-

priate control measures to reduce potential safety concerns.The Group Conducts Quality and Safety Emergency Drills

In November 2025 in order to effectively test and improve the comprehensive ability to respond to sudden Every step from pickup to delivery is closely monitored and controlled to ensure product

drug safety incidents the Group organized emergency drills in accordance with the SOP-0000073 Emergency Storage and quality remains intact. Our logistics processes are designed to meet pharmaceutical stand-

Plan for Drug Safety Issues. This drill was coordinated by the designated executive with the participation of Transportation ards and comply with regulatory requirements throughout the supply chain.multiple departments including the Pharmacovigilance Department Quality Department Commercializa-

tion Department Supply Chain Department Registration Affairs Department Corporate Communication

Department and Legal Department. It simulated real event scenarios and systematically tested the opera-

bility of emergency plans information transmission efficiency and the effectiveness of job responsibilities.Through this practical exercise the familiarity of key personnel with emergency procedures has signifi- Entire Process Quality Management

cantly improved and the cross departmental information sharing and decision-making mechanism has The Group implements end-to-end quality control for its products. We establish corresponding policies and proce-

been further optimized providing strong support for the Company to improve the drug safety emergency dures for each stage including R&D procurement and production to strengthen the standardization and system-

management system and ensure patient medication safety. atization of our quality management processes and continuously elevate our quality standards.

78 79InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Our Group strictly complies with relevant laws regulations and guidelines including the Our Group stringently controls quality requirements throughout the drug manufacturing

Good Clinical Practice (ICH-GCP) the Good Manufacturing Practice (GMP) and the applica- process. We have established internal systems including Production Plan Management

ble requirements for investigational medicinal products. We have developed and maintain Drug Release Management Procedure and Quality Management Review Procedure. A total

165 internal systems and management processes such as the QC Laboratory Safety Manage- of 1029 procedural documents were added or revised this year. By implementing produc-

ment Procedure the Hazardous Chemicals Management System and the QC Laboratory tion planning strictly controlling drug release and conducting regular management reviews

Waste Management Procedure. Among these 107 documents were newly created or revised we reinforce quality management at the production stage.R&D

during the reporting year. This ongoing refinement of our quality system supports all R&D Production

Quality The Group places a strong emphasis on quality testing. We have established Analytical/QC activities—from protocol design and investigational medicinal product (IMP) manufactur- Quality laboratories with comprehensive in-house testing capabilities and systematic quality control

ing to clinical trial operations data collection/management statistical analysis and regula- processes. We perform proactive testing to mitigate potential quality or safety issues cover-

tory submissions—ensuring that clinical trials are conducted to a high standard yielding ing raw/packaging materials in-process and intermediate products and finished product

scientifically sound and reliable data and results. release. Our product testing coverage reaches 100%. The laboratories rigorously record and

The Group conducts regular laboratory audits to verify compliance and quality standards review all test results issue test reports and evaluate result compliance.in clinical research processes. This ensures that all activities including experimental opera- Additionally the Group has executed quality agreements with its Contract Manufacturing

tions hazardous chemical management and laboratory waste handling are performed in Organizations (CMOs). We oversee and monitor the CMOs' production activities to ensure

strict accordance with established procedures thereby guaranteeing the high quality of they meet drug registration requirements thereby maintaining full control over final product

our R&D work. quality.Our Group places great importance on raw material safety and conducts comprehensive

supplier quality management through evaluation/auditing performance monitoring and

Procurement

a complaint feedback mechanism. All new suppliers must complete a quality assessment

Quality

questionnaire and undergo an on-site quality audit while existing suppliers are subject to

Storage and

periodic requalification audits. The Group performs regular quality performance reviews of Our Group strictly manages quality requirements during drug storage and transportation.materials which include an analysis of inspection results for all received batches a history Transportation We have implemented internal systems such as the Standardized Operating Procedures for

of quality issues and the status of quality agreements. Findings are documented in quality Quality Warehousing and Transportation to strengthen internal controls. This ensures robust quality

performance review reports. Furthermore our Supplier Quality Complaint and Feedback management across all logistics processes including pickup transportation warehousing

Management system standardizes the process for handling complaints related to produc- distribution and related information flow.tion materials throughout receipt inspection storage distribution and use ensuring that

all supplier complaints are addressed promptly and effectively.

80 81InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Pharmacovigilance Post-Marketing Safety Monitoring

InnoCare has established a Drug Safety Committee (DSC) comprising senior leadership and representatives from

functions including Preclinical Safety Quality Management and other functional departments responsible for analyz- All employees partners and members of the public are encouraged to report any adverse re-

ing and controlling major drug risks and participating in the decision-making and handling of major or emergency Voluntary actions or other safety-related events to the Group via the dedicated hotline (400-635-1999) or

drug events. At the same time the Group has a dedicated pharmacovigilance department responsible for monitoring Reporting email (PV@innocarepharma.com). The reporting channels have been published on the Compa-

the safety of drugs throughout their entire lifecycle and coordinating with other functional departments to jointly ny's official website.carry out pharmacovigilance work for drugs under research and products on the market ensuring efficient internal

transmission and closed-loop management of drug safety information.Safety reports are proactively collected from multiple sources including regulatory authorities

The Group strictly complies with the requirements of the Good Pharmacovigilance Practice and the Announce- research projects and InnoCare-initiated social media platforms and websites.ment on Direct Reporting of Adverse Reactions by Drug Marketing Permit Holders and formulates and implements Active Collection Medical journals and academic literature are regularly searched to gather product-related

pharmacovigilance quality system documents such as the Pharmacovigilance Policy of InnoCare Pharmaceutical safety data.Co. Ltd. refines the division of responsibilities and workflow of pharmacovigilance work and firmly guarantees the

safety and compliance of drugs.All product-related safety data from various sources are entered into the global safety database

End-to-End Pharmacovigilance Management

Safety Database for review and assessment of adverse reaction information in accordance with the regulatory

requirements of different countries.Preclinical stage Before the drug enters human trials a comprehensive analysis of non clinical

safety data safety information of similar drugs drug action mechanisms etc. In addition the Group attaches great importance to the role of external cooperation in pharmacovigilance work

is conducted to assess the safety risks of drug clinical use and targeted risk and carefully selects partners and outsourcing suppliers with compliance capabilities and professional experience

control measures are developed. to jointly carry out pharmacovigilance activities in order to meet the regulatory requirements of different countries

and regions around the world and improve the compliance and efficiency of pharmacovigilance work.Pharmacovigilance Collaboration

Signed a pharmacovigilance agreements with two multinational companies which clarifies

Pharmacovigilance the division of rights and responsibilities among all parties in safety monitoring reporting

Clinical trial stage Conduct timely evaluation of individual safety reports summarize and analyze Agreements evaluation and communication under cooperation models such as joint development li-

safety data and continuously update safety risk control measures based on cense in or license out to jointly ensure patient safety.this.Continuously strengthen the construction of pharmacovigilance system and actively partici-

pate in industry collaboration and standard co construction:

*Representatives from the Pharmacovigilance Department were invited to participate in

the drafting and discussion of relevant guidelines for the Drug Evaluation Center (CDE) of

After the drug is launched safety surveillance is carried out to collect adverse the National Medical Products Administration and to learn and contribute practical experi-

Post market stage drug reaction reports through various channels and process them according ence through exchanges.to standard operating procedures including report collection and review Pharmacovigilance *Join the consensus working group on “Remote Security Monitoring and Security Eventdata entry data quality control medical review report submission report Activities Reporting” of DCT (Decentralized Clinical Trials) to explore new models of patient safety

follow-up and death case investigation to continuously ensure the safety of monitoring in the digital era.patient medication. *Participated in the “Application of Artificial Intelligence in Pharmacovigilance - ExpertConsensus” project organized by the China Medical Innovation Promotion Association

(PhIRDA) CMAC promoting the compliant and efficient application of cutting-edge tech-

During the Reporting Period the Group did not receive any reports of group adverse reactions caused by drug defects. nologies such as AI in the field of drug safety and empowering the industry to develop with

high quality.

82 83InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

The Group adheres to conducting internal and external audits and continuously improves the management level Product Recall

of pharmacovigilance work. The Group's Pharmacovigilance Department conducts an annual internal review of InnoCare strictly complies with laws and regulations including the Drug Administration Law of the People's Repub-

pharmacovigilance work comprehensively reviewing the integrity compliance and effectiveness of the Group's lic of China and the Drug Recall Management Measures. We have established a robust product recall system with

pharmacovigilance and optimizing relevant systems and processes based on the review results. At the same time procedures that are fully compliant with Good Manufacturing Practice (GMP) requirements. Through documented

the Group regularly accepts special inspections and audits of pharmacovigilance from regulatory agencies and procedures such as the Recall Management Procedureand Deviation Management Procedure the Group has clearly

partners and further improves the pharmacovigilance management system through external evaluations. defined the end-to-end product recall process—from initiation and execution to final closure—along with the specific

In terms of capacity building the Group provides training on pharmacovigilance and safety information reporting responsibilities of each role involved.to all employees enhancing their sensitivity and sense of responsibility towards drug safety. For personnel in This system ensures that when necessary we can act swiftly and effectively to identify control scientifically assess

pharmacovigilance related positions the Group has developed an annual training plan to enhance their professional and properly dispose of non-conforming products. The defined process covers all critical steps including recall

abilities in pharmacovigilance and safety information reporting through offline teaching online learning and decision-making communication regulatory reporting and the return and destruction of products. Our overarch-

distribution of training materials. In addition the Group requires all new employees to sign the "Confirmation Letter ing goal is to prevent any unintended use or entry of such products into the market thereby safeguarding patient

of Responsibility Notification for Pharmacovigilance (PV) of InnoCare" and incorporate relevant regulations and safety and public health. The system also underpins product traceability and ensures the timely execution of any

systems on pharmacovigilance into new employee training urging new employees to fully learn pharmacovigilance required recall actions.knowledge and consolidating the overall quality and safety management foundation of the Group. In 2025 the Group

conducted more than 10 pharmacovigilance training sessions with a 100% participation rate in employee training.Identifying Notifying

product defects Determining the product recalls

Investigation and forming level of product and informing

assessment recall action regulatory

The Group conducted more than with a participation rate in employee reports authorities

training of

10 pharmacovigilance training sessions 100%

Carrying out and Determining Tracking

following up on Forming product

rectification recall reports disposal

product

measures recalls

The Group Carried Out an Awareness Campaign on Pharmacovigilance for All Employees Product Recall Process

In addition we regularly conduct product recall simulation exercises. These drills test the Company's emergency

In September 2025 the Group organized a pharmacov- response protocols the effectiveness of cross-functional coordination and the operability and efficacy of our recall

igilance themed promotional activity during the week procedures. This strengthens our overall risk response capabilities ensuring that patient safety and market stability

of Patient Safety Day. The activity revolves around the can be maintained swiftly in an orderly manner and in full compliance during an actual recall event. During the

theme of World Patient Safety Day 2025 and the require- Reporting Period there were no product recalls caused by quality issues.ments of the Group's pharmacovigilance. Through

a combination of online video promotion and offline Simulated Recall Drill

interaction it aims to popularize pharmacovigilance

knowledge to all employees of the Group and strengthen

In November 2025 the Group conducted a simulated recall drill involving Tafasitamab for injection

their compliance awareness. This promotion effectively

and Zanubrutinib tablets. The exercise simulated key aspects of a recall including event initiation

increased the importance that employees attach to

planning evaluation drug traceability inventory reconciliation and regulatory reporting. Participants

patient safety making them aware of the important

included personnel from multiple departments such as Quality Supply Chain Commercial Medical

significance of pharmacovigilance work in safeguard-

Affairs Pharmacovigilance Regulatory Affairs Analytical Development Production Formulation and

ing patient rights and ensuring the stable development

Corporate Communications. All tasks and objectives set for the drill were completed as planned and met

of the enterprise.The Scene of the Pharmacovigilance Awareness Campaign the predefined criteria confirming that InnoCare's recall processes are capable of executing a product

recall in full compliance with regulatory requirements.

84 85InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Quality Culture Building High-Quality Service

T Group regards quality training as an important tool for shaping the quality culture of the enterprise and strives to InnoCare is committed to providing customers with reliable products and professional services. We have steadily

enhance the quality awareness and professional level of all employees. Focusing on daily promotion and professional improved the overall service quality and customer experience through measures such as regulating marketing

deepening the Group has formed a multi-level training system covering new employee onboarding training behavior unblocking customer feedback and communication channels and strengthening data and privacy

quality promotion month activities quality and deviation management seminars and quality management system protection.(GMP/GSP/GCP) related courses. The Group has developed and implemented GMP specific training procedures

providing systematic regulatory and practical training to employees engaged in GMP related work helping them Customer Service

fully understand and accurately implement GMP requirements and ensuring that they have the necessary abilities to InnoCare adheres to responsible product marketing continuously optimizes customer communication and complaint

fulfill their job responsibilities. As of the end of the Reporting Period the total number of participants in the Group's handling mechanisms and strives to respond promptly and properly to customer opinions and suggestions

quality training reached 94917 with a total of 2788 training projects covering 100% of all employees. continuously improving customer service levels.Responsible Marketing

As of the end of the Reporting Period The Group actively practices responsible marketing and implements an approval mechanism for all external

promotional content. It can only be released after medical and compliance approval ensuring the authenticity

and accuracy of promotional information and effectively safeguarding patient rights and brand reputation. At the

the total number of partici- same time in order to create a professional and compliant marketing team enhance the compliance awareness and

pants in the Group's quality with a total of covering all employees academic literacy of marketing personnel we have carried out a series of training with the theme of "compliance

training reached 100 based and academic core". The training is carried out by the commercialization department in cooperation with

94917 2788 training projects

% various departments using a combination of online and offline models mainly covering two modules: policy

compliance and academic promotion.Responsible Marketing Series Training Content

Policy Compliance *?Systematic interpretation of regulatory requirements such as the Good Clinical Practice for

Module Drug Trial Quality Management safety event reporting system and pharmacovigilance policy

*?Conduct in-depth training on disease and product knowledge

Academic *?Conduct the monthly exam of “Building Small and Going Long”

Promotion Module *?Conduct “Coach Xiao Nuo” AI interactive simulation exercise

*?Organize brand activities such as “Academic Pioneers”

In 2025 this series of training has carried out a total of over 400 sessions covering over 10000 people achieving

100% coverage of national commercial team members effectively improving the team’s professional ability and

compliance execution.In 2025

this series of training has covering over achieving

Training Site carried out a total of

10000 people 100% coverage of national over 400 sessions commercial team members

86 87InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Customer Communication Information and Privacy Protection

The Group prioritizes patient needs and provides customers with smooth and diverse communication and feedback InnoCare attaches great importance to the protection of customer information and privacy security establishes an

channels carefully listening to their expectations and needs. information and privacy protection management system and comprehensively improves the level of information

security management from organizational structure institutional norms to technical measures. During the Reporting

Period the Group did not experience any information security violations or data breaches.Communication mailbox: info@innocarepharma.com Information Security Governance Architecture

channels for To strengthen information security governance the Group has established an Information Security Management

InnoCare customers Dedicated telephone: +86-10-66609999 Committee composed of senior management personnel such as the Chief Executive Officer (CEO) and Chief Operating

Officer (COO) responsible for providing strategic guidance and decision-making support for the Group's information

security work ensuring consistency with the Group's overall strategic objectives. The IT department of the Group is

At the same time the Group has established a medical service liaison channel to collect medication feedback and responsible for the specific implementation of information security protection work conducting regular risk assess-

clinical usage from patients and doctors continuously tracking the performance of commercialized products in ments identifying and evaluating potential data security risks and developing corresponding risk prevention and

practical applications in order to improve the quality of medication support and after-sales service. control measures based on the evaluation results. The dedicated person in charge of emergency management in

Customer Complaints the Group is responsible for refining the emergency response process regularly organizing emergency drills and

improving the collaborative ability of the emergency response team.The Group has formulated the Product Complaint Management Regulations to standardize and refine the complaint Information Security System

reception and handling process. Once a complaint is received the relevant department will initiate the workflow of

registration preliminary evaluation cause investigation process tracking and result summary. In the evaluation The Group strictly complies with relevant domestic and foreign laws and regulations such as the Cybersecurity Law

stage complaints are graded based on their severity and corresponding functional departments are coordinated of the People’s Republic of China the Data Security Law of the People’s Republic of China the Personal Information

to carry out inspections and rectification. Professional and clear handling results and improvement measures are Protection Law of the People’s Republic of China the General Data Protection Regulations and has formulated 16 sets

provided to customers to ensure timely and professional responses. During the Reporting Period the Group received of management systems including the Overall Guidelines for Information Security Management the Organizational

a total of 15 customer complaints all of which were properly handled and the complaint resolution rate was 100%. Norms for Information Security Management the Information System Security Risk Management System the Third

Party Information Security Management System and the Security Incident Reporting and Disposal Management

System which clarify the responsibilities requirements protection measures and processes for the Group’s infor-

mation security and privacy protection and improve its own data security capabilities and risk management. In 2025

the Group issued and implemented the Management Regulations for Information System Backup Archiving andRecovery establishing a closed-loop system for the entire process of “backup point inspection recovery archivingmedia management”. The effectiveness of backup is ensured through monthly inspection and annual review. At

the same time we establish standardized emergency plans clarify the data recovery process and conduct annual

recovery drills.

88 89InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Information Security Measures Responsible Procurement

Our group has taken various measures to protect information and data security building an integrated protection InnoCare adheres to Responsible Procurement continuously strengthens the construction of supply chain manage-

system around data security and network security. By implementing multidimensional control measures covering key ment system pays attention to the performance of suppliers in ESG and promotes the construction of a mutually

links such as data backup and recovery access rights management network threat identification and vulnerability beneficial and sustainable supply chain through a sound supplier management mechanism and close communi-

governance we have effectively reduced the risk of information leakage and network attacks. cation and interaction.Supplier Management

*?Unify and standardize the updated data security management requirements from the information

application system end to the employee's personal computer terminal. InnoCare strictly complies with relevant laws and regulations such as the Tendering and Bidding Law of the People's

*?To ensure the continuity of the Company's important business in disaster scenarios a disaster recovery Republic of China the Implementation Regulations of the Tendering and Bidding Law of the People's Republic of

center will be established in the cloud data center and data backup and encrypted storage strategies China and formulates internal systems such as the Procurement Management System the Supplier Management

will be formulated. A unified data backup center will be established to complete the remote multi-site the Material Supplier Management the Consumable Supplier Management the Contractor Management the

backup mechanism.Data *?Execute ERP system disaster recovery plan testing to achieve key recovery indicators. Supplier Monitoring and Maintenance and so on to facilitate the admission evaluation review elimination and

Security *?Implement differentiated permission management for cloud storage platforms and other data storage exit of InnoCare suppliers. And strict management processes are established for communication and other aspects

platforms based on different departments and responsibilities and further optimize backup manage- and standardized operations are constrained by signing quality agreements with suppliers to enhance supply chain

ment strategies. resilience and ensure supply quality.*?Establish information management regulations for third-party visitors including visitor registration

visitor reception and visitor dedicated wireless networks. Supplier Quality Management Process

*?It is explicitly stipulated that except for work needs any act of lending or disseminating the Group's

documents to third parties will be held legally responsible.*?Conduct multi-dimensional background checks on suppliers including qualification documents

*?Use the SIEM daily audit platform to conduct 7x24h monitoring and early warning of network threats. feasibility site visits proposal evaluation and due diligence.*?Establish a secure operation and maintenance fortress improve server security management and access Access *?Require suppliers to provide samples for small batch trial production and evaluate their equiva-

access and implement a public whitelist access strategy for critical business systems to strengthen lence with the materials from existing suppliers.security control.Net- *?Install a security protection platform on the server side to improve protection capabilities.work and *?Establish a security risk monitoring and response mechanism discover and warn risks in a timely *?Stipulate the corresponding auditing frequency and auditing method requirements based on the

Server Se- manner through MSS security monitoring services and further optimize the security strategy configu- categories of suppliers and continuously assess suppliers in terms of quality service cost and ration of network security equipment. other dimensions in accordance with the procurement management system to ensure ongoing

curity *?Conduct regular penetration testing and exposure analysis of critical business systems through security Evaluation and alignment with the Group’s requirements and expectations.platforms and tools and add a series of targeted security protection strategies including public network Review *?Conduct regular on-site audits for all key suppliers and set KPIs for monthly reviews.whitelist access strategies. *?Based on supplier review and evaluation results organize investigation plans and implement

*?Conduct regular vulnerability scans on core networks servers etc. fully fix any security vulnerabilities corrective or preventive measures to effectively prevent and control supplier risks.discovered and proactively identify and control security risks.*?In cases where a supplier fails to meet assessment standards conduct a risk assessment of the

During the Reporting Period the Group invited third-party audit institutions to conduct information security audits. non-conformities and depending on the results take measures such as rectification within a

After strict and meticulous review there were no non-conformities further ensuring the effectiveness of information certain period of time or suspension of supply qualification for such suppliers.Elimination and Exit

security and privacy protection work. *?Before disqualifying a supplier the Procurement Department must organize a cross-functional

team to evaluate and identify relevant action items and weigh the associated risks and benefits

Information Security Training including current inventory management supplier transition plans and other related actions.In terms of information security awareness cultivation the Group provides information security training to

all employees and incorporates relevant training into new employee onboarding training to help employees

systematically master basic information security knowledge and strengthen their emphasis on data and privacy

protection. At the same time the Group regularly organizes information security emergency drills to identify potential Communication *?Have bi-weekly online meetings and annual on-site communication with key suppliers covering demand forecasting post-supply review quality assessment and issues and deviations.weak links enhance employee security awareness and strengthen the collaborative response capabilities of the

emergency response team. During the Reporting Period the Group conducted one full staff information security

training and two full staff phishing email drills to enhance employees' ability to identify security risks and awareness

of prevention.

90 91InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Supply Chain ESG Management Supplier Empowerment

Our group incorporates ESG management requirements in supply chain management taking labor business ethics In terms of supply chain collaboration InnoCare focuses on improving the comprehensive capabilities of suppliers

quality safety environment and other aspects as important dimensions for supplier admission and evaluation and continuously communicates with them on services technical requirements and quality management through

promoting suppliers to carry out ESG practices and enhancing their understanding of sustainable development various forms such as on-site training online meetings and written communication. The Group and major suppliers

concepts. conduct online communication every two weeks focusing on demand forecasting post supply review quality evalu-

In terms of labor management we require suppliers to comply with relevant laws and regulations such as national ation and problem deviations. An on-site communication is organized once a year to jointly discuss the causes of

labor laws pay attention to protecting the personal safety of employees and require certain suppliers to provide quality problems and rectification plans. The Group assists suppliers in optimizing their processes and management

employees with onboarding medical examinations occupational health examinations necessary safety measures processes while enhancing their capabilities and further consolidating product and service quality.and labor protection equipment. In terms of business ethics we require suppliers to sign the Anti Commercial

Bribery Agreement and No Conflict of Interest Declaration strictly prohibiting any illegal or irregular behavior that

violates the principle of integrity. In 2025 a total of 2480 suppliers signed letters of commitment to integrity and

self-discipline. In addition we attach great importance to examining the management level of suppliers in terms of

environment quality and other aspects. We sign EHS agreements with suppliers based on categories set clear and

strict requirements for EHS performance and review the relevant management system certification of suppliers.We prioritize selecting suppliers with good management practices such as those who actively use environmentally

friendly products and services and regularly carry out quality improvement activities.In 2025

a total of 2480 suppliers signed letters of commitment to integrity and self-discipline.Guangzhou InnoCare Purchases Packaging Materials with FSC Certification

In 2025 Guangzhou InnoCare practices green procurement and actively purchases packaging materials

with FSC certification.FSC Certification Certificate For Packaging Materials

InnoCare guides suppliers to continuously improve their sustainable management level through ESG review and

inspection. For potential partners the Group selects suppliers that meet the requirements through ESG related

reviews. For existing suppliers conduct routine inspections and supervision to evaluate their ESG performance and

urge them to continuously improve their ESG management practices.

92 93InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

04

Caring for Employees People-

oriented Approach

SDGs Addressed in this Chapter

InnoCare always puts talents at the core of enterprise innovation and sustainable

development continuously optimizing talent management mechanisms and employee

cultivation and development systems and improving comprehensive salary and

benefits and long-term incentive mechanisms effectively safeguarding the legitimate

rights and interests of employees strictly controlling safety production ensuring

occupational health and safety and continuously creating a safe healthy equal

inclusive and dynamic work environment.

94 95Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Compliant Employment We continuously improve the business system and management process of talent acquisition. In terms of manage-

ment processes we have enhanced the intelligent management of recruitment processes. Through talent recruitment

InnoCare adheres to the principle of combining compliant operation with people-oriented approach strictly abides channels such as Beisen and Liepin we carry out AI assisted talent management and interview practices to improve

by national laws and regulations such as the Labor Law of the People’s Republic of China the Labor Contract Law overall recruitment efficiency and accuracy. At the same time we have optimized and upgraded the construction of

of the People’s Republic of China the Law of the People’s Republic of China on the Protection of Minors the Social internal referrals rehiring and the “industry-university-research” talent ecosystem to ensure the high adaptability

Insurance Law of the People’s Republic of China. Furthermore by improving internal systems such as the Recruit- and sustainability of the talent pipeline. In 2025 the Company actively improved its brand image in the recruitmentment Handbook the Group systematically regulates key aspects including employee recruitment compensation market released more than 20 popular professional job postings and won the “HR Asia Best Companies to Work forand benefits promotion and development working hours and leave as well as anti-discrimination. in Asia” from HR Asia marking the Company's authoritative recognition in talent management and organizational

The Group firmly prohibits any form of child labor and forced labor and ensures the authenticity and validity of construction.employee identities by strictly reviewing candidate identity information during the recruitment process thereby

avoiding the occurrence of child labor and forced labor from the source. During the Reporting Period the Group did

not engage in any violations of child labor or forced labor.The Group adheres to the employment philosophy of equal employment and diversity & inclusion strictly adhering

to job oriented selection standards in recruitment promotion salary and career development and resolutely elimi-

nating any differential treatment based on factors such as gender age religious beliefs race ethnicity region and

disability effectively ensuring equal opportunities for all employees. In 2025 InnoCare had 673 female employees

accounting for 52% of the total workforce; There are 66 ethnic minority employees accounting for 5% of the total

workforce.In 2025

673 HR Asia Best Companies to Work for in AsiaFemale employees Ethnic minority employees 66

accounting for 52% of the total workforce accounting for 5% of the total workforce

The Group prohibits any form of harassment including but not limited to physical verbal visual and other forms Building the "Industry-University-Research" Talent Ecosystem

of harassment. We strictly regulate employee behavior and hold a zero tolerance attitude towards any form of

harassment by employees customers suppliers or other partners. At the same time the Group encourages

employees to actively report any form of harassment they encounter or discover and will take strict punishment In 2025 the Company launched an initiative to build the “industry-university-research” talent ecosystem

measures once violations are found. inviting faculty and students from the Peking University Health Science Center and doctoral graduates

returning from overseas for exchanges and on-site visits in order to build a sustainable talent pipeline.This initiative not only effectively attracted outstanding graduates to join the Company but also laid a solid

foundation for future collaboration with top research institutions in talent cultivation and research projects.Industry-University-Research Collaboration Event

96 97Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Talent Development

InnoCare BoLe Internal Referral Program Upgrade

InnoCare firmly believes that the continuous growth of employees is inseparable from the long-term development

of the organization. To this end we are committed to building a systematic and forward-looking training and devel-

In 2025 the Company planned and launched the “InnoCare BoLe” internal referral program upgrade opment system comprehensively empowering the career development of every employee through diverse learning

migrating the internal referral process from desktop to mobile platforms. We effectively enhanced employee paths and clear promotion channels.engagement and identification with the Company through Company-wide promotion multi-channel

publicity and tiered incentives. This year employees hired through internal referrals reached 61% of total Talent Training

hires an increase of 16 percentage points from the previous year which successfully validated the value of Supported by a systematic and forward-looking training system InnoCare has built a diversified and three-dimen-

the internal talent network in efficiently matching high-potential talents with a strong cultural fit providing sional training project matrix around key areas such as management capability development enhancing professional

an effective path for the continuous optimization of the recruitment system. expertise and vocational skills new employee integration and growth and external qualification certification. The

Group is committed to providing comprehensive learning resources and training paths accurately addressing to

the growth needs of employees at different stages continuously improving talent competitiveness and injecting

lasting momentum into the long-term development of the organization. During the Reporting Period RMB 867300

Exploring the Implementation of the "Boomerang" Program was invested in employee training.In 2025 the Company launched the “Boomerang” program aimed at attracting eligible departing employ- During the Reporting Period

ees to return to their positions. This plan not only quickly filled job vacancies and shortens the integration

cycle but also further demonstrated the cohesion of the Company culture and the attractiveness of the

employer brand through this initiative. During the Reporting Period the Company successfully rehired six RMB 867300 was invested in employee training.individuals providing strong support for sustainable development.InnoCare Employee Training System

*?Providing systematic management training for middle and senior managers including online

Management management training at China Europe International Business School offline workshops and

trainings a series of the Manager Handbook training continuously strengthening leadership and strate-

gic thinking.*?Covering departmental onboarding and on-the-job training specialized lectures on drug research

Professional production and sales and lectures on the “InnoCare New Drug Club” focusing on product knowl-

trainings edge GMP/EHS standards and management skills enhancing professional competency for the

respective position.Skills *?Organizing professional title assessment and coaching for R&D personnel strengthen pharmaceu-

tical training for commercialization teams and specialized occupational safety training programs

trainings to support employees in achieving skill advancement and qualification certification.New *?Providing standardized onboarding training supported by the New Employee Onboarding Guide

employee and a position mentoring mechanism to help new employees quickly integrate and enable a

trainings smooth start.External *?Providing vocational certification training regulatory compliance update courses and industry

cutting-edge skill enhancement projects ensuring alignment with external standards and broaden

trainings professional perspectives.

98 99Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Employee Development

Organizing the "New Drug Club" Lecture Series InnoCare continues to optimize the talent mechanism that emphasizes both motivation and development deeply

integrating clear promotion channels scientific performance management and a competitive compensation and

return system helping each employee achieve personal value while jointly promoting the continuous achievement

In 2025 The Group meticulously organized three sessions of the “New Drug Club” series. This series of the Company's strategic goals.systematically analyzed the end-to-end knowledge of drug development covering topics from registration Salary Performance

and application clinical pharmacology to cutting-edge advances in hematologic oncology effectively

enhancing the professional depth and versatile skills of the relevant teams. This initiative represents an Based on the job rank system specified in the Employee Handbook the Group provides employees with salary and

important effort by The Group to build a learning organization and promote the continuous growth of its benefits that are in line with the market. In the design of the compensation system the Group has introduced "3P1M

employees. As of the end of the Reporting Period The Group had organized a total of 3 lectures with over " principle. Based on external market dynamics internal job development and individual employee performance

500 participants in attendance. a systematic review and dynamic optimization of the salary structure and level are carried out and targeted annual

salary adjustment arrangements are implemented accordingly to ensure that the salary system combines external

competitiveness and internal fairness and continuously stimulate talent vitality.InnoCare Employee Incentive Plan

*?Recognized the “Annual Star Team” and “Outstanding Employees” and awarded the Long-term

Honor recognition Service Award the Nuoxin Award (InnoCare Core Value Award) as well as Core Values Badges

that provide dual “Material and Spiritual” motivation.Guest Speakers of the "New Drug Club" *?Established equity incentive mechanisms to reward core technical talent key role holders

and senior management.Equity incentive

*?The Company implemented the Hong Kong Stock incentive plan and the Science and Technol-

ogy Innovation Board incentive plan covering more than 300 employees.Core Leadership Empowerment Training

On August 19 2025 the Group conducted three core courses "IMPACTFUL Influencing" "Manager

Communication 2.0" and "DISC: Self Awareness and Understanding Others—Building High-Performance

*?Milestone-based rewards are offered for key R&D projects. The Annual Breakthrough Award

Teams" in Beijing. This initiative marks a significant step forward for the Group in building a systematic R&D incentive

is presented to employees who achieve significant advancements.manager training system. This is not only a talent gift to the tenth anniversary of the Group but also a

long-term investment to reserve core leadership for the continuous implementation of the strategy and

promote the common growth of the organization and talents.

5 3P1M: Designing the remuneration system based on four factors namely Position Person Performance and Market.

100 101Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Promotion and Development Employee Care

InnoCare has established a dual-track development system that covers professional and managerial paths aiming InnoCare regards employee care welfare protection and rights protection as the key cornerstone for consolidating

to provide clear and diverse promotion options for employees with different characteristics and fully support their the team and practicing the people-oriented concept committed to building a comprehensive multi-level and

long-term career planning. warm employee support system.Governance

Guided by its distinctive ESG governance framework InnoCare advances initiatives for employee rights and welfare

Professional Manage protection. The Board of Directors provides overall leadership and coordination for the management and execution

Career Path Career Path of employee rights safeguards and welfare care laying a solid foundation for fostering a harmonious and sustainable

environment for employee development.Strategy

The Company treats employee care welfare safeguards and rights protection as the cornerstone for team cohesion

Dual Career Development Paths for Employees and the embodiment of its people-oriented philosophy dedicating itself to building a comprehensive multi-tiered

and supportive employee assistance

The Group conducts multidimensional evaluations of employees' work performance professional behavior job

abilities and development potential through a systematic promotion evaluation mechanism every year. The Impact Risk and Opportunity Management

evaluation process fully combines the personal wishes and career development direction of employees providing

a continuous upward development platform for outstanding talents on the basis of ensuring procedural fairness Employee Rights and Interests

and equal opportunities and achieving common progress between individuals and organizations. InnoCare has established and improved internal communication mechanisms regularly held democratic man-

To continuously optimize the talent management system we regularly organize and implement systematic talent agement meetings and effectively protected employee rights and interests. The Group has successively formu-

reviews relying on the Company's independently developed talent review methodology to scientifically evaluate lated and implemented internal regulations such as the Employee Representative Election Policy and the Ration-

and classify the existing talent structure ability potential and development direction. Based on this targeted training alization Proposal Policy and has established an employee representative meeting to conduct regular employee

plans are formulated to achieve effective talent screening key cultivation and dynamic management providing satisfaction surveys. The relevant measures have effectively expanded the channels for employees to express and

sustainable talent support for organizational development. provide feedback ensuring that the Company can timely and comprehensively listen to their opinions and de-

mands. This practice not only facilitates a thorough understanding of employee sentiments but also effectively

safeguards their rights to information participation expression and oversight in corporate operations. During

the Reporting Period the Group conducted one employee satisfaction survey which resulted in an employee

satisfaction rate of 72.7%.During the Reporting Period the Group conducted:

Employee satisfaction survey Employee satisfaction rate

172.7%

102 103Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

InnoCare's Employee Communication Channels InnoCare Employee Care Measures

*?By holding all-staff meetings the Company systematically communicates the latest informa- *?Provide maternity benefits and maternity rooms for female employees who have given birth;

All-Staff meetings tion on project progress business development operational status strategic planning and *?Regularly organize International Women’s Day themed activities and promote outstanding

policy adjustments to employees. Female employees women's rights;

*?Add dedicated women’s health screenings to the annual physical examination provide

Employee *?The Group has established a team of employee representatives with different levels organ-

comprehensive protection for female employees’ rights and health.representative izations and genders regularly hold employee representative meetings reviewed impor-tant systems such as the Employee Handbook and provided guarantees for employees to

meeting exercise their democratic rights. *?Provide support to employees facing family difficulties critical illnesses or unforeseen

Employees in need emergencies which includes assisting with public rental housing applications facilitate access to critical illness protection policies and issue relief grants to effectively alleviate

Rationalization *?The Group has set up a Rationalization Proposal Column for employees to submit suggestions their pressure.related to R&D innovation business development daily operations and internal policies and

proposal column systems.Online *?The Group has established online communication channels such as Enterprise WeChat

communication Microsoft Teams Outlook email and a reporting hotline to ensure real-time transmission The Group attaches great importance to the physical and mental health of employees and team cohesion. We have

channels and sharing of information. continued to carry out a series of cultural and sports activities held the third "Incredible Women Contest" prepared

holiday gifts for employees' children and organized team building activities with the theme of "Unite for the Future"

*?The Group regularly conducts InnoCare employee satisfaction surveys which cover the "five effectively promoting the balance between employees' work and life and enhancing the team's centripetal force Employee

key dimensions" of genuine concern to employees and actively encourages them to voice and cohesion.satisfaction survey their opinions.Caring for Children's Day on June 1st

Employee Welfare

InnoCare is committed to building a highly competitive welfare system from basic social security to employee welfare In order to deepen the care for employees' families on this year's Children's Day the Company has

care providing solid support and a warm sense of belonging for every employee truly achieving a harmonious optimized the form of care for employees' children. By directly delivering carefully prepared holiday

balance between work and life. gifts to all employees' children the Company conveys its sincere blessings to the next generation and

InnoCare Welfare System sincere gratitude to employees' families in a more direct and equal manner. This not only reflects the

Company's continuous attention to the well-being of employees' families It also further strengthens the

warm connotation of employees' sense of belonging and the Company's "home culture".*?Pay the social insurances and housing funds for all employees;

Basic social *?Provide paid sick leave for all employees;

security *?Regularly organize routine health check-ups and psychological counseling;

*?Additional supplemental commercial insurance critical illness insurance twin child medical insur-

ance etc..*?Provide statutory holidays parental leave maternity leave caregiver leave and other welfare leave

for all employees;

Employee *?Provide transportation subsidies or shuttle services meal allowances or staff canteens for all

welfare care employees;

*?Establish health clubs such as badminton and basketball clubs;

*?Prepare holiday gifts wedding cash gifts birthday presents etc. for all employees.The Group pays special attention to the actual needs of female employees disadvantaged employees and special

needs groups and conveys organizational warmth through a series of targeted measures.

104 105Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Indicators and Objectives

The Third "Incredible Women Contest"

In 2025 the Company organized an annual “InnoCare Employee Satisfaction Survey” for employees who have

been employed for three months or more to ensure a comprehensive evaluation and continuous improvement of

The “Incredible Women Contest” was successfully held during the International Women’s Day in 2025. The employee rights and welfare levels

activity closely adheres to the five qualities of “focus resilience innovation collaboration and excellence”

The purpose of this survey is to fully understand the employee experience and core demands focusing on five dimen-

that align with the Company’s values. Through fun team challenges it provides an exclusive platform for

sions: Company culture and work environment job content and development Company management mechanism

female employees to showcase their talents and enhance cohesion. This event has become an important

comprehensive salary and benefits system and Company brand identity. It further enhances the effectiveness

cultural brand of the Company vividly demonstrating the Company’s firm commitment to creating a diverse

of information transmission and feedback from employees to the Company providing important references for

inclusive and mutually supportive growth oriented workplace environment.optimizing human resource management deepening employee rights and welfare protection work in the future.The survey results indicated a Company-wide employee satisfaction rate of 72.7% for 2025.The survey results indicated

a company-wide employee satisfaction rate for 2025 is

72.7%

The "Incredible Women Contest" Fun Event

"Unite for the Future" All Staff Walking Activity

To celebrate the 10th anniversary of the establishment of InnoCare the Company successfully held the

"Unite for the Future" all staff walking activity on June 8 2025 by the bank of the Wenyu River in Beijing.The location of the event symbolizes the continuous development of the Company over the past decade.Through the participation of all staff and joint efforts not only has team integration been effectively

promoted and employees' health awareness been enhanced but the Company's spirit of striving and unity

and cooperation has also been vividly demonstrated opening a vibrant prelude to the 10th anniversary

celebration series.The 10th Anniversary Walking Activity of InnoCare

106 107Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Safety and Health

Director

Deputy General Manager

InnoCare strictly regulates production safety operations regularly arranges hidden danger inspections and improves

its safety risk control capabilities. At the same time the Group strengthens its occupational health defense line contin-

uously improves the working environment prevents and controls occupational disease hazards and ensures the Deputy DirectorDeputy Director of EHS

physical and mental health and safety of every employee. During the Reporting Period the Company has set safety

and health management goals of “0” for work-related accidents “0” for lost time accidents and “0” for occupational

disease accidents and all have been achieved. During the Reporting Period we also completed the internal audit Quality Formulation Engineering Advanced Active R&D Procurement Human Finance Administration

Department Production Department Pharmaceutical Department Department Resources Departm ent Department

and management review of its occupational health and safety management system with no major nonconformities Department Ingredient(API) Department

Deputy Executive Production R&D Deputy Deputy Director Senior Manager

identified and successfully passed the ISO 45001 recertification audit. Director Production Director Department Manager Director Deputy of Finance

of Quality Director of Procurement Director of Departme nt

Deputy Director Human

of API Production Resources

Work-related accidents Occupational Quality Quality Production Operations Project Deputy Lost time accidents Control Assurance Manager Manager M anager Production

disease accidents (QC) (QC) for Phase II ManagerManager Manager

000

EHS Committee Structure of Guangzhou InnoCare

The Group strictly complies with laws and regulations such as the Work Safety Law of the People’s Republic of

China the Fire Protection Law of the People’s Republic of China the Regulations on Safety Management of Hazard-

ous Chemicals and has revised the Work Safety Responsibilities for All Employees the EHS Safety Publicity and

Education Training System the Safety Production Accident Hidden Danger Investigation and Treatment System the

Accident Hidden Danger Internal Report Reward System the Accident Incident Investigation and Handling Procedure

and the Contractor Management Procedure. By implementing a safety management system we will promote the

comprehensive implementation of safety production responsibilities ensure that responsibilities are clearly defined

processes are standardized and safeguards are implemented and establish a new pattern of safety management

with clear rights and responsibilities and orderly operation. In 2025 we continued to improve the construction of the

safety management system released 16 management system documents optimized 23 existing safety management

system documents and provided reliable institutional guarantees for the standardization of safety management.Production Safety

InnoCare attaches great importance to production safety management and continues to improve its scientific

and rigorous safety management system. Through systematic investigation and management of hidden dangers To establish a solid foundation for safety production and

strengthening emergency response capabilities for emergencies deepening the construction of a safety culture for strengthen responsibility orientation InnoCare has set clear and In 2025

all employees multiple measures are taken to strengthen the safety defense line and promote the Company's safety quantifiable annual safety management goals. The Group has the Guangzhou InnoCare achieved

management level to move towards specialization and refinement. comprehensively and systematically incorporated the fulfillment significant safety performance by

Production Safety Management of safety responsibilities into the performance evaluation system continuously working

at all levels implemented a strict linkage mechanism between

In order to comprehensively coordinate and deepen the Company's safety production management InnoCare safety performance and rewards and punishments ensuring

continuously improves its EHS management structure and has officially established an EHS management committee that safety goals and business goals are deployed implemented

with clear rights and responsibilities. As the core hub of the Company's EHS governance system this committee and assessed together fundamentally ensuring the high-quality 5109000 hours.is committed to systematically promoting collaborative work mechanisms unifying management standards achievement of the Group's annual safety management goals.strengthening risk prevention and control and continuously improving the safety literacy and emergency response In 2025 the Guangzhou InnoCare achieved significant safety

capabilities of all employees thereby building a solid and stable management foundation for the Company's performance by continuously working 5109000 hours.sustainable operation and high-quality development.

108 109Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Risk Identification InnoCare's Hazard Identification Measures and Achievements

The Group has integrated a dual prevention mechanism into the safety information system identifies and assesses

safety risks implement differentiated and precise control based on risk levels and ensure that control measures *?By auditing the conformity effective-

match risk levels. In 2025 the Group identified a total of 1576 risk scenarios through systematic sorting and compre- ness regulatory applicability achieve- *?During the Reporting Period the Group completed Systematic internal system audits management reviews and a

hensive identification of hazards and developed corresponding control measures for each risk. The Group identifies ment of targets and implementation of auditing surveillance recertification audit for the system and

assesses and manages key control measures such as process safety risks and material chemical hazards. During management review resolutions of the

ISO 45001 management system. no major nonconformities were found.the Reporting Period the Group conducted risk scenario HAZOP for key projects Analyze and reduced 218 extremely

high risk scenarios 225 very high risk scenarios and 152 high risk scenarios to 0.Hazard Identification *?Develops an annual safety inspection *?During the Reporting Period The Group conducted

Normalized risk plan covering inspections prior to a total of 13 inspections and we encouraged all

With the goal of "Dynamic Risk Clearance and Continuous Closed-Loop Management" InnoCare continues to deepen important holidays specialized inspec- employees to participate in the “I Identify I Act”ini-investigation tiative. A total of 1755 items were reported with a

the construction of a dual prevention mechanism of "Safety Risk Classification and Control" and "Hazard Identification tions and seasonal inspections. timely rectification rate of 97%.and Treatment" comprehensively promoting the upgrading of the safety review system to normalization intelligence

and integration. Through systematic auditing and normalized risk and hazard investigation we ensure that the entire *?During the Reporting Period the Personnel Position-

process from internal operations to external contractors is controlled with more accurate hazard investigation and ing System provided full-time dynamic behavioral

more efficient treatment and more sustainable operation. safety management for personnel entering high-risk

areas. It was also integrated with the special work

At the same time the Group adheres to the principle of "Contractor Safety Equals Self-Management" fully integrating *?Promotes the application of digital permit management process achieving intelligent

contractors into the Company's unified EHS management system and implementing a full process closed-loop management tools namely the control over the behavioral norms of personnel “Personnel Positioning System” and

management covering pre-qualification audit process supervision and performance evaluation. Digital risk involved in the work.the “EHS AI Assistant” strictly requires

control personnel in high-risk areas to use *?The EHS AI Assistant integrates national EHS-related

positioning cards and utilizes the AI regulations and standards as well as the Guangzhou

assistant for daily safety inquiries and InnoCare internal EHS management system and

learning supervision. SDS building a professional and systematic knowl-

edge base. It can respond in real-time to employee

inquiries on environmental health safety and other

professional matters providing accurate and stand-

ardized answers.*?Through standardized review mecha-

nisms and dynamic assessments we *?During the Reporting Period the access and regular

Third-Party aim to promote the homogenization audit mechanisms were strictly implemented to

(contractor) of contractor safety management with promote the alignment of safety management stand-

Company standards and continuously ards and contractors achieved LTI =0. TRI =0 a 100% safety review

improve the overall security level of the on-site training rate and a 100% closed-loop rate for

supply chain. hazard rectification.Emergency Management

To ensure the continuous safety and rapid recovery of R&D activities during emergencies InnoCare attaches great

importance to enhancing emergency preparedness in laboratories and hazardous chemical storage rooms. By

regularly conducting systematic hazard identification and emergency-specific audits we focus on testing the

emergency response and compliance disposal capabilities of experimental operations hazardous chemical manage-

ment and waste disposal in emergency situations. In 2025 The Group organized 13 emergency drills covering

scenarios such as chemical spills fire response and emergency incident handling with a total of 202 participants.

7 LTI: Lost Time Injury

6 HAZOP: Hazard and Operability Study 8 TRI: Total Recordable Incident

110 111Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Emergency Drill for Laboratory Chemical Leakage Accidents Comprehensive Emergency Drill for Centrifuge Fire Accident in Workshop F

In August 2025 Guangzhou InnoCare organized an on-site handling drill for chemical leakage accidents In November 2025 Guangzhou InnoCare organized a comprehensive emergency drill for a fire accident

in research and analysis laboratories simulating scenarios of chemical container damage and leakage of the Workshop F centrifuge. The drill simulated a scene of a fire caused by the volatilization of material

focusing on training laboratory personnel in emergency response skills in the event of leakage ensuring solvents during the discharge process of the F workshop centrifuge resulting in an explosive atmosphere

that relevant personnel are proficient in the containment collection and safe disposal processes of and static electricity generated by the working tools. Each emergency response team responded quickly

chemical leaks. with clear division of labor and orderly deployment from initial firefighting process isolation personnel

evacuation to peripheral warning and communication firefighting and rescue demonstrating the Compa-

ny’s excellent professional competence and collaborative combat ability of the emergency team.Emergency Drill and Disposal Site for Laboratory Chemical Leakage Comprehensive Emergency Drill Site for Fire Accidents

112 113Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Construction of Safety Culture

InnoCare attaches great importance to the construction of safety culture. Through holding a series of activities such as Security In July 2025 the EHS department established a “Safety Corner”

“the Safety Month” actively carries out various forms of safety activities continuously improves the safety awareness Corner in the office area integrating safety culture into employees’ daily

of all employees and enhances the safety atmosphere of the enterprise. The Company adopts a mixed training mode Creation work environment through display continuously attracting em-

combining “online theoretical teaching+offline practical exercises” to ensure that the training content is practical ployees to stop and communicate effectively increasing the visi-

the forms are flexible and diverse and the safety literacy and operational ability of employees are comprehensively bility and impact of safety culture.improved. In 2025 the Group conducted 19 types of training with a total of 2457 participants.InnoCare Safety Culture Construction Activities

Leader-

On June 6 2025 Guangzhou InnoCare held a safety month ship On-

Safety kick-off meeting attended by Dr. Gao Nan general manager of site Safety In July 2025 Company-level leaders were organized to conduct

Month Guangzhou InnoCare Lu Xianfeng the deputy general man- Inspec- safety inspections and on-site walkthroughs and addressing

Kick-off ager and department heads. During the meeting the Safety tion & Walk- daily safety related issues. This created a channel for direct dia-

Meeting Month activity plan was officially released and a promotional through logue between management and frontline employees enabling

video titled “Safety Production Month” was screened. A crea- them to listen to employee feedback and suggestions.tive building block competition with safety-themed keywords

as elements was held on-site.Safety

Knowl- In June 2025 Guangzhou InnoCare set up offline safety knowl-

edge edge check-in points incorporating QR code scanning for

"Safety Leadership" Training

Check-in safety quizzes on display boards. By leveraging digital tools to

& Quiz transcend time and space limitations it effectively reinforced

employees' mastery of safety knowledge operating proce- On October 23 2025 to enhance the safety leadership ability of the management team Guangzhou

dures and key emergency response points. InnoCare specially invited external experts to conduct a special training on “Safety Leadership” for super-

visors and above management personnel. Training promotes the upgrading of safety management from

“Supervision” to “Guidance” through case studies interactive teaching and other forms helping managers

master key methods of setting safety examples strengthening risk communication and fostering team

On July 4 2025 Guangzhou InnoCare organized a safety skills

Safety safety awareness.Skills competition. The competition revolves around the standard-

Competi- ized use of personal protective equipment (PPE) at the work-

tion site. Each participating team needs to quickly and accurately

identify the required protective equipment and complete

standard wearing based on the simulated specific work sce-

nario.Firefight- On July 9 2025 Guangzhou InnoCare specially invited local

ing Practi- firefighters to enter the factory and provide specialized practi-

cal Train- cal training on firefighting facilities for employees from various "Safety Leadership" Training Site

ing departments. The training focused on the usage skills of key

emergency equipment such as positive pressure air respira-

tors smoke masks and fire hoses with nozzles. This activity has In addition the Group attaches great importance to contractor safety management and safety culture development

significantly enhanced the practical operation skills and emer- and fully integrating contractor personnel into the Company's unified safety training system. By organizing special

gency awareness of employees. safety training systematically promoting and implementing safety production regulations job site risk control

requirements and emergency response processes effectively strengthening the safety responsibility awareness

and independent management ability of contractor personnel and promoting the homogenization of contractor

safety standards and the Group's management requirements.

114 115Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Occupational Health Occupational Health Protection Measures

InnoCare always puts the occupational health of its employees at the core of the Company's development strictly

adhering to the requirements of laws and regulations such as the Law of the People's Republic of China on Preven- *?Comprehensively identify occupational hazards and high-risk positions in the workplace

tion and Control of Occupational Diseases and systematically establishing and continuously improving its internal Occupational and implement tiered control based on OEB (Occupational Exposure Band).occupational health management system. The Company has developed and implemented a series of management Hazard Monitoring *?Engage a qualified third-party organization to conduct regular monitoring of occupational

systems including the Occupational Hazard Warning and Notification System the Chemical Hazardous Factors and Assessment

hazard factors. During the Reporting Period the monitoring results for all positions complied

with national standards.and Occupational Health Risks Assessment System and the Occupational Disease Hazard Emergency Rescue and

Management System comprehensively covering all aspects of hazard identification risk assessment protection

measures and emergency response aiming to build and maintain a healthy safe and compliant work environment Occupational *?Equip all employees with personal protective equipment (PPE) that complies with national

Health Protection standards ensuring effective protection and full coverage.for all employees.and Workplace *?Regularly update key equipment such as pressure vessels to ensure safe operation of the

Occupational Health Management Targets for InnoCare equipment.Environment *?Install engineering control facilities such as negative pressure operation and local exhaust

Improvement ventilation for high-risk positions to continuously reduce occupational exposure risks.Target classification Target setting Achievement status

*?Organize practical first-aid skill training to enhance employees' on-site emergency response

Occupational

Qualified detection of occupational hazards capabilities.

100% 100% Health *?Conduct safety alerts and education on typical accidents in the pharmaceutical and chemical

factors in the workplace

Training and industry for the API (Active Pharmaceutical Ingredient) department.Capacity Building *?Invite professional psychologists to conduct mental health lectures helping employees

Declaration of occupational hazards 100% 100% alleviate stress and enhance psychological resilience.*?Provide full-cycle (pre-placement periodic and post-placement) occupational health

Post occupational hazard notification rate 100% 100% Occupational examinations for employees in positions with occupational disease risks.Health Surveillance *?Contribute to the work-related injury insurance for all employees in accordance with the law

and procure safety production liability insurance. During the Reporting Period a cumulative

and Safeguards

Qualification rate for occupational health total of 500000 RMB was invested in safeguard funds achieving 100% employee coverage

100% 100% and establishing a solid risk protection system.

training

Employee health examination rate 100% 100% To effectively enhance employees' awareness of health and safety the Group continues to improve our employee

safety and health training mechanisms regularly carries out warning education skill practical training health

lectures and invites external experts to provide professional training covering areas such as occupational safety

The Group deeply integrates occupational health and safety protection mental health and occupational health protection to ensure the effective implementation of safety and

work into the entire lifecycle of enterprise operation and During the Reporting Period health related training.development. By establishing a systematic management cycle

covering hazard identification risk assessment engineer-

ing control health surveillance emergency response and the employee health examination quali-

continuous improvement we strengthen the occupational fication rate was

health defense line from multiple dimensions such as system 100 %

technology culture etc. effectively fulfill the main responsi-

bility of the enterprise and fully guarantee the physical and

mental health and legitimate rights and interests of every

employee. During the Reporting Period the employee health

examination qualification rate was 100% and the Group did

not identify any suspected occupational diseases or employ-

ees with occupational diseases.

116 117Caring for Employees People-oriented Approach

InnoCare 2025 ESG Report

Occupational Safety Protection Training Mental Health Salon

In 2025 in order to continuously strengthen the occupational safety protection of chemical operators’ On August 14th Guangzhou InnoCare invited Professor Hu Bingmei a psychological consultant from the

hands the Company invited senior engineers from professional glove suppliers to provide specialized “Pufa Station” of the Huangpu District People’s Procuratorate to participate in an OH Cards Group salons

hand protection practical training for employees who are in contact with chemicals in API production utilizing the multidimensional interpretation mechanism of OH Cards promote individuals to break through

quality control (QC) and R&D etc. The training focused on the characteristics of chemicals systematically occupational cognitive patterns reduce workplace internal friction and achieve the concrete presentation

explaining the material selection grade identification wearing standards and scenario evaluation of gloves. and systematic sorting of professional values.Through demonstration and practical operation it ensured that employees master the skills of “selectwear and use correctly” to reduce hand exposure risks from the source.Mental Health Salon Activity

Occupational Health and Safety Protection Training Session

Special Training on First Aid Skills

Special Health Lecture on "Self-Care for Neck Shoulder Waist and Leg Pain"

On March 21 2025 the Beijing Life Science Park specially invited emergency experts from Beijing Health

In July 2025 the Group held a special health lecture on "Self-Care for Neck Shoulder Waist and Leg Pain". Network to conduct special training on emergency skills systematically explaining and demonstrating key

The purpose of this event is to address the common health risks of sedentary work empower employees to emergency procedures such as the use of AED (Automatic External Defibrillator) chest compressions and

master effective self-care skills through the guidance of professional physicians alleviate musculoskeletal artificial respiration on site. The trainees conducted a full process practical exercise under the guidance of

discomfort improve overall well-being and work efficiency and demonstrate the Company's continuous experts effectively mastering the practical skills of cardiopulmonary resuscitation (CPR) and AED opera-

investment in employee health. tion significantly improving their emergency rescue capabilities in the face of emergencies such as sudden

cardiac arrest.Health Lecture Activity Site Specialized First-Aid Skills Training Session

9 OH Cards: Projective Cards for the Subconscious

118 119InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

05

Health Equity and

Welfare Sharing

SDGs Addressed in this Chapter

InnoCare always prioritizes the health needs and well-being of patients fully utilizes its

own technological and resource advantages promotes industry cooperation develops

inclusive healthcare actively fulfills corporate social responsibility and contributes to

social harmony and sustainable development.

120 121InnoCare 2025 ESG Report Health Equity and Welfare Sharing

Industry Cooperation InnoCare Hosts "Intelligence Without Bounds Journeying Together in Medicine" Cross-Border

Engineer Salon

InnoCare firmly believes that industry cooperation and development are effective driving forces for innovative

research and development. We actively participate in business exchanges in the biopharmaceutical industry strive

to seek cooperation opportunities and work together with all parties to promote cutting-edge breakthroughs in In October 2025 as the only private enterprise among the 20 organizers approved by the Beijing Associa-basic research and drug innovation. The Group organizes business exchange meetings through a "offline+online" tion for Science and Technology InnoCare hosted the “Intelligence Without Bounds Journeying Togetherapproach and showcases over 80 research achievements at important academic conferences both domestically in Medicine” Cross-Border Engineer Salon. The event brought together experts from industry academia

and internationally receiving unanimous praise from industry experts at home and abroad. research and medical fields to discuss topics such as AI-enabled diagnosis and treatment digital twins

and new paradigms in drug R&D. The salon aimed to establish a cross-disciplinary platform integrating

2025 InnoCare's Participation in Industry Exchange Activities medicine and engineering promote industrial practice and talent cultivation in “AI + healthcare” and

implement the national “AI + healthcare” strategy.

2025 Zhongguancun Forum The 43rd JPMorgan Healthcare Conference

SAPA China 2025 Pharmaceutical Industry

The 24th Morgan Stanley Asia Pacific Summit

Conference

The 27th China Beijing International Science

2025 Beijing Changping Life Science Forum

and Technology Industry Expo

2025 Hong Kong World Youth Creative 67th American Society of Hematology

Talent Development Summit (ASH) Annual Meeting

2025 European Society for Medical 2025 European Hematology Association

Oncology (ESMO) Annual Meeting (EHA) Annual Meeting

The 18th International Conference on 2025 American Academy of Dermatology

Malignant Lymphoma (ICML) (AAD) Annual Meeting

2025 International Society of Pediatric Oncology (SIOP) Annual Meeting

"Intelligence Without Bounds Journeying Together in Medicine" Cross-Border Engineer Salon Site

122 123InnoCare 2025 ESG Report Health Equity and Welfare Sharing

InnoCare Appears at the 2025 Zhongguancun Forum to Display New Quality Productivity InnoCare Participates in the 2025 Hematological Malignancies Innovation ConferenceIn March 2025 at the Zhongguancun National Independent Innovation Demonstration Zone Exhibition On August 17 2025 InnoCare successfully participated in the “Illuminating New Life Pioneering the FutureCenter InnoCare showcased its innovative pipeline in the fields of hematologic malignancies and autoim- — 2025 Hematological Malignancies Innovation Conference” hosted by the Beijing Dadi Medical Charity

mune diseases including the new BTK inhibitor orelabrutinib (trade name: Yinuokai) anti-CD19 monoclo- Foundation. The conference gathered leading domestic and international experts and scholars in the field

nal antibody tafasitamab and two TYK2 inhibitors ICP-332 and ICP-488. In recent years the Group has of lymphoma. In-depth academic exchanges focused on topics such as the unmet needs in diffuse large

continued to showcase our latest research and development achievements at the Zhongguancun Forum B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

a national platform for global scientific and technological innovation exchange and cooperation. We have cutting-edge advancements and novel drug research. The event aimed to promote the optimization of

also strengthened communication and exchange with the industry injecting strong momentum into the treatment decision-making in hematology illuminating the path to treatment for Chinese patients with

biopharmaceutical industry with new quality productivity. its guiding light.v

Exhibition Site of Research and Development Achievements at Zhongguancun Forum Scene from the 2025 Hematological Malignancies Innovation Conference

124 125InnoCare 2025 ESG Report Health Equity and Welfare Sharing

Inclusive Healthcare In terms of health education we have collaborated with patient organizations to carry out various types of patient

care science popularization activities effectively helping patients establish a correct understanding of disease

InnoCare is committed to expanding the coverage of its products to regions and populations and strives to improve diagnosis and treatment and building confidence in scientific treatment and active recovery; Promoted under-

the accessibility and affordability of drugs by assisting disadvantaged groups reducing medical costs and conduct- standing and communication between doctors and patients emphasizing the importance of standardized and full

ing health education. process management; At the same time it has increased public attention to different disease fields highlighting the

Governance important value of social forces in health science popularization.InnoCare has established an ESG governance structure clarifying that the board of directors bears the main respon-

Care and Health Education Practice for InnoCare Lymphoma Patients

sibility for pharmaceutical accessibility matters ensuring that innovative drugs are more accessible and affordable

and effectively fulfilling social commitments to benefit more patients.Strategy In 2025 InnoCare carried out a series of patient care science popularization activities effectively enhancing

trust and understanding between doctors and patients and building a positive and mutually supportiveInnoCare actively responds to the Healthy China Initiative and adheres to the mission of “To leverage cutting-edge patient community atmosphere.science technology and driving force to offer new drugs for patients and improve public health”. It is committed to *?Carry out 12 online science popularization live broadcasts with a focus on disease diagnosis nursing and full

expanding the regions and populations that the product benefits and making every effort to improve the accessi- process management of lymphoma.bility and affordability of drugs. *?Produce and publish 6 episodes of "Expert Talk" science popularization videos and 4 episodes of "Patient Stories" to deeply interpret the characteristics of diseases and treatment progress and convey the positive force of "accepting

diseases and living bravely" through real patient stories.Impact Risk and Opportunity Management *?Carry out the "Star Power Science Popularization Video Competition" calling on clinical doctors with passion and

In terms of assistance to disadvantaged groups the Group provides drug charity assistance insurance and welfare ability for science popularization to pass on correct and professional disease knowledge to patients and the public through the production of science popularization videos and improve their understanding of lymphoma.returns and other support to economically disadvantaged groups. On the basis of ensuring the continuity of *?Carry out the "New Life: Dialogue between Art and Science - Lymphoma Patient Imaging Exhibition" to convey

treatment we effectively reduce the economic pressure on patients' medication. In 2025 we launched patient scientific knowledge and humanistic care to patients through exhibition of patient imaging works sharing of real

assistance programs for both tafasitamab and the newly approved innovative drug zurletrectinib in December of stories and multidisciplinary expert salons.the same year. We cooperated with charitable foundations to carry out patient education and apply for assistance

providing support for patients who meet medical conditions but face economic difficulties and helping them obtain

sustained treatment. At the same time we actively cooperate with major institutions to provide patients with more comprehensive disease

In terms of reducing medical costs the Group deepens medical insurance access and constructs a multi-level security management and treatment plans making it more convenient for patients to obtain the necessary drugs.system. Through active medical insurance negotiations and diverse innovative payment plans we systematically Indicators and Objectives

reduce the burden of patients' medication and promote innovative treatment to benefit a wider population. As

of the end of the Reporting Period the Group has included one product in the National Reimbursement Drug List In order to further increase the Group's investment in inclusive healthcare the Group has set a series of indicators

(NRDL) bringing hope for rehabilitation to patients in a more affordable way through various accessible channels. and goals related to inclusive healthcare such as the inclusion of new indications in NRDL.The prices of products included in NRDL can be queried on the medical insurance platform achieving openness

and transparency in drug prices.Establishing the Dual Channel of "Basic Medical Insurance + Commercial Insurance": InnoCare

Explores a New Path for Innovative Drugs to Increase Access and Reduce Costs

In 2025 InnoCare will continue to deepen the accessibility layout of innovative drugs. The core product

of the Grouporelabrutinib has further improved the breadth and sustainability of clinical medication

by adding key indications and completing the renewal of national medical insurance. At the same time

another heavyweight product of the Group tafasitamab has been successfully included in the Huimin

Insurance (Universal Health Insurance) coverage of 25 cities nationwide by actively expanding cooperation

with local governments and insurance institutions establishing a supplementary payment channel for

patients beyond basic medical insurance effectively alleviating their medication burden. This dual channelmodel of “national medical insurance foundation commercial insurance benefiting the people and strongsupplementation” effectively improves the accessibility of innovative drugs and patient protection capacity

while optimizing the medical cost structure.

126 127InnoCare 2025 ESG Report Health Equity and Welfare Sharing

Social Responsibility

Empowering Lymphoma Patients through Visual Stories

InnoCare remains committed to fulfilling its social citizenship responsibilities with dedicated efforts in key philan-

thropic areas including rural revitalization educational support and patient care. Meanwhile the Group has estab-

lished a well-structured volunteer service mechanism to actively encourage and motivate employees to participate In 2025 the Company joined hands with the public welfare organisation “Lymphoma Home” to launch

in social welfare initiatives contributing to enhanced social well-being and the development of harmonious the second “New Life Together - Photos and the Stories Behind Them” award collection campaign and

communities. the “New Life Together 2025” short video competition encouraging patients to share their lives through

photographs and short videos showcasing the resilience and inner strength of people living with lymphoma

Rural Revitalization and promoting greater public attention and support. The campaign collected 222 submissions attracted

nearly 1500 participants and generated more than 20000 cumulative views and interactions receiving

InnoCare continues to respond to the national rural revitalization strategy adding momentum to rural economic

an enthusiastic response from the lymphoma community. By conveying emotion through real stories the

development and residents' well-being through diversified assistance paths. The Group focuses on improving the

campaign further fostered understanding care and support for this group across society.infrastructure and healthcare of rural schools committed to cultivating good personal hygiene and health habits

for left behind children and using professional strength to escort their healthy growth.Patient Care

InnoCare always adheres to a patient-centred approach and remains highly attentive and responsive to patients’

unmet needs. The Company actively leverages its professional influence in the biopharmaceutical industry to initiate

and advance a series of targeted public welfare programmes for patients aiming to raise wider social awareness of

different patient groups and secure greater social support and understanding for them.Lymphoma Patient Care Programme

In 2025 InnoCare supported the recovery of lymphoma patients through diversified science communi-

cation and care initiatives. The Group worked closely with patient organisations and focusing on core

topics such as disease diagnosis and home care organised 12 online science communication livestreams

during the year. We also produced and released six “Experts Talk” science communication videos and four

“Patient Stories” episodes conveying scientific knowledge and confidence in recovery. At the same time the

Company launched innovative projects such as the “Star Power” science video competition and the “NewLife Together” lymphoma patient photography exhibition combining medical education with humanistic

care and helping strengthen communication between doctors and patients.New Life Together - Photos and the Stories Behind Them

Volunteer Activities

InnoCare actively fulfils its corporate citizenship responsibilities and strongly advocates a volunteer service culture

of “participation by all and care for others”. The Company regularly organises volunteer activities and supports

employees in carrying out various voluntary services in local communities with the aim of enhancing employees’

"New Life Together" Patient Story Painting Activity awareness of social participation and dedication while contributing tangible efforts to social harmony and sustain-

able development.

128 129InnoCare 2025 ESG Report Patient-Centric Innovation and R&D

Appendix

130 131InnoCare 2025 ESG Report Appendix

ESG Key Performance Table

Performance Indicator Unit 2025 2024 2023

Environmental performance 10 Biochemical oxygen demand (BOD)

ton 0.37 0.15 0.74

emissions

Performance Indicator Unit 2025 2024 2023

Ammonia Nitrogen NH3-N emissions ton 0.10 0.02 0.08

Energy Consumption Management of waste gas

Total steam consumption ton 7967.00 11469.50 12108.71 Total amount of exhaust gas emis-

m3 678667297 664071224 280835184

sions

Natural gas usage m3 352092.00 10408.00 9152.00

Exhaust gas emission intensity m3/RMB 10000 2857.66 6578.56 3802.57

Total purchased electricity MWh 18409.86 16319.11 14995.03

Compliance rate of exhaust gas

%100.00100.00100.00

treatment

Total energy usage MWh 23180.29 18278.56 17045.54

Volatile organic compound (VOCs)

kg 18.93 125.49 73.30

Energy use intensity MWh/RMB 10000 0.10 0.18 0.23 emissions

Methyl alcohol emissions kg 33.75 1601.35 234.26

Water Consumption

Hydrogen chloride emissions kg 16.32 8.20 74.48

Total water consumption m3 165019.00 139712.00 134988.00

Ammonia emissions kg 51.91 48.08 64.34

Water consumption intensity m3/RMB 10000 0.69 1.38 1.83

Nitrogen oxides emissions kg 11.41 / /

Management of Packaging

Sulfur oxides emissions kg 4.87 / /

Total usage of packaging materials

ton 29.09 14.30 6.50 Suspended particles and particulate

for finished products kg 7.70 / /

matter (PM) emissions

Management of waste water Non-methane hydrocarbon emis-

kg 959.21 / /

sions

Industrial wastewater discharge m3 104991.31 87454.00 84395.00

Waste management

Industrial wastewater discharge in-

m3/RMB 10000 0.44 0.87 1.14 Total amount of non-hazardous

tensity ton 146.59 651.63 1189.94

waste

Chemical oxygen demand (COD)

ton 1.66 2.01 2.67

emissions Total amount of hazardous waste ton 368.86 318.49 228.79

Intensity of non-hazardous waste

10 In accordance with the latest requirements the total energy consumption and greenhouse gas data for 2023 and 2024 have been retrospectively ton/RMB 10000 0.0006 0.0065 0.0200generation

updated with additional disclosure of Scope 3 greenhouse gas emissions added for this Reporting Period.

132 133InnoCare 2025 ESG Report Appendix

Performance Indicator Unit 2025 2024 2023 Social Performance

Intensity of hazardous waste gener-

ton/RMB 10000 0.0016 0.003 0.003 Employment and Labor Routine Performance

ation

Waste disposal compliance rate % 100.00 100.00 100.00 Performance Indicator Unit 2025 2024 2023

Mitigation and adaptation of climate change Employment

Total amount of greenhouse gas emis-

tCO e 11048.97 9417.28 8752.97 Total number of employees person 1297 1167 1113

sions (Scope 1+Scope 2) 2

Number of full-time labor contract employees person 1272 1146 1089

Greenhouse gas emission intensity

tCO2e/RMB 10000 0.047 0.09 0.12(Scope 1+Scope 2)

Number of full-time dispatched employees person 10 15 19

Scope 1 Greenhouse gas emissions tCO2e 769.73 22.75 20.01

Number of part-time employees person 15 6 5

Scope 2 Greenhouse gas emissions tCO2e 10279.24 9394.52 8732.97 Number of male employees person 624 537 531

Number of female employees person 673 630 582

Total greenhouse gas emissions

tCO e 49589.36 / /

(Scope 1+Scope 2+Scope 3) 2

Number of employees aged below 30 person 328 340 372

Scope 3 Total Greenhouse Gas emis-

tCO2e 38540.39 / /sions Number of employees aged 30-50 person 942 810 721

Scope 3 Greenhouse Gas Emissions -

Category 1 Purchased Goods and Ser- tCO e 2163.73 / / Number of employees aged above 50 person 27 17 202

vices

Scope 3 Greenhouse Gas Emissions - Number of senior management employees person 6 6 5

Category 4 Upstream Transport and tCO2e 2.32 / /

Distribution

Number of middle management employees person 228 198 185

Scope 3 Greenhouse Gas Emissions

- Category 9 Downstream Transport tCO2e 36374.34 / /

and Distribution Number of general employees person 1063 963 923

Environmental compliance

Number of employees in the Chinese mainland person 1287 1152 1093

Number of incidents in which

penalties were imposed for exceeding

cases 0 0 0 Number of employees in Hong Kong Macau Taiwan and

permitted pollutant standards or person 10 15 20

overseas

violating emissions regulations

134 135InnoCare 2025 ESG Report Appendix

Performance Indicator Unit 2025 2024 2023 Performance Indicator Unit 2025 2024 2023

Employee Turnover RMB Total safety investment 153.41 / /

10000

Employee turnover 11 % 12.18 10.97 12.31 Coverage of safety training % 100.00 100.00 /

Turnover of male employees % 10.90 12.85 13.56 Total safety training hours hour 4506 5228 /

Turnover of female employees % 13.37 9.37 11.17 Employee training

Turnover of employees aged below 30 % 13.72 15.00 13.98 Coverage of employees receiving training 12 % 100.00 100.00 100.00

Turnover of employees aged 30–50 % 11.78 9.38 11.10 Coverage of male employees receiving training % 100.00 100.00 100.00

Turnover of employees aged above 50 % 7.41 5.88 25.00 Coverage of female employees receiving training % 100.00 100.00 100.00

Turnover of employees in the Chinese Mainland % 12.04 10.94 12.35

Coverage of senior management receiving training % 100.00 100.00 100.00

Turnover of employees in Hong Kong Macau Taiwan and

%30.0013.3310.00

overseas Coverage of middle management receiving training em- % 100.00 100.00 100.00

ployees

Employee Health and Safety

Coverage of general employees receiving training % 100.00 100.00 100.00

Number of work-related fatalities person 0 0 0

Training hours per employee 13 hour 49.22 40.70 29.27

Work-related fatality rate % 0 0 0

Training hours per male employee hour 53.34 43.33 29.35

Number of working days lost due to work-related injuries day 0 68 0

Training hours per female employee hour 45.39 38.46 29.20

Coverage of occupational disease physical examination % 100.00 100.00 /

RMB Training hours per senior management hour 71.67 41.67 45.00

Investment in occupational disease physical examinations 14.99 16.24 /

10000

Training hours per middle management hour 73.66 67.07 66.31

Coverage of work-related injury insurance % 100.00 100.00 /

Training hours per general employee hour 43.84 35.27 24.70

RMB

Investment in work-related injury insurance 173.70 107.95 /

10000 person-

Total number of employee training attendances 25940 21006 /

time

Coverage of work safety liability insurance % 100.00 / /

person-

RMB Number of male employee training attendances 12480 9666 /

Investment in work safety liability insurance 1.01 / / time

10000

12 Coverage rate of employees receiving training = Number of employees trained in this category during the Reporting Period/Number of employees in

11 Employee turnover=Number of employees lost in this category during the Reporting Period/Number of employees in this category at the end of the this category at the end of the Reporting Period*100% .

13

Reporting Reriod * 100% Training hours per employee=Total training hours of the employees trained in this category during the Reporting Period/Number of employees in

this category at the end of the Reporting Period

136 137InnoCare 2025 ESG Report Appendix

Performance Indicator Unit 2025 2024 2023 Performance Indicator Unit 2025 2024 2023

person-

Number of female employee training attendances 13460 11340 / Other

time

person- Coverage of social insurance % 100.00 100.00 /

Number of senior management training attendances 120 108 /

time

Number of employees assisted through hardship support

person- person 2 / /

Number of middle management training attendances 4560 3564 / programs

time

person-

Number of general employee training attendances 21260 17334 /

time Supply Chain Performance

RMB

Total investment in employee training 86.73 52 / Performance indicators Company 2025 2024 2023

10000

RMB Total number of suppliers

Per capita training investment 0.07 / /

10000

Total number of suppliers supplier 3100 2654 1031

Employment Compliance

Total number of mainland suppliers supplier 2917 2513 976

Total number of penalties imposed on the Company for vi-

times 0 0 0

olations of employment-related laws and regulations Total number of Hong Kong Macao Taiwan and

supplier 183 141 55

overseas suppliers

Number of penalties for violations of laws and regulations

times 0 0 0

related to employee recruitment and dismissal Supplier evaluation and supervision

Number of penalties for violation of laws and regulations

times 0 0 0 Number of suppliers certified by ISO 9001 supplier 37 68 /

related to employee's working hours and holidays

Number of suppliers certified by ISO 14001 supplier 26 40 /

Number of penalties for violations of laws and regulations

times 0 0 0

related to employee's promotion and equal opportunity

Number of suppliers certified by ISO 45001 supplier 17 6 /

Number of penalties for violations of laws and regulations

times 0 0 0 Number of suppliers who have conducted envi-

related to anti-discrimination and diversity supplier 1550 0 0ronmental and social impact assessments

Labor Diversity Number of suppliers who have conducted envi-

supplier 1550 0 /

ronmental impact assessments

Number of disabled employees person 2 2 /

Number of suppliers who have conducted social

supplier 1550 0 0

impact assessments

Number of ethnic minority employees person 66 58 /

Number of suppliers identified as having actual

and potential significant negative environmental supplier 0 0 0

Proportion of female senior management % 16.67 57 /

and social impacts

138 139InnoCare 2025 ESG Report Appendix

Product and customer service performance

Performance Indicator Unit 2025 2024 2023

Performance Indicator Unit 2025 2024 2023

Amount committed to community welfare

RMB 10000 0 0 0

(Culture and sports)1

Product Responsibility Compliance

Amount committed to community welfare (Other

Total number of penalties imposed by the Com- RMB 10000 0 4 20areas)

pany for violating laws and regulations related to case 0 0 0

product liability Employee volunteer hours hour / 5163 /

Total number of illegal and irregular events in Person-

Employee volunteer participation / 734 /

marketing promotion (including advertising pro- case 0 0 0 time

motion and sponsorship)

Total number of violations in the health and

case 0 0 0

safety aspects of products and services Governance Performance

Total number of incidents that violate regula- Anti-Corruption Performance

tions and voluntary guidelines related to product case 0 0 0

and service information and labeling Performance Indicator Unit 2025 2024 2023

Data Security and Customer Privacy Protection

Corruption Reports and Litigation Cases

Number of data security incidents case 0 0 / Number of corruption lawsuits that have been filed by regulators

against the Company and its employees and case 0 0 0

Number of incidents of violating customer pri-

case 0 0 0 have been concluded

vacy regulations

Amount involved in customer privacy breach in- Anti-Corruption Training

RMB 0 0 /

cident

person-

Number of employees receiving anti-corruption related training 2173 1028 1113

time

Social public welfare performance

Percentage of employees covered by anti-corruption training % 100.00 100.00 100.00

Performance Indicator Unit 2025 2024 2023

Social welfare Training hours per employee for anti-corruption related training hour 1.8 0.9 0.58

Amount committed to community welfare RMB 10000 23.67 21.99 20 Percentage of Board of Directors members covered by anti-cor- % 35 28.57 37.5

ruption training

Amount committed to community welfare (La-

RMB 10000 0 0 0 Training hours per Board of Directors member for anti-corrup-

bour needs) hour 0.5 0.67 0.67tion related training 14

Amount committed to community welfare

RMB 10000 23.67 17.99 0

(Healthcare)

14 Training hours per Board of Directors member for anti-corruption related training= The total number of hours of anti-corruption training received by

directors during the Reporting Period/number of directors participating in anti-corruption training.

140 141InnoCare 2025 ESG Report Appendix

HKEX Codes

Performance Indicator Unit 2025 2024 2023

Report

Anti-Unfair Competition Subject Areas Aspects General Disclosures and KPIs Section

Number of lawsuits or major administrative penalties related to General disclosure: Relating to air emissions discharges into wa-

case 0 0 / Climate

unfair competition ter and land and generation of hazardous and non-hazardous Change

waste:

（a）the policies; and Pollution Internal Control Training

（b）information on compliance with laws and regulations that Prevention

have a significant impact on the issuer and Control

Compliance training (anti-corruption and anti-bribery etc.) session 26 18 /

Pollution

A1.1 The types of emissions and respective emissions data. Prevention

Employee participation in compliance training (anti-corruption person- and Control

21731028/

anti-bribery etc.) time

A1.3 Total hazardous waste produced (in tonnes) and where Pollution

A1

applicable intensity (e.g. per unit of production volume per Prevention

Emissions facility). and Control

A1.4 Total non-hazardous waste produced (in tonnes) and where Pollution

applicable intensity (e.g. per unit of production volume per Prevention

facility). and Control

Pollution

A1.5 Description of emission target(s) set and steps taken to

Prevention

achieve them.and Control

Environmental

A1.6 Description of how hazardous and non-hazardous wastes Pollution

are handled and a description of reduction target(s) set and Prevention

steps taken to achieve them. and Control

General disclosure: Policies on the efficient use of resources Resource

including energy water and other raw materials. Conservation

A2.1 Direct and/or indirect energy consumption by type (e.g.Resource

electricity gas or oil) in total (kWh in ’000s) and intensity (e.g. per

Conservation

unit of production volume per facility).A2.2 Water consumption in total and intensity (e.g. per unit of Resource

A2 production volume per facility). Conservation

Use of

Resources A2.3 Description of energy use efficiency target(s) set and steps Resource

taken to achieve them. Conservation

A2.4 Description of whether there is any issue in sourcing water

Resource

that is fit for purpose water efficiency target(s) set and steps

Conservation

taken to achieve them.A2.5 Total packaging material used for finished products (in Resource

tonnes) and if applicable with reference to per unit produced. Conservation

142 143InnoCare 2025 ESG Report Appendix

Subject Areas Aspects General Disclosures and KPIs Report Section Subject Areas Aspects General Disclosures and KPIs

Report

Section

Green Operation

General disclosure: Policies on minimising the issuer’s significant B3.1 The percentage of employees trained by gender and em-A3 Future Built on Talent

impacts on the environment and natural resources. B3 ployee category (e.g. senior management middle manage-Environ- Development

Environmental Integrity Development ment).ment and

Science

Natural A3.1 Description of the significant impact of activities on the en- Green Operation

and Training

B3.2 The average training hours completed per employee by Talent

Resources vironment and natural resources and the actions taken to man- Future Built on gender and employee category. Development

age them. Integrity

General disclosure: Relating to the preventing of child or forced

General disclosure: Relating to compensation and dismissal re- labour: Compliant

cruitment and promotion working hours rest periods equal op- (a)the policies; and Employment

portunity diversity anti-discrimination and other benefits and (b)information on compliance with relevant laws and regula-

Compliant B4

welfare: tions that have a significant impact on the issuer

Employment Labour

(a)the policies; and

Standards B4.1 Description of measures to review employment practices Compliant

(b)information on compliance with laws and regulations that to avoid child and forced labour. Employment

B1 have a significant impact on the issuer

Employment B4.2 Description of steps taken to eliminate such practices Compliant

B1.1 Total workforce by gender employment type (for example Compliant when discovered. Employment

full- or part-time) age group and geographical region. Employment

General disclosure: Policies on managing environmental and Responsible

social risks of the supply chain. Procurement

B1.2 Employee turnover rate by gender age group and geograph- Compliant Responsible

ical region. Employment Sociology B5.1 Number of suppliers by geographical region. Procurement

B5.2 Description of practices relating to engaging suppli-

General disclosure: Relating to providing a safe working environ- Responsible

B5 ers number of suppliers where the practices are being imple-

Sociology ment and protecting employees from occupational hazards: ProcurementSupply Chain mented and how they are implemented and monitored.(a)the policies; and Safety and Health

Management

(b)information on compliance with relevant laws and regulations B5.3 Description of practices used to identify environmental

that have a significant impact on the issuer Responsible and social risks along the supply chain and how they are im-

Procurement

plemented and monitored.B2 B2.1 Number and rate of work-related fatalities occurred in each

Safety and Health B5.4 Description of practices used to promote environmentally Health and of the past three years including the reporting year. Responsible preferable products and services when selecting suppliers and

Safety Procurement

how they are implemented and monitored.B2.2 Lost days due to work injury. Safety and Health General disclosure Relating to health and safety advertising la-

belling and privacy matters relating to products and services

provided and methods of redress: Quality

B2.3 Description of occupational health and safety measures B6 (a)the policies; and AssuranceSafety and Health

adopted and how they are implemented and monitored. Product (b)information on compliance with relevant laws and regula-

Responsibility tions that have a significant impact on the issuer

B3 General disclosure: Policies on improving employees' knowledge

Talent

Development and skills for discharging duties at work. Description of training B6.1 Percentage of the total products sold or shipped subject to Quality

Development

and Training activities. recalls for safety and health reasons. Assurance

144 145InnoCare 2025 ESG Report Appendix

Subject Areas Aspects General Disclosures and KPIs Report Section Climate related disclosures

Governance Governance Climate Change - Governance

B6.2 Number of products and service related complaints re- High-

ceived and how they are dealt with. Quality Service

Climate-related risks and opportunities Climate Change - Strategy

Business model and value chain Climate Change

B6.3 Description of practices relating to observing and protect-

Innovative R&D

ing intellectual property rights. Strategy and decision-making Climate Change - Strategy

B6 Product Re-

sponsibility Strategy Financial position financial perfor-

B6.4 Description of quality assurance process and recall proce- Quality Climate Change - Strategymance and cash flows

dures. Assurance

Climate resilience Climate Change - Strategy

B6.5 Description of consumer data protection and privacy poli- High- Financial impact of climate related risks Climate Change - Strategy

cies and how they are implemented and monitored. Quality Service and opportunities

Risk Climate Change -

Risk management

General disclosure: Relating to bribery extortion fraud and Management Risk Management

money laundering:

(a)the policies; and Business Ethics Climate Climate Change - Greenhouse gas emissions

(b)information on compliance with relevant laws and regula- Related Indicators and Objectives

tions that have a significant impact on the issuer Disclosures

Climate-related transition risks Climate Change - Strategy

Sociology

B7.1 Number of concluded legal cases regarding corrupt prac-

B7

tices brought against the issuer or its employees during the re- Business Ethics Climate-related physical risks Climate Change - Strategy

Anti-corruption

porting period and the outcomes of the cases.Climate-related opportunities Climate Change - Strategy

B7.2 Description of preventive measures and whistle-blowing

Business Ethics Capital deployment 15 /

procedures and how they are implemented and monitored. Indicators and

Objectives Internal carbon pricing 16 /

B7.3 Description of anti-corruption training provided to direc-

Business Ethics

tors and staff. Remuneration 17 /

18

General disclosure: Policies on community engagement to un- Industry-based metrics /

derstand the needs of the communities where the issuer oper-

/ Climate Change - Indicators

ates and to ensure its activities take into consideration the com- Climate-related targets

and Objectives

munities’ interests.B8 Applicability of cross-industry metrics

Community /

B8.1 Focus areas of contribution (e.g. education environmental Social and industry-based metrics 19

Investment

concerns labour needs health culture sports). Responsibility

15 The Company has not yet incorporated climate change analysis into its capital operations.

16 The Company does not currently apply an internal carbon pricing mechanism in its decision-making.

B8.2 Resources contributed (e.g. money or time) to the focus Social

17 The Company has not yet linked executive remuneration to climate-related performance.

area. Responsibility

18 The Company has not yet disclosed the relevant industry metrics.

19 The Company has not yet analysed cross-industry metrics or the applicability of industry-specific metrics.

146 147InnoCare 2025 ESG Report Appendix

Guidelines for the Shanghai Stock Exchange Feedback

Serial Corresponding

Dimension Issues Report Section Dear readers

Number Articals

Hello! Thank you very much for reading the "2025 ESG Report of InnoCare Pharmaceutical Co. Ltd.".

1 Addressing climate change Articles 21 to 28 Climate Change We attach great importance to and look forward to hearing your feedback on the Company's ESG

management practices and reporting. Your opinions and suggestions are an important basis for us

2 Pollutant emissions Article 30 Pollution Prevention and Control to continue promoting enterprise ESG management and practice. We look forward to your reply!

3 Waste disposal Article 31 Pollution Prevention and Control

1. Which type of stakeholder does your workplace belong to within this group

Ecosystem and biodiversity conserva-

4 Article 32 Environmental Management

tion □ Shareholders and investors □ Employees □ Suppliers □ Customers □ Government and regulatory agencies

Environment □ Communities □ Partners □ Industry associations/NGO □ Others (please specify)_____________

Environmental compliance manage-

5 Article 33 Environmental Management

ment 2. What is your overall evaluation of this report

6 Energy utilization Article 35 Resource Conservation □ Excellent □ Good □ General □ Poor

7 Water resources utilization Article 36 Resource Conservation

3. What do you think of the clarity accuracy and completeness of the information and data disclosed in this

8 Circular economy Article 37 Green Office report

9 Rural revitalization Article 39 Social Responsibility □ Excellent □ Good □ General □ Poor

10 Social contribution Article 40 Social Responsibility 4. How comprehensive do you think this report reflects the economic responsibilities undertaken by the Group

11 Innovation driven Article 42 Innovative R&D □ Excellent □ Good □ General □ Poor

12 Technology ethics Article 43 Innovative R&D 5. How comprehensive do you think this report reflects the environmental responsibility undertaken by the

13 Supply Chain Security Article 45 Responsible Procurement Group

Society □ Excellent □ Good □ General □ Poor

14 Equal treatment of SMEs Article 46 Responsible Procurement

6. How comprehensive do you think this report reflects the social responsibility undertaken by the Group

15 Product and Service Safety and Quality Article 47 Quality Assurance

□ Excellent □ Good □ General □ Poor

Data Security and Customer Privacy

16 Article 48 High-Quality Service

Protection 7. Do you think the information provided in this report is readable

Caring for Employees People-ori- □ Excellent □ Good □ General □ Poor

17 Employees Article 50

ented Approach

8. What do you want to know but have not been disclosed in this report

18 Due Diligence Article 52 Risk Control

Sustainable 19 Shareholders' communication Article 53 Communication with Stakeholders 9. What are your opinions and suggestions on the environmental social and governance work and report

Development preparation of the Group

Governance 20 Anti-Bribery and Anti-Corruption Article 55 Business Ethics

21 Anti-Unfair Competition Article 56 Business Ethics

148149